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Abstract 
 
Alzheimer’s disease (AD) is a devastating neurodegenerative disease characterized by strong 
cognitive impairment and memory loss. These symptoms are caused by neuronal death, induced by 
two pathological hallmarks: extracellular senile plaques composed of aggregated amyloid-beta (A?) 
peptides, and intracellular neurofibrillary tangles generated by the hyperphosphorylation of the 
actin-binding protein Tau. Genetic and biochemical analysis resulted in the generation of the so-
called amyloid cascade hypothesis, which stipulates that A? aggregation precedes neurofibrillary 
tangles and initiate AD pathogenesis. A? originates from the proteolytic cleavage of the amyloid 
precursor protein (APP) by ?-secretase, an intramembrane cleaving protease. Thus, pharmacological 
modulation of ?-secretase emerged as a promising strategy for the treatment of AD. However, 
strong side effects, including cognitive function worsening, were reported following clinical 
inhibition of this enzyme, caused by altered processing of the numerous ?-secretase substrates. 
Pharmaceutical industries, alongside with academia, oriented their research toward the discovery of 
compounds selectively affecting the processing of APP, without altering the cleavage of other 
substrates. 
 
In the first part of this thesis work, we focused our research on endogenous modulation of ?-
secretase, and its consequences on actin cytoskeleton dynamics. We performed mass spectrometric 
analysis of purified ?-secretase, and identified the adipocyte plasma membrane associated protein 
APMAP as a ?-secretase interacting protein. We showed that APMAP modulates the generation of 
A? peptides without affecting the processing of other ?-secretase substrates, and controls APP 
degradation by the lysosomal/autophagic pathway. We also investigated the regulation of ?-
secretase by post translational modifications, and concluded that its enzymatic activity is not 
affected by its phosphorylation. We then observed the effects of ?-secretase inhibition on 
physiological processes, and discovered a ?-secretase-dependent regulation of the binding of Cofilin 
to actin filaments. These observations showed a direct link between ?-secretase and the actin 
cytoskeleton required for cell motility and neuronal plasticity. 
 
In the second part of this work, we aimed at finding a new method for monitoring brain structure 
alteration and provide new tools for the study of neurodegenerative disease progression in animal 
models. We performed ex-vivo electrical impedance measurement from intracerebral electrode in 
mice brain, and succeeded in the visualization of cortical layers as well as brain nuclei. Moreover, 
we used this method to visualize structural alteration caused by A? plaques in an AD mouse model. 
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After imaging, we aimed at repairing neuronal loss causing the structural alterations observed in 
neurodegenerative diseases. We developed a compressible and injectable extracellular-matrix-like 
cell culture scaffold (cryogel) to promote neuronal growth in brain lesions. Primary cortical neuron 
culture on our cryogel scaffold showed good axonal sprouting, not affected by cryogel compression.  
 
 
 
Keywords: 
Alzheimer’s Disease, Gamma-Secretase, Amyloid Precursor Protein, Autophagy, Endogenous 
Modulator, Phosphorylation, Electrical Impedance, Brain Structure, Extracellular Matrix 
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Résumé 
 
La maladie d’Alzheimer (MA) est une maladie neurodégénérative dévastatrice caractérisée par un 
important déficit cognitif et la perte de mémoire. Ces symptômes sont causés par la mort de 
neurones, induite par les deux marqueurs de la MA : les plaques séniles extracellulaires composées 
de peptides beta-amyloïde (?A) agrégés, et les enchevêtrements neurofibrillaires générés par 
l’hyperphosphorylation de la protéine Tau. Des analyses génétiques et biochimiques ont permis 
l’élaboration de l’hypothèse de la cascade amyloïde, qui stipule que l’agrégation des ?A précède les 
enchevêtrements neurofibrillaires et déclenche la pathogénèse de la MA. Les ?A proviennent du 
clivage protéolytique de la protéine précurseur de l’amyloïde (PPA) par la ?-sécrétase, une protéase 
coupant dans le domaine transmembranaire. C’est pourquoi la modulation pharmacologique de la ?-
sécrétase est une stratégie intéressante pour le traitement de la MA. Cependant, d’importants effets 
secondaires, incluant la détérioration des fonctions cognitives, ont été observés suite à l’inhibition 
clinique de cette enzyme, causés par l’altération du clivage des nombreux substrats de la ?-
sécrétase. En conséquence, les industries pharmaceutiques aux côtés des universités, ont orienté 
leurs recherches vers la découverte de composés altérant de manière sélective la coupure de la PPA, 
sans modifier le clivage d’autres substrats. 
 
Dans la première partie de ce travail de thèse, nous focalisons nos recherches sur la modulation 
endogène de la ?-sécrétase, et les conséquences sur la dynamique du cytosquelette d’actine. Nous 
avons analysé la ?-sécrétase purifiée par spectrométrie de masse, et avons identifié la protéine 
membranaire d’adipogénèse APMAP interagissant avec la ?-sécrétase. Nous avons montré que 
APMAP module la production des ?A sans affecter le clivage d’autre substrats de la ?-sécrétase et 
contrôle la dégradation de la PPA par la voie de signalisation autophagique/lysosomale. Nous avons 
aussi investigué la régulation de la ?-sécrétase par modifications post-translationelles, et conclu que 
la phosphorylation ne modifie pas son activité enzymatique. Puis, nous avons observé les effets de 
l’inhibition de la ?-sécrétase sur les processus physiologiques, et avons découvert une régulation ?-
sécrétase-dépendante de l’interaction entre la Cofilin et les filaments d’actine. Ces observations ont 
montré un rôle direct de la ?-sécrétase dans l’organisation du cytoskelette d’actine, nécessaire à la 
mobilité cellulaire et la plasticité neuronale.  
 
Dans la seconde partie de ce travail, nous cherchions une méthode simple pour surveiller 
l’altération de la structure cérébrale, et permettre l’étude de la progression des maladies 
neurodégénératives dans les modèles animaux. Nous avons effectué des mesures d’impédance 
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électrique ex-vivo dans le cerveau murin, et avons réussi à visualiser les couches corticales ainsi que 
des noyaux cérébraux. Cette méthode nous a permis de visionner les altérations structurelles 
causées par les plaques ?A dans un model murin de la MA. Après cette étape de visualisation, nous 
avons eu pour but de réparer la mort neuronale responsable de changements cérébraux dans les 
maladies neurodégénératives. Nous avons développé un substrat cellulaire similaire à la matrice 
extracellulaire (cryogel), compressible et injectable, dans le but de promouvoir l’intégration et la 
croissance des cellules neuronales dans les lésions cérébrales. La culture de neurones primaires sur 
nos cryogels a montré un bon développement axonal, non-affecté par la compression du cryogel. 
 
 
 
Mots clés: 
Maladie d’Alzheimer, Gamma-Sécrétase, Protéine Précurseur de l’Amyloïde, Autophagie, 
Modulateur endogène, Phosphorylation, Impédance électrique, Structure cérébrale, Matrice 
Extracellulaire 
6
 
 
Abbreviations 
 
A?  Amyloid-beta 
ADF  Actin depolymerizing factor 
AICD  Amyloid precursor protein intra-cellular domain 
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Chapter I 
General introduction 
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I.1) The pathological hallmarks of Alzheimer’s disease 
Alzheimer's disease (AD) is the most common dementia affecting the elderly population. Patients 
suffering of AD display progressive cognitive impairment including memory loss and emotional 
instability1,2. In the late stages of the disease, metabolism, motor functions and immune system 
alteration lead to patient's death, often linked to infections by opportunistic diseases (for a review, 
see 3). By the examination of AD patient’s brain, we see that these symptoms are triggered by an 
important brain shrinkage caused by neuronal death (Fig. 1). At a molecular level, 
neurodegeneration is triggered by both AD pathological hallmarks, extracellular senile plaques 
composed of aggregated amyloid-beta peptides (A?)4, and intraneuronal neurofibrillary tangles 
(NFT) induced by Tau protein hyperphosphorylation5 (Fig. 1). 
 
 
 
Figure 1: AD pathological hallmarks. Left panel, MRI-based image representing tissue shrinkage 
in advanced AD versus healthy brain. Right panel, cellular zoom in AD brain where the two AD 
pathological hallmarks, intraneuronal neurofibrillary tangles and extracellular senile plaques are 
observed. Adapted from https://www.alz.org/braintour/healthy_vs_alzheimers.asp and 
http://www.thealzheimerssolution.com/-category/plaques-tangles/ 
 
 
Interestingly, both senile plaques and neurofibrillary tangles spread in the human brain according to 
a well-characterized pattern6,7 (Fig. 2). In the early presymptomatic stage of the disease, A? 
aggregation starts in the entorhinal cortex and induces NFT formation. A? spread according to a 
prion-like mechanism8, whereas NFT travel through synapses by cell-to-cell transmission9,10 and 
progress to the hippocampus as well as to more distal cortical regions (Fig. 2, stages 1-3). While in 
AD patients neurodegeneration progresses in the latter brain regions, A? reach various pons nuclei 
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and progressive cognitive impairment is diagnosed (Fig. 2, stage 4). In the last stages of the disease, 
almost all brain structures are altered by strong neurodegeneration and A?-induced synaptic 
impairment, leading to dysregulation of a high number of physiological functions (Fig.2, stage 5). 
 
 
 
Figure 2 : AD progression pattern. Senile plaques and neurofibrillary tangles generation start in 
the entorhinal cortex in presymptomatic very early AD, then spread into the hippocampus and 
extended cortex area and induces neuronal death (black, or grey for lower tissue alteration). Strong 
alteration in cortical/hippocampal circuitry and affectation of pons nuclei lead to important 
cognitive symptoms. In last phase 5, almost all brain regions are affected. Damaged structures are 
marked in grey/black, newly altered brain areas are marked in red. Adapted from 11. 
 
 
Alterations in A? levels precede AD onset and can be detected up to 25 years before the first 
symptoms appear12. Patient’s death appears on average 8-10 years following AD onset. Progressive 
loss of cognitive functions and the alteration of AD patients day-to-day life requires long constant 
care, explaining the high economic burden for this disease (200 billion € / year for 90 million AD 
patients in Europe in 201513). Moreover, with the progress of medicine and the prolonged human 
lifespan, a 25% increase in the amount of population suffering from dementia, but also in money 
expenses are expected in the next 15 years13. With this expected economic burden for our society, it 
becomes urgent to find a solution to slow down or stop the disease's progression. 
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I.2) Current treatments and detection 
1.8 % of total European population suffer from dementia, 60% of them are diagnosed with AD. As 
people age, AD statistics are striking: the disease affects 10% of individuals over 65 years old, 20% 
over the age of 80, and more than the third over 90 years old14,15. Because these values are expected 
to increase, important efforts have been deployed in the discovery of a cure. Despite those efforts, 
medical expectations have not been met, as of today no treatment has the capacity to alter the 
progression of AD. The unique AD treatments are solely symptomatic and display important side 
effects (listed in table 1, for a review see16). 
 
Drug name AD stages Class Mechanism of action Side effects 
Donepezil® Mild to 
severe 
Cholinesterase 
inhibitor 
Prevents the breakdown of 
acetylcholine in the brain 
Nausea, vomiting, 
diarrhea, muscle cramps, 
fatigue, weight loss 
Rivastigmine® Mild to 
moderate 
Cholinesterase 
inhibitor 
Prevents the breakdown of 
acetylcholine in the brain 
Nausea, vomiting, 
diarrhea, weight loss, 
decreased appetite, 
muscle weakness 
Galantamine® Mild to 
moderate 
Cholinesterase 
inhibitor 
Prevents the breakdown of 
acetylcholine and stimulates 
nicotinic receptors to release 
more acetylcholine in the brain 
Nausea, vomiting, 
diarrhea, weight loss, 
decreased appetite 
Memantine® Moderate 
to severe 
NMDA 
receptor 
antagonist 
Blocks the toxic effects 
associated with excess glutamate 
and regulates glutamate activation
Dizziness, headache, 
diarrhea, constipation, 
confusion 
 
Table 1: Current symptomatic treatments for AD. The four compounds listed are the only FDA-
approved drugs and reduce AD symptoms severity. Notice that none of these drugs impact the 
progression of the disease. Adapted from https://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-
medications-fact-sheet 
 
 
Cholinergic neurotransmission is strongly impaired in AD, and its alteration correlates with a strong 
decrease in individual cognitive functions17–19. Thus, inhibition of acetylcholine esterase – 
responsible of acetylcholine neurotransmitter degradation – to stimulate the survival of the 
cholinergic neurons appeared to be an appealing strategy to compensate network alteration and 
restore cognitive functions. Indeed, three acetylcholine esterase inhibitors – Donepezil®, 
Rivastigmine® and Galantamine® – were approved by the US food and drug administration (FDA) 
10 years ago, and remain routinely used to treat AD. In addition to its inhibitory effect on 
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acetylcholine esterase, Galantamine® was shown to bind to the allosteric site of the nicotinic 
acetycholine receptors and potentiate their activation20. Also, Donepezil® inhibits N-methyl-D-
aspartate receptor (NMDAR) activation21. In addition to cholinergic alteration in AD, overactivation 
of NMDAR by the main excitatory neurotransmitter, glutamate, has been reported to induce 
neuronal excitotoxicity and triggers cell death22–24. Treatment with the NMDAR non-competitive 
partial antagonist Memantin® decreased receptor activation, cytotoxicity and improved cognitive 
functions. In AD’s severe stage, synergistic treatment with both Memantine® and Donepezil® is 
often recommended25. 
 
 
 
Figure 3: Biomarker dynamics in the pathological cascade of AD. Changes in CSF A? levels and 
appearance of senile plaques precede Tau-mediated neuronal injury and dysfunction, leading to 
neuronal death and synaptic impairment. These pathological events trigger brain structure 
alterations such as white matter changes and volume loss, leading to mild cognitive impairment 
(MCI). AD progression then affects clinical functions like behavior and social interactions 
characterized by a dementia stage. Adapted from http://adni.loni.usc.edu/study-design/background-rationale/ 
 
 
To initiate potent anti-AD drug research and discovery, the diagnosis has to be performed as early as 
possible to minimize brain damage and increase chances of complete cognitive function recovery. 
However, first symptoms characterized by mild cognitive impairment (MCI)26 appear only after the 
brain reaches high senile plaque load, as well as important neuronal and structural damages. In 
accordance with the most recent findings, a cascade of neuropathological events occurs in the brain 
and lead to AD (Fig. 3, reviewed in 12,27): up to 25 years before symptom onset, cerebrospinal fluid 
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(CSF) biochemical measurements show a decrease in the most pathogenic A? species, A?42 (see 
more details in section I.4: APP trafficking and A? generation), linked to its aggregation into senile 
plaque. The latter can be detected up to 15 years before symptoms appear, by positron-emission 
topography (PET) of radioactive senile plaque-binding molecules, including the highly used 
Pittsburgh compound B28–30 and more recently synthetized organofluorine compounds31. 
 
In parallel, increased Tau is observed in the CSF, highlighted by impaired glucose metabolism 
measured by F18-fluorodeoxyglucose PET32, and precedes the generation of NFT and NFT-related 
impairment including neurotoxicity and synaptic dysfunction. These alterations further lead to 
impaired neuronal network activity33,34, white matter alteration35 and brain shrinkage36 revealed by 
magnetic resonance imaging. As a consequence, MCI starts and evolves into dementia while 
progression of the neurotoxic hallmarks and brain volume loss are observed (Fig. 3). Due to 
treatment unavailability, current AD diagnosis is performed by MCI detection with 
neuropsychological tests. Because high number of factors may induce MCI including other 
neurodegenerative diseases, AD diagnostic is confirmed by senile plaques PET scan imaging26,37. 
The other techniques listed in this section are used for scientific research and clinical trials. 
 
Biomarker analysis (Fig. 3) shows that A?42 variations in the CSF precedes the AD pathological 
cascade, and suggest that this short peptide may initiate the pathogenesis of AD. 
 
 
I.3) The amyloid cascade hypothesis and AD genetics 
Since the first diagnosis of AD more than hundred years ago38, tremendous amount of effort has 
been provided to identify the molecular cause of the disease. While AD onset appears commonly 
after the age of 65 years old39, several patients exhibited similar symptoms but at a much lower age. 
Genetic analysis of this group of individuals led to the identification of missense mutations on 3 
genes: PSEN1, PSEN2 and APP (reviewed in 40). PSEN1 and PSEN2 encode for presenilins (PS), 
the catalytic subunit of the ?-secretase complex, while APP encodes for the amyloid precursor 
protein (APP), the cleavage of which produces A? peptides of various length (38 to 43 amino-acid 
long)41. Important investigations showed that these mutations either increase the amount of total A? 
produced, or specifically induce the production of the longest and most pathogenic A?42 42. 
 
Based on these observations, the amyloid cascade hypothesis (Fig. 4) stipulates that increased A?42 
levels, either caused by mutations in PSEN or APP (early onset familial AD, FAD) or linked to 
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abnormal A? degradation and risk factors such as the ApoE4 allele (late onset sporadic AD), 
induces A? oligomerization and initiates the molecular cascade leading to AD pathogenesis43. A? 
oligomers generate senile plaques, synaptic dysfunctions, induce neuroinflammation and 
consequently microglia activation44,45. Impaired synaptic activity breaks neuronal ionic homeostasis 
and deregulates a myriad of physiological processes - including kinases and phosphatases - leading 
to pathological phosphorylation of Tau, causing the formation of toxic NFT. The latter alters actin 
cytoskeleton and triggers neuronal death, thus causing dementia (Fig. 4)46,47. 
 
 
 
Figure 4: The amyloid cascade hypothesis of AD. The amyloid cascade hypothesis stipulates that 
increased A?42 levels, either provoked by genetic mutations in PSEN or APP (familial form of AD) 
or by a lack of clearance and risk factors including ApoE4 allele, initiate the pathogenesis of AD. 
Inflammation, altered synaptic function, NFT formation and finally dementia are consequences of 
A?42 toxicity. Adapted from 48. 
 
 
This hypothesis is supported by the appearance of the A? phenotype prior to NFT genesis in the 
brain of AD patients12,27. Indeed, almost all FAD mutations increase brain levels of A?42, with the 
exception of APP Dutch mutation (E693Q), which increases A? aggregation without affecting the 
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processing of APP40,49,50. In addition, triplication of the APP gene-carrier chromosome 21 in Down 
syndrome increases total A? production, and leads to early AD pathogenesis starting at 12 years 
old51,52. In contrast, recent investigation highlighted the discovery of a new mutation in APP 
(A673T) that inhibits its processing by ?-secretase and protects against age/AD-related cognitive 
decline53. These clinical observations provide strong evidence that increased A?42 levels or 
aggregation are necessary and sufficient to induce the disease. 
 
 
I.4) APP trafficking and A? generation 
The APP gene is widely expressed and transcribed into 4 major isoforms named according to their 
length: APP770, APP751, APP714 and APP695, encodes for a type-I transmembrane protein54,55. 
APP695 is the major central nervous system-specific isoform and consequently the most relevant 
for AD research56,57. The processing of APP is characterized by two competitive pathways: the non-
amyloidogenic and the amyloidogenic pathways, with the latter being toxic and leading to A? 
production, senile plaque formation and AD (Fig. 5, reviewed in 58). In the non-amyloidogenic 
pathway APP is first processed by ?-secretase, releasing its extracellular domain (sAPP?)59,60. Next, 
the residual membrane embedded C-terminal 83 amino-acid long fragment (C83) is cleaved by ?-
secretase, thus liberating the APP intracellular domain (AICD) and the extracellular p3 peptides. In 
the amyloidogenic pathway, APP is cleaved by ?-secretase and generates a 99 amino-acid long 
(C99) membrane embedded fragment. Its processing by ?-secretase leads to the release of cytosolic 
AICD and A? in the extracellular space (Fig. 5)61. Recently, a work of Willem M. and colleagues 
highlighted the cleavage of APP by ?-secretase, leading to the generation of a 192 amino-acid long 
membrane-embedded C-terminal fragment (CTF). Subsequent processing of this ?-CTF by ? and ?-
secretases release soluble toxic A?-like fragments named A?-? and A?-?, as well as C83 and C99, 
respectively62. Importantly, APP and its membrane-embedded fragments can be degraded in a 
secretase-independent mechanism implicating the lysosomal/autophagy pathway63. 
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Figure 5: APP processing and A? generation. The transmembrane protein amyloid precursor 
protein (APP) can be processed in two main pathways. In the non-toxic pathway, APP is first 
cleaved by ?-secretase and releases sAPP? in the extracellular space, generating an 83 amino-acid 
long C-terminal fragment (C83). Processing of C83 by ?-secretase releases the APP intracellular 
domain (AICD) into the cytosol and the p3 peptide in the extracellular space. In the toxic or 
amyloidogenic pathway, APP is first processed by the ?-secretase and releases sAPP? in the 
extracelullar space. The residual C-terminal fragment (C99) is finally cleaved by ?-secretase, thus 
secreting amyloid-? peptides (A?) in the extracellular space and intracellular AICD. A? 
aggregation into senile plaques is believed to lead to the onset of Alzheimer's disease. Adapted from 58. 
 
 
The release of A? apparently occurs during all stages of human life, suggesting that A? is not toxic 
if it does not aggregate into oligomers or senile plaques, which are observed in the brain of AD 
patients64–67. Indeed, C99 can be cleaved in a stepwise process by ?-secretase, liberating 34, 37, 38, 
40, 42 or 43 amino-acid long A? peptides, with A?42 and A?43 being the most hydrophobic as well 
as the main aggregating and pathogenic peptides68–70. In addition to these observations, the brain 
A?42:A?40 ratio is equal to 0.1-0.2 in healthy humans and increases up to 2 in AD patients, causing 
A? plaque formation that initiates the disease42,71.  
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Figure 6: APP trafficking and processing. APP-containing vesicles are transported from the trans-
golgi network to the plasma membrane where APP gets cleaved by ?-secretase. This step leads to 
the release of sAPP? in the extracellular space, and the generation of an 83 amino-acid long C-
terminal fragment (C83). C83 can either be processed by ?-secretase at the plasma membrane, or 
be endocytosed with uncleaved APP. Then, APP is processed by ?-secretase in the endosome and 
generate a 99 amino-acid long membrane embedded fragment (C99) and a soluble sAPP? 
counterpart. Both C83 and C99 are cleaved by ?-secretase and secrete P3 and A? in the lumen, 
respectively, while cytosolic AICD translocates to the nucleus. Finally, APP fragments are either 
transported back to the membrane (endosomal recycling) or traffic via late endosome to undergo 
lysosomal degradation. Also, APP may be directly transported from the golgi directly to the 
endosome (dashed arrow). Adapted from 72. 
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The processing of APP by secretases occurs in distinct cellular organelles (depicted in Fig.6, 
reviewed in 73,74), thus its trafficking modulates its cleavage and degradation. When traveling 
through the secretory pathway, the addition of various post-translational modifications (PTM) 
affects its trafficking and processing. After protein translation in the cytosol, APP is translocated to 
the endoplasmic reticulum where the phosphorylation of its cytoplasmic domain regulates the later 
processing of C99/C83 and the translocation of AICD to the nucleus75. Its arrival to the golgi 
apparatus allows immature unglycosylated APP evolution into mature N- and O-glycosylated APP 
(mAPP), and ensure its proper trafficking and secretion76,77. Additionally, palmitoylation has also 
been reported on a limited proportion of APP at position Cys186 and Cys187: either palmitoylation or 
disulfide bonds between both cysteins is required for APP to exit the golgi apparatus78.  
 
After exiting the trans-golgi network, mAPP is transferred to the plasma membrane of axons and 
dendrites by vesicular transport. In the vesicles and at the plasma membrane, mAPP is processed by 
?-secretase, then possibly by ?-secretase (Fig. 6). Then, clathrin-dependent endocytosis brings both 
?-secretase cleavage product, C83 and intact mAPP to the endosomes, which light acidic pH 
confers optimal activity to ?- and ?-secretase79,80. Cleavage of intact mAPP by ?-secretase generates 
C99 and sAPP?. Then, processing of C83 and C99 by ?-secretase releases p3 and A? in the lumen, 
respectively, while cytosolic AICD translocates to the nucleus and regulates gene expression81. Both 
p3, sAPP? and A? are released in the extracellular space by exocytosis or exosomal transportation. 
Importantly, C83/C99 and to a lower extent APP can be degraded by the secretase-independent 
lysosomal/autophagic pathway. Indeed, acidification of late endosomes and fusion with lysosomes 
leads to APP degradation, likely by cathepsins82 (Fig. 6).  
 
 
I.5) APP cellular function 
The evident implication of APP and PSEN genes in AD development led to important findings, to 
decipher their physiological functions. APP is an evolutionary well conserved protein, showing high 
sequence homology with the non-amyloidogenic amyloid precursor-like protein 1 and 2 genes 
(APLP1 and APLP2)83. Genetic depletion of these proteins in mice allowed better understanding of 
the function of these genes, and revealed important developmental roles for APP (reviewed in 84,85). 
Constitutive APP deletion (APP-KO) yields in viable and fertile mice displaying several 
abnormalities, including weight loss as well as a decrease in brain volume and memory 86–88. These 
phenotypes were explained by the implication of APP in synaptic transmission88,89. Furthermore, 
increased cholesterol levels in these mice suggest a metabolic role for APP90. APLP1-KO mice only 
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exhibited somatic growth deficit, while no abnormalities have been detected in APLP2-KO mice. In 
sharp contrast with single knockout models, double KOs exhibited more pronounced phenotypes. 
Deficiency in APP / APLP2 and APLP1 / APLP2 were lethal whereas APP / APLP1-KO mice 
displayed no abnormality91,92. Consistent with previous observations, genetic deletion of the 3 APP 
family members was lethal93. In addition, various studies demonstrated the binding of APP 
extracellular domain to matrix components, as well as its dimerization, and proposed a cell adhesion 
function for APP94–98. 
 
The physiological functions of the highly regulated proteolytic processing of APP remains poorly 
understood, hence it appears that ?-secretase-mediated cleavage displays neurotrophic properties, 
whereas ?-secretase processing alters synaptic activity. Indeed, the overexpression in APP-KO mice 
of sAPP?, but not sAPP?, was shown to rescue the phenotype99. Complementarily, several studies 
highlighted the important role of sAPP? in synaptic plasticity and memory 100,101. This observation 
is of relevance for AD, as reduced levels of sAPP? and ?-secretase have been measured in the CSF 
of AD cases 102–104. Striking functional differences between sAPP? and sAPP? were explained by a 
decrease of Cdk5-mediated Tau phosphorylation by the first105, while the second may bind the 
death receptor DR6 and initiate cellular degeneration106. 
 
The next step in APP processing involves ?-secretase and produces equal amounts of intracellular 
AICD, and luminal p3 or A?. In contrast to the neuroprotective effects of sAPP?, p3 toxicity – 
although lower than A?107 – has been shown both in vitro and in vivo108–110. Also, same AICD are 
generated from the processing of both C99 and C83 by ?-secretase111. Translocation of AICD to the 
nucleus is Fe65-dependent and regulates transcription of AD-related genes involved in A? 
levels112,113, Tau phosphorylation 114,115, as well as a high diversity of cellular pathways including 
phagocytosis and lipid dynamics 116, calcium homeostasis 117, cytoskeletal dynamics 81, and tumor 
regulation118. Additionally, the processing of AICD by caspases leads to the generation of a toxic 31 
amino-acid long CTF, supposed to play a minor role in AD pathology119–121. In conclusion, if the 
implication of A? in the pathogenesis of AD is now well accepted, the physiological and 
pathological importance played by each APP fragment remains unclear. 
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I.6) Assembly and structure of the ?-secretase complex 
?-Secretase is an intramembrane cleaving aspartyl protease complex composed of 4 subunits: Aph1, 
Nicastrin (NCT), PS, and Presenilin enhancer 2 (Pen2), mainly located in the trans-golgi network, 
on the plasma membrane, in the endosomes and in the lysosome122–124. It cleaves type-I membrane 
proteins in their transmembrane domain, thus releasing intra- and extracellular cleavage products125. 
This enzyme is implicated in a high number of physiological processes, as it cleaves many 
substrates (listed in 125), including APP, the cell differentiation protein Notch126, the synaptic 
plasticity-related Neurexin127 and Ephrin128 as well as the cell adhesion protein N-cadherin129. The 
implication of the ?-secretase complex in a myriad of physiological functions explains the strong 
adverse effects linked to its in vivo enzymatic inhibition130–133.  
 
The assembly of ?- secretase implicates the association of Aph1 and immature NCT (iNCT) in the 
endoplasmic reticulum, then supplemented by PS holoprotein (Fig. 7). Binding of Pen2 to the 
Aph1/iNCT/PS-FL trimeric subcomplex elicits (i) PS endoproteolysis into PS N- and C-terminal 
fragments (PS-NTF & PS-CTF, respectively), (ii) iNCT maturation into mature NCT (mNCT) 
induced by changes in glycosylation pattern, and (iii) activation of the ?-secretase complex (Fig. 7, 
reviewed in 134). Whereas PS contains the ?-secretase catalytic site, Aph1 and Pen2 are thought to 
play a structural role in the transmembrane complex134–136, and NCT might be implicated in 
substrate recognition137. In a mechanism independent of the ?-secretase complex, PS holoprotein 
was shown by Coen K. and colleagues to modulates lysosomal function by regulating the 
endosomal/lysosomal calcium influx138. Finally, atomic structure of the ?-secretase complex was 
recently elucidated and gives great hope to the design of new modulators139. 
 
 
20
 
 
 
 
Figure 7: Assembly of the ?-secretase complex. Assembly of ?-secretase starts in the endoplasmic 
rediculum (ER) / cis-golgi by the formation of a dimeric complex made of partially glycosylated 
immature NCT (iNCT, green) and Aph1 (blue). Presenilin holoprotein (PS, red) binding generates a 
trimeric complex, finally supplemented by PEN-2 (black). Addition of the last subunit induces NCT 
maturation (mNCT) characterized by change in its glycosylation pattern, PS endoproteolysis into 
N- and C-terminal fragments (PS-NTF and PS-CTF, respectively) leading to the activation of the ?-
secretase complex. Black dots on NCT subunit represent complex glycans. Modified from 134. 
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I.7) Therapeutic strategies in AD 
Existing AD symptomatic treatments are limited to short term cognitive improvement, hence 
tremendous efforts have been produced to identify approaches capable to slow down or stop the 
disease’s progression. Depending on their targets, therapeutic strategies can be separated in three 
main groups (described in Fig. 8, reviewed in 140): alteration of A? levels and aggregation (in blue), 
inhibition of its toxic downstream signaling (green), and rescue of disrupted cell homeostasis 
(purple). 
 
Dysregulation of APP processing and A? aggregation are believed to initiate the first step of AD 
pathogenesis, thus secretases appeared as a first target to block neurodegeneration. The most direct 
approach consists of the inhibition of the amyloidogenic ?- and ?-secretases. Full depletion of the ?-
secretase BACE1 in mice abolished A? production while having no major deficits, in contrast to 
lethal PS removal 141,142. Thus inhibition of ?-secretase was supposed safer than ?-secretase. Indeed, 
phase I clinical trial showed CSF A? reduction following BACE1 inhibitor administration143. 
However poor efficiency linked to weak blood brain barrier penetration and low drug specificity 
raised additional challenges in the development of such compounds144.  
 
?-Secretase is directly implicated in the generation of A? peptides. Thus, inhibiting its enzymatic 
activity to abolish A? production emerged as a promising opportunity to treat AD, but clinical trials 
were halted due to strong adverse effects mainly attributed to impaired Notch cleavage130–133. The 
development of Notch sparing compounds which specifically alters A? production and A?42:A?40 
ratio is believed to be safer options to treat AD, and are currently tested in clinical trials145,146. 
Alternatively, activation of the major ?-secretase ADAM10147 competes with A? production and 
increases production of neuroprotective sAPP?. This protease can be stimulated by upstream M1 
muscarinic receptor activation and lower A?148,149. The development of M1 chemical activators was 
hampered by the difficulty of generating specific compounds and render this approach risky, 
especially because ?-secretase activation effects remain unknown. To bypass pharmacokinetic 
challenges faced by the pharmacological inhibition of secretases, other mechanisms were targeted 
with the aim of lowering A? peptides or senile plaques, including immunotherapies150,151, anti-
aggregation compounds152,153, and stimulation of A? degradation/clearance154–156 as well as 
autophagy-mediated APP degradation157 (fig. 8). 
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Figure 8: AD therapeutic strategies. Current AD therapeutic strategies can be divided into 3 major 
groups depending on their targets: alteration of A? levels and aggregation (blue), inhibition of A? –
mediated NFT formation and neuronal death (green), and rescue of disrupted cell homeostasis 
(purple). Modified from 158. 
 
 
The second step in AD pathogenesis corresponds to the A?-mediated activation of signaling 
pathways (reviewed in 159) affecting the activity of Tau kinases (cdk5, JNK and GSK3?) and 
phosphatases (protein phosphatase PP2A, calcineurin) (Fig. 8). This enzymatic dysregulation leads 
to Tau hyperphosphorylation, NFT formation, and caspase-mediated cell death (Fig. 4). Despite the 
fact that that every single step of this toxic cascade has been pharmacologically targeted, including 
Tau phosphorylation/aggregation160–162 as well as caspase163,164 and cell death inhibitors165–167, no 
significant improvement in the cognitive functions of treated AD patient has been observed so 
far159. 
 
A?-induced neuroinflammation and metabolic dysregulation are observed in AD brains, and 
strongly participate to cognitive impairment and neuronal death (Fig. 8). Their therapeutic potential 
was confirmed by the identification in genome-wide association studies of inflammatory (eg. 
Chemokine ligand, interleukin receptor, the triggering receptor expressed on myeloid cells TREM2) 
as well as metabolic messengers (eg. cholesterol/triglycerides levels, apolipoprotein E) as risk factor 
23
 
 
for AD168–172. Failure of well-known non-steroidal anti-inflammatory drugs to improve cognition in 
AD patient suggested a preventive use of these compounds rather than a treatment, or can be 
explained by a lack of efficacy to prevent microglial activation173,174. Interfering with the 
metabolism appeared less challenging, cholesterol and lipid lowering compound developed for 
diabetes were “recycled” for AD clinical trials. These trials included cholesterol synthesis inhibitors 
such as statins or the insulin sensitivity modulator rosiglitazone, but did not show significant 
benefits in AD patients174,175. A final approach attempted to restore brain integrity by replacing dead 
neurons by newborn cells, either by promoting endogenous stem cell division, or by 
transplantation176. This approach has only been tested on mice models, but its potential may be 
considered for AD treatment176. 
 
Although the high amount of therapeutic strategies and drugs tested against AD, no treatment has 
been proving its efficacy. It should be considered that all these treatments were done on MCI and 
demented AD patients, where maximum plaque load and strong neurodegeneration are present. 
Recent refining of selection criteria for clinical tests (early preclinical AD patients, ApoE4 allele, 
depicted in 177) supplemented by drug optimization offers great opportunities for next the generation 
clinical trials. 
 
 
I.8) Aim of the thesis work 
In the first part of this thesis work (Chapter II), we aimed at modulating the enzymatic activity of ?-
secretase, and investigate the physiological functions of this enzyme. Endogenous modulation of ?-
secretase affects the genesis of A? and is considered as potent therapeutic strategy. For this reason 
we searched for ?-secretase interacting proteins, and identified 3 new endogenous modulators of A? 
production. In parallel, we focused on the post translational modifications of ?-secretase, and 
assessed the effect of PS phosphorylation on the maturation and enzymatic activity of the ?-
secretase complex. Modulating ?-secretase may influence the downstream signaling of its numerous 
substrates. Notably, ?-secretase is implicated in synaptic plasticity, which require the recruitment of 
the actin cytoskeleton. Hence we investigated the influence of ?-secretase on the regulation of the 
actin-depolymerizing protein Cofilin. 
 
In the second part of this thesis work (Chapter III), we aimed at monitoring brain structure 
alterations and repair damage caused by neuronal death in neurodegenerative diseases. We 
implanted microelectrodes in mice brain and visualized brain nuclei by measuring the electrical 
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impedance of the tissue. Next, we used this method to detect A? plaques in the brain of a mouse 
model of AD. In another project, we further developed a neurotrophic extracellular matrix-like 
polymer to promote neuronal repair in the brains of patients affected by neurodegenerative 
disorders. 
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Chapter II 
Modulation and physiological 
functions of ?-secretase 
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II.1) Introduction 
II.1.a) Endogenous modulators of A? production 
?-Secretase processing of C99 is the last step before the release of A? peptides, believed to initiate 
the pathological cascade of AD. Also, ?-secretase controls the pathophysiological-relevant 
A?42:A?40 ratio, the increase of which is believed to play a central role in the disease42,71. In vivo 
inhibition of ?-secretase induces strong adverse effects mainly attributed to impaired Notch 
cleavage130–133. Thus clinical research focused on Notch-sparing chemical molecules able to 
specifically affect APP processing (Notch sparing compounds), and decrease A?42:A?40 ratio145,146. 
In addition to these investigations which focus on chemical compounds, the identification of 
endogenous ?-secretase interacting protein affecting the generation of A? would also raise great 
therapeutic potential. Yet, only TMP21178 and the highly controversed ?-secretase activating protein 
GSAP179,180 have been suggested to be physically associated with the ?-secretase complex and 
modulate its enzymatic activity. 
 
Other groups focused on APP interacting proteins that affect its trafficking and consequently its 
cleavage by the secretases. A growing list of proteins fulfill these functions, among them the sorting 
protein-related receptor sorLA181, X11182, and the AICD-binding protein Fe65183 184. Autophagy is 
also known to be altered in AD brain63. Thus, more recent findings focused on regulators of APP 
degradation and led to the identification of the autophagy regulator Beclin1185 and the autophagy 
cargo receptor AP2186. So far, none of these APP/?-secretase interacting proteins have been 
validated as a therapeutic targets in clinical research. 
 
In the first manuscript described in this PhD thesis (see manuscript page 31), we aimed at 
identifying new ?-secretase interacting proteins able to specifically modulate the production of A? 
peptides. In contrast to ?-secretase inhibitors, endogenous ?-secretase modulating proteins do not 
interfere with the processing of other substrates. Also, we studied the influence of the newly 
identified ?-secretase modulators on the lysosomal/autophagic pathway. 
 
II.1.b) Effects of post-translational modifications on the enzymatic activity of ?-secretase  
Interfering with the activity of an enzyme by controlling the addition of post translational 
modifications has been widely reviewed187,188, and thus appear to be an elegant possibility for 
modulating ?-secretase activity. So far, several PTMs including phosphorylation, glycosylation and 
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palmitoylation have been identified on the ?-secretase subunits NCT, PS and Aph1. NCT complex 
N-glycosylation is required for the proper subcellular trafficking of active ?-secretase in vitro189, 
and consequently modulates A? production. In addition, recent purification of active enzyme 
lacking complex sugar motifs has been achieved recently190. In accordance with these observations, 
glycosylation of NCT was proposed to play a role in its trafficking to the plasma membrane, 
without affecting its enzymatic activity191. In contrast, serine 437 phosphorylation of this subunit by 
the Akt1 kinase or glucocorticoid-induced protein kinase 1 accelerate its degradation by the 
lysosomal and proteasomal pathways192,193.  
 
Instead of modulating ?-secretase activity, palmitoylation of Aph1 and NCT appeared to play a role 
in the subcellular localization and stability of the enzymatic complex194. PS phosphorylation has 
been highlighted by several studies demonstrating its involvement in various cellular functions 
including insulin signaling and cell survival195–197. Interestingly, PS is phosphorylated by two 
kinases implicated in Tau phosphorylation in AD, GSK3?198 and (cdk5)199, and point out a feedback 
loop for the regulation of ?-secretase activity. 
 
Because the effect of PS phosphorylation on the ?-secretase processing machinery has not been 
fully characterized, we studied the influence of this PTM on the maturation of the ?-secretase 
complex and on its enzymatic activity (see manuscript page 60). 
 
II.1.c) The role of ?-secretase in the cytoskeleton dynamics 
It is now well assumed that in AD brains, ?-secretase - via A? toxic effects - leads to NFT formation 
and breaks actin microtubule dynamics43. An emerging idea suggested that the ?-secretase complex 
may influence the cytoskeleton dynamics under physiological conditions. Indeed, impaired synaptic 
plasticity has been reported in mice overexpressing PS loss of function FAD mutation, together with 
variations in actin-binding protein levels200. It was hypothesized that synaptic activity-mediated ?-
secretase activation201 involves the remodeling of the actin cytoskeleton200, required for synaptic 
plasticity202,203. Previous studies showed that AICD affected the expression of genes related to 
cytoskeleton dynamics81, but the important players of ?-secretase-mediated actin remodeling have 
yet to be identified. 
 
Among numerous actin binding proteins, the actin depolymerizing factor (ADF)/Cofilin protein 
family comprises ADF (also known as Destin), the non-muscle type Cofilin1 and the muscle-type 
Cofilin2. This protein familyparticipates in the depolymerization of actin filaments, and 
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consequently controls the actin cytoskeleton dynamics204,205. ADF/Cofilin signaling has also been 
shown to be impaired in AD and may be involved in the disruption of the actin cytoskeleton206,207. 
The mechanisms linking AD and impaired ADF/Cofilin pathways are not yet clearly understood. 
This latter observation motivated us to study the implication of ?-secretase in the regulation of the 
Cofilin1 pathway (see manuscript page 86). 
 
 
II.2) Results 
II.2.a) The Adipocyte Differentiation Protein APMAP is an Endogenous Suppressor of A? 
Production in the Brain 
In this first manuscript (see manuscript page 31), we aimed at identifying new ?-secretase 
interacting proteins able to modulate the production of A?, without altering the levels and 
processing of other ?-secretase substrates. We characterized by LC-MS/MS mass spectrometry the 
proteome of highly purified ?-secretase, and identified the adipogenesis-related protein APMAP 
(adipocyte plasma membrane associated protein, APMAP), Reticulon4 and Tetraspanin6 as new ?-
secretase interacting proteins. We further demonstrated that APMAP is an endogenous suppressor of 
A? both in vitro and in vivo, by interacting physically with the ?-secretase complex and its substrate 
APP. Importantly, APMAP did not affect the cleavage of other ?-secretase substrates. Interestingly, 
partial depletion of APMAP in cells increased the levels and affected the length of APP-CTFs. 
Lysosomal inhibition experiments suggested a role for APMAP in the transport/degradation of APP-
CTFs through the lysosomal/autophagic pathway. 
 
In this study, I first screened and validated the ?-secretase associated proteins that affect APP 
processing, by siRNA and overexpression experiments. Then, I performed cell culture and 
biochemical analyses, APP-CTFs mass spectrometry analysis, cell-free ?-secretase activity assays, 
mouse primary cortical neurons and immunofluorescence analyses, subcloning and shRNA/siRNA 
design, as well as in vivo stereotaxic injections. I also participated in the experimental design. 
 
II.2.b) Identification of New Presenilin-1 Phosphosites: Implication for ?-Secretase Activity 
and A? Production 
In this study (see manuscript page 60) we questioned the importance of PS phosphorylation for the 
assembly, maturation and activity of the ?-secretase complex. We performed LC-MS/MS mass 
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spectrometry analysis on the purified active ?-secretase complex, and identified 15 PS1 
phosphorylated peptides corresponding to 12 single and 3 double PS1 phosphosites. Among them, 4 
phosphosites have already been investigated by other research groups. Interestingly, no 
phosphorylation has been detected on the other ?-secretase subunits NCT, Aph1 or PEN2. We 
focused our study on the 11 newly identified phosphosites including 8 single and 3 double PS1 
phosphorylation. Our cell-free ?-secretase activity assays performed with the PS1 phospho-mutants 
revealed no changes in the maturation or enzymatic activity of ?-secretase. 
 
In this manuscript, I performed cell free ?-secretase activity assay in SH-SY5Y cells, and performed 
experiments in HEK-N7 cells (supplementary figure 7 and 8, see pages 84 and 85). 
 
II.2.c) Inactivation of Brain Cofilin-1 by Age, Alzheimer's Disease and ?-Secretase 
In this study we aimed at understanding the implication of ?-secretase in the regulation of the 
Cofilin1 pathway (see manuscript page 86) which participates in the depolymerisation of actin 
filaments. We found an increased phosphorylation/inactivation of Cofilin1 in human AD brains, as 
well as in the brain of the AD mouse model APPPS1208. Similar observations were made in aged 
WT mice and in aged mouse primary cortical neurons. In contrast, decreased 
phosphorylation/inactivation of Cofilin1 was detected following the inhibition of ?-secretase 
enzymatic activity. Moreover, we showed that these changes in phosphorylation/inactivation state of 
Cofilin1 were mainly induced by variations in the phosphatase activity of slingshot1 (SSH1). 
Finally, age-related morphological changes as well as ?-secretase enzymatic activity inhibit SSH1, 
thus increasing the phosphorylation/inactivation of Cofilin1, and affecting actin cytoskeleton 
dynamics. 
 
In this study, I prepared mouse primary cortical neurons and performed western blot analyses of 
supplementary figure 1 and 10 (see pages 98 and 110). 
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The adipocyte differentiation protein APMAP
is an endogenous suppressor of Ab production
in the brain
Sebastien Mosser, Jean-Rene´ Alattia, Mitko Dimitrov, Alexandre Matz, Justine Pascual,
Bernard L. Schneider and Patrick C. Fraering∗
Brain Mind Institute and School of Life Sciences, Ecole Polytechnique Fe´de´rale de Lausanne (EPFL),
Lausanne CH1015, Switzerland
Received July 11, 2014; Revised and Accepted August 26, 2014
The deposition of amyloid-beta (Ab) aggregates in the brain is a major pathological hallmark of Alzheimer’s
disease (AD). Ab is generated from the cleavage of C-terminal fragments of the amyloid precursor protein
(APP-CTFs) by g-secretase, an intramembrane-cleaving protease with multiple substrates, including the
Notch receptors. Endogenous modulation of g-secretase is pointed to be implicated in the sporadic, age-
dependent formofAD.Moreover, speciﬁcallymodulatingAbproductionhasbecomeapriority for the safe treat-
ment of AD because the inhibition of g-secretase results in adverse effects that are related to impaired Notch
cleavage. Here, we report the identiﬁcation of the adipocyte differentiation protein APMAP as a novel endogen-
ous suppressor of Ab generation.We found that APMAP interacts physically with g-secretase and its substrate
APP. In cells, the partial depletion of APMAP drastically increased the levels of APP-CTFs, as well as uniquely
affecting their stability, with the consequence being increased secretion of Ab. In wild-type andAPP/ presenilin
1 transgenicmice, partial adeno-associated virus-mediated APMAP knockdown in the hippocampus increased
Ab production by∼20 and∼55%, respectively. Together, our data demonstrate that APMAP is a negative regu-
latorofAbproduction through its interactionwithAPPandg-secretase.AllobservedAPMAPphenotypescanbe
explained by an impaired degradation of APP-CTFs, likely caused by an altered substrate transport capacity to
the lysosomal/autophagic system.
INTRODUCTION
In the neurodegenerative amyloid cascade of Alzheimer’s
disease (AD), quantitative andqualitative changes in the produc-
tion of amyloid-beta (Ab) peptides and their aggregation into
senile plaques precede the formation of neuroﬁbrillary tangles
and initiate the pathological process causing the disease (1,2).
Neurotoxic Ab peptides are generated by successive cleavages
of the amyloid precursor protein (APP) by b- and g-secretases.
APP is ﬁrst processed by the b-secretase BACE1, leading to
the formation of a 99-amino-acid longAPPC-terminal fragment
(APP-C99 or APP-CTFb). The cleavage of APP-CTFb by
g-secretase liberates Ab peptides that are 38–43 amino acids
in length, with Ab42 being a major component of the senile
plaques (3). Yet, APP is mainly cleaved within the Ab region
by thea-secretases ADAM10/17 to release APP-CTFa, the pro-
cessing ofwhich byg-secretase results inN-terminally truncated
and non-toxic Ab peptides. g-Secretase is a ubiquitously
expressed membrane protease complex that processes a long
list of type I transmembrane proteins, including APP, the
Notch-1 receptor and several synaptic cell adhesion molecules
(4–6). Active g-secretase is comprised of ﬁve protein compo-
nents: Nicastrin (NCT), Presenilin N- and C-terminal fragments
(PS-NTF and PS-CTF), Aph1 and Pen-2 (7). Because they
prevent the production of Ab peptides, g-secretase inhibitors
(GSI) have been extensively investigated in the clinic for the
treatment ofAD.However, recent humanGSI trials revealed sig-
niﬁcant side effects linked to impaired Notch cleavage (8).
Therefore, speciﬁcally modulating g-secretase and Ab produc-
tion, without interfering with other physiological processes, is
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an attractive strategy to safely treatAD (9). Because endogenous
g-secretase modulating factors are potential therapeutic targets,
but also possibly implicated in the sporadic forms of AD, we
aimed to identify new g-secretase-interacting proteins (GSPs)
that are capable of modulating Ab production.
RESULTS
Identiﬁcation of GSPs modulating Ab production
Highly puriﬁed and active g-secretase prepared from Chinese
hamster ovary (CHO) cells overexpressing the four subunits of
the protease complex (10) was resolved by blue-native gel
electrophoresis (Fig. 1A), and the band corresponding to the
complex was excised for protein content analysis by LC-MS/
MS mass spectrometry. This approach led to the identiﬁcation
of seven GSPs encoded by the genes ATP1a1, RTN4, VAMP2,
VAMP3, TSPAN6, APMAP and HSPA5 (Fig. 1A; peptides
identiﬁed by LC-MS/MS are listed in Supplementary Material,
Fig. S1). As expected from a g-secretase overexpression
system, the silver-stained SDS–PAGE of the protease prepar-
ation used for the native gel (Fig. 1A) conﬁrmed the trace
amounts of GSPs relative to the predominant g-secretase subu-
nits (Supplementary Material, Fig. S2). Because ATP1a1,
VAMP2/3 and HSPA5 had previously been reported to interact
physically with either g-secretase or APP (11,12), we focused in
our study on RTN4, APMAP and TSPAN6. RTN4 encodes for
the myelin-associated multi-pass membrane protein reticulon-4
(Nogo), a neurite outgrowth inhibitor limiting plasticity in the
healthy adult brain and neuronal regeneration during brain
injury (reviewed in13). APMAP encodes for a 415-amino-acid
long single-pass type-II glycosylated membrane protein that is
implicated in the regulation of white adipose tissue differenti-
ation (14,15). TSPAN6 belongs to the tetraspanin superfamily
of multi-pass membrane proteins interacting with multiple
immune-related molecules, including immune receptors, integ-
rins, signaling molecules and functioning as important immune
response modulators (16). The neurobiological functions of
APMAP and TSPAN6 remain unknown.
First, the expression of the RTN4, APMAP and TSPAN6
genes was reduced by small-interfering RNA (siRNA) in HeLa
cells as well as in HEK cells overexpressing APP harboring
the Swedish double mutation near the b-secretase cleavage
site (mutation resulting in increased total Ab levels; HEK-
APPSwe). In HeLa and HEK-APPSwe cells, depletion by
60% of TSPAN6 lowered APP-CTFs levels by 38 and 40%,
respectively (Fig. 1B and C). In contrast, depletion of RTN4
and APMAP (both by 75%) caused a strong accumulation of
APP-CTFs, respectively, by 181 and 286% in HeLa cells and
by 25 and 52% in HEK-APPSwe cells (Fig. 1B and C and Sup-
plementary Material, Fig. S3). This siRNA knockdown of indi-
vidual genes did not interfere with the maturation or protein
levels of a-, b- or g-secretases, with the exception of increased
ADAM10 associated with reduced RTN4 (Supplementary
Material, Fig. S4). Importantly, Ab secreted from HEK-
APPSwe cells depleted for the expression of TSPAN6, RTN4
and APMAP directly reﬂected the levels of intracellular APP-
CTFs (Fig. 1D). Indeed, siRNAs targeting TSPAN6 reduced
the levels of Ab40 by 25+ 7.5%, while siRNAs targeting
RTN4, and APMAP raised Ab40 levels by 52+ 1.8 and
60+ 10.1%, respectively (Fig. 1D). Yet, full-length APP
(APP-FL) protein levels remained unchanged in the APMAP
knockdown experiments (Fig. 1B and C and Supplementary
Material, Fig. S3). In contrast, depletion of RTN4 in both
HeLa and HEK-APPSwe cells, respectively, caused 170 and
140% increases in APP-FL levels (Fig. 1B and C).
Figure 1. Identiﬁcation of endogenous modulators of g-secretase and Ab pro-
duction. (A) Analysis by LC-MS/MS of the protein components of the highly
puriﬁed g-secretase complex. (B and C) siRNA knockdown of TSPAN6,
RTN4 and APMAP affects APP-CTFs in HeLa cells (B) and HEK cells overex-
pressingAPP bearing the Swedishmutation that causes early-onset familial Alz-
heimer’s disease (HEK-APPSwe; C). Biological duplicates are shown for each
siRNA condition. (D) Correlation between APP-CTFs levels and Ab40 produc-
tion in HEK-APPSwe cells with reduced TSPAN6, RTN4 and APMAP expres-
sion. APP-CTFs levels were estimated by densitometric analysis, while Ab40
levels were quantiﬁed by ELISA. Student’s t-test was applied for statistical
analysis; signiﬁcance is shown as mean+ SD, ∗P, 0.05; ∗∗P , 0.01; Ab40:
n ¼ 6/group; APP-CTFs: n ¼ 4/Scramble, TSPAN6and APMAP groups;
n ¼ 3/RTN4 group. b-Actin served as a protein loading control. mAPP-FL and
iAPP-FL: mature and immature APP full-length.
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Genetic inhibition of APMAP increases Ab production
We further focused on the adipocyte plasma membrane-
associated protein APMAP because (i) its knockdown displayed
the biggest variations in APP-CTFs and Ab40 (Fig. 1B–D), (ii)
its knockdown was associated with a unique effect on the stabil-
ity against proteolytic degradation of APP-CTFs (see below and
Fig. 3), and (iii) its brain functions remain unknown. First, we
conﬁrmed by ELISA and a high-resolution Tris-Tricine urea
gel that reduced APMAP expression in HEK-APPSwe cells
increased the secretion of full-length total Ab (Ab1-x),
Ab1-40 and Ab1-42 in a dose-dependent manner (Supplemen-
taryMaterial, Fig. S5), without affecting the levels or the matur-
ation of the secretases (Supplementary Material, Fig. S6). Mass
spectrometric analysis of secretedAb revealed no changes in the
Ab proﬁle (Supplementary Material, Fig. S5), suggesting that
APMAP does not affect the sequential and speciﬁc processing
of APP by g-secretase. Moreover, APMAP1 puriﬁed from
E. coli or CHO cells did not interfere with the processing of
APP-CTFb in our cell-free g-secretase activity assays, arguing
against a direct effect of APMAP on the activity of the mature
g-secretase (Supplementary Material, Figs S7 and S8). Finally,
puriﬁed APMAP1 did not prove to be a substrate for g-secretase
(Supplementary Material, Figs S7 and S8). The latter observa-
tion excludes an APP phenotype (accumulation of APP-CTFs)
caused by substrate competition, after siRNA-dependent deple-
tion of APMAP1.
APMAP is expressed in neurons and interacts physically
with g-secretase and APP
Next, the physical interaction between APMAP1 and the
g-secretase complex and APP was conﬁrmed in both HEK-
APPSwe and CHO cells overexpressing APMAP1-Flag or an
untagged control APMAP1 (Fig. 2 and SupplementaryMaterial,
Fig. S9). In these experiments, all subunits of the g-secretase
complex, as well as APP-FL and APP-CTFs, speciﬁcally and
sequentially co-sedimented and co-precipitated with APMAP1-
Flag (Fig. 2A). In sharp contrast, these proteins did not co-
precipitate with the untagged control APMAP1 (Fig. 2A).
Under our experimental conditions, other APP processing
enzymes including BACE1 or ADAM10 did not bind to
APMAP (Fig. 2A). Next, by combining immunohistochemistry
and confocal imaging, we also found that APMAP1 is highly
expressed in mouse primary cortical neurons where it adopts
an axonal and somatodendritic distribution (Fig. 2B and Supple-
mentary Material, Fig. S10). Our results further show that
APMAP partially co-localizes with Nicastrin, a subunit of the
g-secretase complex, mainly in the neuronal cell body (Fig. 2B
and SupplementaryMaterial, Fig. S10). Consistent with the pre-
dicted topology of APMAP (type-II transmembrane protein),
our data suggest that APMAP1 trafﬁcs via the secretory
pathway to the plasma membrane and adopts a somatodendritic
cellular distribution.We further found thatAPMAP co-localizes
partiallywithAPP-FL/APP-CTFs, both in cytosolic and neuritic
cellular compartments (Fig. 2B and Supplementary Material,
Fig. S10).Altogether, these data support the existence of neuron-
al high molecular weight complexes made of APMAP and
g-secretase, APMAP and APP-FL/CTFs, and possibly all three
components.
APMAP controls the levels and stability of APP C-terminal
fragments
Further supporting an association with APP, we found that
partial depletion of APMAP in HeLa cells altered the proﬁle of
endogenous APP-CTFs. As observed on a high-resolution Tris-
Tricine urea gel, APMAP siRNA combinedwith low concentra-
tions of the GSI DAPT led to the generation of three distinct
forms of APP-CTFa (CTFa1, a2 and a3), with two forms
migrating with apparent sizes of 8.5 and 8.0 kDa, instead of
9.0 kDa (Fig. 3A). The mass spectrometric characterization of
APP-CTFa1-3 (APP-C80,C74 andC71; Fig. 3B andC andSup-
plementary Material, Fig. S11) further suggested that endogen-
ous APP-CTFs undergo either partial degradation by yet
unknown proteases or further proteolytic processing [possibly
by BACE2 (17)], supporting a possible APP stabilization func-
tion for APMAP.
APMAP modulates Ab production in WT and Alzheimer’s
mice
Next, and to determine whether our ﬁndings are relevant in vivo,
we induced the partial knockdown ofAPMAP inwild-typemice
and transgenic APP/ presenilin 1 (PS1) Alzheimer’s mice. Five
week-old mice (males and females) were bilaterally injected in
the dorsal hippocampus with serotype 9 adeno-associated viral
vectors (AAV9) encoding shRNAs targeting APMAP (Fig. 4A
and C and Supplementary Material, Figs S12 and S13). As
recently demonstrated by Aschauer et al. (18), AAV9 vectors,
when injected in the hippocampus, have a generally broad
tropism for many different brain cell types, including oligoden-
drocytes, microglia, astrocytes and neurons (including inhibi-
tory neurons). In our study, four weeks post-hippocampus
injection, the global expression of APMAP was reduced by
50% in male WT mice (Fig. 4B) and by 35% in male APP/
PS1 mice (Fig. 4D), whereas Ab production was increased by
20% in male WT mice (Fig. 4B) and by 55% in male APP/
PS1mice (Fig. 4D). Interestingly, under our experimental condi-
tions, no signiﬁcant effect onAbproductionwas found in female
mice (Supplementary Material, Fig. S13), which may be linked
to the weaker APMAP knockdown observed in these animals
(APMAP knockdown by 35% in female WT mice and by
25% in female APP/PS1 mice). Finally, APMAP depletion
in the brain of WT and AD mice does not seem to affect
APP-CTF levels (Fig. 4B and D), in contrast to HeLa and
HEK-APPSwe cells (Fig. 1B and C). This apparent discrepancy
may result from the weaker APMAP knockdown in mice (by
35–50%), when compared with that observed in HeLa and
HEK-APPSwe cells (by 75%). In support of this explanation,
the dose-dependent reduction ofAPMAP inHEK-APPSwe cells
revealed a critical step for APMAP depletion (50% depletion,
0.2 nMAPMAP siRNA), abovewhich small changes inAPMAP
expression are associated with big changes in APP-CTFs accu-
mulation (Supplementary Material, Fig. S14).
APMAP modulates APP-CTFs through the lysosomal
pathway
Finally, we investigated whether the main APMAP phenotype,
namely co-increases of both APP-CTFs and Ab after APMAP
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Figure 2. APMAP interacts physically and co-localizes with g-secretase, APP-FL and APP-CTFs. (A) Velocity co-sedimentation and co-immunoprecipitation of
APMAP with the g-secretase complex, APP-FL and APP-CTFs. Total membrane protein extracts from HEK-APPSwe cells transiently overexpressing
hAPMAP1 or hAPMAP1-Flag were sedimented on an 18–28% glycerol gradient containing 0.1% CHAPSO. Each fraction was collected and analyzed by
western blot for APMAP1, APP-FL, APP-CTFs and mature and immature g-secretase (top panels). Next, proteins interacting with hAPMAP1-Flag (Flag) were
afﬁnity-precipitated in the fractions labeled in red with M2 anti-Flag afﬁnity resin (lower panel). Untagged APMAP (hAPMAP1, also labeled ‘-’ in the ﬁgure)
served as a control for the speciﬁc co-precipitation. (B) Immunohistochemical co-localization of APMAP (green) with the g-secretase subunit Nicastrin (red,
upperpanel) orAPP (red, lowerpanel) in 14days in vitromouseprimarycortical neurons.Scale bar: 10 mm.Both confocal images (left panels) andZ-stackprojections
(right panels) are shownwith amicroscopeobjectivemagniﬁcationof 40×. For comparison, un-merged images forAPMAP,NCT,APP-CTFs andDAPI are shown in
Supplementary Material, Fig. S10. mNCT and iNCT, mature and immature Nicastrin.
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knockdown, could be explained by an impaired degradation of
APP-CTFs through the lysosomal–autophagic pathway. To do
so, a pharmacological approach was used, by taking advantage
ofChloroquine, awell-known inhibitor of the lysosomal–autop-
hagic pathway. Chloroquine is a lysosomotropic agent that
impedes the lysosomal pathway by inhibition of lysosomal
enzymes and lysosomal protein degradation, and by preventing
the fusion of endosomes and lysosomes (19). Chloroquine,
because it raises the lysosomal pH, also inhibits autophagy
(20). To test whether APMAP can regulate the levels of
APP-CTFs through the lysosomal pathway, HEK-APPSwe
and HeLa cells were incubated for 12 h with, respectively, 25
and 50 mM Chloroquine, in the presence of APMAP or after
APMAP depletion. As shown in Fig. 5A and B, Chloroquine
treatments in the presence of APMAP (scramble siRNA) were
associated with a 2.1-fold increase of APP-CTFs in
HEK-APPSwe cells and a 3.4-fold increase of the same proteins
in HeLa cells, when compared with DMSO-treated controls.
This observation clearly supports a lysosomal degradation of
the APP-CTFs in these two cell types. Interestingly, APMAP
depletion strongly reinforced the Chloroquine-dependent accu-
mulation of APP-CTFs. The densitometric analysis of the
western blots indeed revealed additional 2.2-fold and 1.6-fold
increases of APP-CTFs in HEK-APPSwe and HeLa cells
co-treated with Chloroquine and the APMAP siRNA, when
compared with cells co-treated with Chloroquine and the
scramble siRNA. The latter observation is consistent with a
Chloroquine- and APMAP-dependent synergistic effect pos-
sibly caused by reduced lysosomal degradation and reduced
lysosomal transport of APP-CTFs.
Altogether, our data suggest that APMAP modulates the
levels of APP-CTFs through the lysosomal–autophagic system.
DISCUSSION
In this study,weanalyzed theprotein compositionof highlypuri-
ﬁed and active g-secretase complexes and identiﬁed seven pro-
teins that interact physically with the enzymatic complex.
Among these proteins, TSPAN6was found to positively regulate
Figure 3. APMAP controls the levels and the stability of APP-CTFs. (A) siRNA knockdown of APMAP in HeLa cells quantitatively and qualitatively impacts
APP-CTFs. Reduced APMAP expression correlates with increased APP-CTFs and the formation of three forms of APP-CTFa (CTFa1, a2 and a3), as revealed
on a Tris-Tricine urea gel (left panel). This phenotype is further ampliﬁed in the presence of 1 mM GSI DAPT (right panel). Biological triplicates are shown. (B)
MALDI-TOF mass spectrometric analysis of APP-CTFa1, a2 and a3 immunoprecipitated from DAPT-treated cells with siRNA-reduced APMAP expression.
(C) Peptide sequences of N-terminal truncated APP-CTFa1 (C80), -CTFa2 (C74) and -CTFa3 (C71).
Human Molecular Genetics, 2015, Vol. 24, No. 2 375
35
the processing of APP and the production of Ab, consistent with
previous work on tetraspanins TSPAN12, TSPAN28 and
TSPAN29 (12,21). Another of our proteins identiﬁed to be asso-
ciated with the g-secretase complex is RTN4, which has been
shown previously to negatively regulateAb production by inter-
acting with the b-secretase BACE1 (22). We conﬁrmed this
effect, as reduced RTN4 led to increased Ab production
(Fig. 1D) and suggest for the ﬁrst time that the Ab-suppressing
function of RTN4 may also be based on a physical interaction
with the g-secretase complex.
Importantly, we further identiﬁed the adipocyte differenti-
ationproteinAPMAP (15) as anendogenous inhibitor ofAbpro-
duction that binds to both APP and g-secretase, and controls the
levels and the stability of APP-CTFs. Additionally, APMAP
does not affect the processing of other g-secretase substrates,
including the Notch receptor, and the neuronal cell adhesion
molecules Neurexin-3b and Neuroligin-1 (Supplementary Ma-
terial, Fig. S15). Consistent with the Allen Brain and Human
Protein Atlases (Supplementary Material, Fig. S16), we further
showed that APMAP is expressed in the brain, and more specif-
ically in neuronswhere it co-localizes at least partially withAPP
and g-secretase (Fig. 2B). In mice, APMAP knockdown in both
neuronal and glial cells (18; Fig. 4A and C) increased Ab levels
in the hippocampus 4 weeks after injection of the AAV9 with
shRNAs targeting APMAP (Fig. 4). Yet, a decade of research
on which forms and structures of Ab impair neuronal functions
has concluded that (i) small and diffusible assemblies of mis-
folded and self-aggregatingAb peptides are probably the princi-
pal cytotoxic forms, but also that (ii) insoluble amyloid ﬁbrils
and the amyloid plaques cause neuritic alterations including a
Figure 4. APMAP modulates Ab production in vivo. Five-week-old wild-type (A and B) or APP/PS1 transgenic (C and D) male mice were injected in the dorsal
hippocampus with AAV9 expressing APMAP shRNA or a scrambled control shRNA, together with a GFP reporter. Four weeks post-injection, AAV9 transduction
is highly efﬁcient and is mainly restricted to the hippocampus (A and C). Wild-type (B) or APP/PS1 (D) males displayed signiﬁcant 50% and 35% decreases of
APMAPexpression (mean+ SD; ∗∗∗P, 0.001;n ¼ 6/group), associatedwith signiﬁcant20 and55% increases in totalAb levels in the hippocampus (∗P, 0.05;
∗∗P, 0.01; n ¼ 6/group). Student’s t-test was applied for the statistical analysis. b-Actin served as a protein loading control. (A and C) Scale bar: 500 mm.
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decreased efﬁciency of neurotransmission (reviewed in 23).
Whether APMAP preferentially affects the production of
soluble Ab assemblies or the deposition of Ab plaques
remains unknown and will require speciﬁc and long-term inves-
tigations in AD transgenic mice.
At the molecular level, APP is cleaved into sAPP-a and
CTF-a by a-secretase or cleaved into sAPP-b and CTF-b by
b-secretase. Then, g-secretase cleaves CTF-a into secreted
24–26 residues long P3 peptides and cytoplasmic APP-
intracellular domain (AICD), and cleaves CTF-b into 38–43
residues long Ab peptides and AICD. Under physiological con-
ditions, APP processing by g-secretase is associated with
increased Ab production and reduced CTFb levels. In contrast,
if a molecule inhibits g-secretase, reduced Ab production is
associated with increased CTFb levels. In our study, depletion
of APMAP led to both increases of Ab and CTFs (Figs 1 and
3). Moreover, depletion of APMAP did not affect the levels of
sAPP-a or sAPP-b (Supplementary Material Figs 4 and 6), or
the expression of APP-FL (Figs 1 and 3), suggesting that (i) a-
andb-secretases are not targets for APMAP, and (ii) both cleav-
age and production of APP-FL are not affected by APMAP. All
observed phenotypes including the co-increases of APP-CTFs
and Ab after APMAP knockdown could be explained by an
impaired degradation ofAPP-CTFs (depicted in Fig. 6). This hy-
pothesis is supported by the observation that APMAP depletion
caused an increased accumulation of APP-CTFs in cells treated
with Chloroquine, a well-known inhibitor of the lysosomal–
autophagic pathway (Fig. 5).
In themolecular hypothesis proposed in Figure 6,APMAP, by
interacting physically with APP-CTFs (Fig. 2), would promote
the transport of these substrates from the endosomes to the lyso-
somes, with the consequence being their degradation, thus redu-
cing both APP-CTFs and Ab levels. Indeed, it has been
previously reported that APP-CTFs can be delivered to the lyso-
somes by two pathways: the endosomal–lysosomal pathway
(heterophagy) and the authopagic pathway, causing the degrad-
ation of the Ab precursor proteins (24–26). Similar to the phe-
notypes observed in our study with reduced APMAP, genetic
or pharmacological inhibition of the lysosomal–autophagic
system led to the signiﬁcant intracellular accumulation of
APP-CTFs and increased Ab secretion (27,28). Thus, APMAP
depletion would lead to impaired degradation, with the conse-
quence being both increases of APP-CTFs and Ab. Moreover,
impaired APP-CTFs degradation would make these g-secretase
substrates accessible to yet unidentiﬁed proteases and trigger
their proteolysis (Fig. 3). Alternatively, and still by interacting
physically with APP-CTFs, APMAP could also transport these
substrates to the g-secretase complex, explaining the possible
physical interaction between APMAP, APP-CTFs and the
enzyme (Fig. 2). Since abnormalities in the neuronal lyso-
somal–autophagic system have been associated with the path-
ology of AD (reviewed in 29), understanding the precise
Figure 5. APMAP regulates cellular APP-CTFs levels through the lysosomal–autophagic pathway. HEK-APPSwe (A) and HeLa (B) cells treated either with a
scrambled control siRNA or with APMAP siRNAwere incubated for 12 h with the lysosomal inhibitor Chloroquine (25 and 50 mM, respectively). Total membrane
protein extractswere preparedand analyzedbywestern blot forAPMAP1,APP-FLandAPP-CTFs (left panels).Biological duplicates are shownandb-actin servedas
a protein loading control. Next, APP-CTFs bands were quantiﬁed by densitometry (right panels) and Student’s t-test was applied for statistical analysis with n ¼ 4/
group. ∗∗P , 0.01; ∗∗∗P , 0.001.
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molecularmechanisms bywhichAPMAPcan regulateAPP-CTFs
degradation deserves further investigation.
Yet, APP-CTFs do not seem to only be degraded through the
lysosomal–autophagic system. Indeed, Bustamante et al. (30)
have recently demonstrated in human H4 neuroglioma cells
that APP-C99 is actively degraded in the endoplasmic reticulum
in an ubiquitin and proteasome-dependent manner. Whether
APMAP can play an active role in the proteasome-dependent
degradation of APP-CTFs (including a crosstalk between the
lysosomal and proteasomal systems) also requires further
investigation.
APMAP also controls adipogenesis and consequently the
adipocytic release of potential g-secretase modulators, includ-
ing leptin (31,32) and cholesterol (33–35). Moreover, the
Figure 6.Molecular hypothesis for the regulation of APP-CTFs/Ab levels byAPMAP. In this hypothesis, APMAP is implicated in the transport of APP-CTFs to the
lysosomal–autophagic system,where it undergoes substratedegradation.Consistentwith theobservedcellular phenotypes (Figs 1 and3), depletionofAPMAPwould
impair this transport capacity and consequently trigger increasedAPP-CTFs levels,which in turn cause increasedAb production. Impaired degradationwould further
make APP-CTFs substrates accessible to yet unidentiﬁed proteases, explaining the N-terminal truncated species observed in cells with depleted APMAP (Fig. 3).
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expression of APMAP is regulated by the peroxisome prolifer-
ation-activated receptor PPARg (14,15), which has also been
shown to decrease Ab production (36). In return, the processing
of Notch by g-secretase inhibits PPARg and adipocyte differen-
tiation (37). Thus, reducing Ab production by interfering with
the PPARg/APMAP/g-secretase regulatory loop could poten-
tially represent a therapeutic approach to slow down the path-
ology of AD. Moreover, APMAP, by participating in the gut/
adipose tissue/brain crosstalk and regulating cerebral Ab
levels, could possibly provide new molecular insight into the
statistical link between AD and obesity or diabetes.
MATERIALS ANDMETHODS
g-Secretase puriﬁcation, tryptic digestion and mass
spectrometry
The g-secretase complex was puriﬁed as previously described
(10) and was run on a NativePAGE Novexw Bis–Tris 4–16%
gel for BN-PAGE analysis (Invitrogen, Carlsbad, CA, USA).
Next, the complex was visualized by Coomassie staining,
excised and cut into small pieces. Proteins were reduced, alky-
lated and subjected to in-gel digestion with trypsin. Brieﬂy, gel
pieces were destained, desiccated by incubating twice in
200 ml of 50 mM ammonium bicarbonate and 50% ethanol for
20 min and dried with a vacuum concentrator. The samples
were then incubated overnight at 378C with trypsin (12.5 ng/ml).
For liquid chromatography coupled to tandem mass spectro-
metry (LC-MS/MS) analysis after extraction from gel slices,
peptides were resuspended in 2% Acetonitril/0.1% Formic
Acid and separated by reverse-phase chromatography on a
Dionex Ultimate 3000 RSLC nanoUPLC system connected
in-line with an Orbitrap Elite (Thermo Fischer Scientiﬁc,
Waltham, MA, USA). The instrument was operated in an
information-dependent mode where peptide masses were
selected for collision-induced dissociation to generate tandem
mass spectra. A database search was performed using Mascot
2.3 (Matrix Science, Boston, MA, USA) and SEQUEST in
Proteome Discoverer v.1.3 against a human database (UniProt
release 2013_01; 87613 sequences) and Mammalian database
(UniProt release 2011_07; 91104 sequences). All searches
were performed with trypsin cleavage speciﬁcity, with up to
three missed cleavages allowed, an ion mass tolerance of
10 ppm for the precursor and 0.5 Da for the fragments. Carbami-
domethylation was set as a ﬁxed modiﬁcation, whereas oxida-
tion (M), acetylation (protein N-term) and phosphorylation
(STY) were considered variable modiﬁcations. Data were
further processed and inspected using Scaffold 3 software
(Proteome Software).
Cell lines, cell cultures and treatments with siRNA or GSI
Human embryonic kidney cells (HEK 293T), human cervical
carcinoma cells (HeLa) and CHO cells were routinely grown
in DMEM with 10% fetal bovine serum and penicillin/strepto-
mycin in a humidiﬁed 5% CO2 atmosphere. The CHO cells
stably expressing Flag-tagged APMAP and the HEK cells
stably expressing APP with the Swedish mutation [HEK-
APPSwe (38)] were maintained in DMEM with 10% FBS sup-
plemented with 150 mg/ml Geneticin G418 (Gibco, Thermo
Fischer Scientiﬁc). HEK cells stably expressing the g-secretase
substrateNotchDE[HEK-N7 (39)]were cultured inDMEMwith
10% FBS supplemented with 250 mg/ml Zeocin (Gibco). For
siRNA knockdown experiments, cells were treated for 3 days
with allstar negative control siRNA (Qiagen, Germantown,
MD, USA), APMAP (5′-TTCACCGATTCTAGCAGCAA
A-3′, Qiagen), RTN4 (5′-CAGGGCATATCTGGAATCTGA-
3′, Qiagen) orTspan6 (5′-CTCTCGTGCCATAACAAATAA-3′,
Qiagen) siRNA duplexes complexed with Lipofectamine
RNAiMax from Invitrogen. ForAb peptides secreted in the con-
ditionedmediumofHEK-APPSwe cells, Ab1-X (IBL), Ab1-40
(Invitrogen) and Ab1-42 (Invitrogen) were quantitatively mea-
sured by ELISA, according to the protocol provided by the
manufacturer. For inhibition of cellular g-secretase activity,
cells were incubated for 4 h with 10 mM of the g-secretase-
speciﬁc inhibitor N-[N-(3,5-diﬂuorophenacetyl)-L-alanyl]-S-
phenylglycine t-butyl ester (DAPT; Sigma-Aldrich, GmbH,
Buchs, Switzerland). For inhibition of the lysosomal pathway,
HEK-APPSwe and HeLa cells were incubated for 12 h with 25
and 50 mM of Chloroquine (Sigma-Aldrich), respectively.
Western blotting and antibodies
Whole cell extracts were prepared in 50 mMHEPES buffer con-
taining 1% NP40 and complete protease inhibitor cocktail
(Roche Applied Sciences, Basel, Switzerland) and were sepa-
rated by electrophoresis on homemade 12% acrylamide Tris-
glycine SDS–PAGE or NuPAGE Novexw 4–12% Bis–Tris
gels (Invitrogen) for SDS–PAGE analysis of APMAP puriﬁca-
tion and g-secretase activity. High separation of APP-CTFs or
Ab peptides was resolved using 15% acrylamide and 6 M urea
Tris-Tricine SDS–PAGE as described previously (40) or by a
Tris-bicine-urea gel (41), respectively. Proteinswere transferred
onto nitrocellulose membranes and probed with antibodies
against APP-FL and APP-CTFs (CT15, Sigma-Aldrich, Saint
Louis, MS, USA), as well as sAPPa (6E10; Covance, Berkeley,
CA, USA) and total sAPP (22C11; Millipore, Billerica, MA,
USA), NCT (N1660 or NCT164, BD Bio-Sciences, Bedford,
MA, USA), PS1-NTF (MAB1563, Chemicon International,
Temecula, CA, USA), PS1-CTF (MAB5232, Chemicon Inter-
national), Aph1 (O2C2, Covance), Pen-2 (UD1, a gift from
Helena Karlstro¨m, KI Stockholm, Sweden), ADAM10 (Prosci,
Poway, CA, USA), BACE1 (EE17, Sigma-Aldrich), APMAP
(4F6, AbCam, Cambridge, UK), RTN4 (Ab2, Sigma-Aldrich),
Tspan6 (AbCam), Notch-ICD (Val1744, Cell Signaling,
Boston, MA, USA) or b-actin (Sigma-Aldrich). Anti-mouse,
rabbit and rat IgGs conjugated to Alexa 680 were purchased
from Invitrogen, and the Odyssey infrared imaging system
(LICOR, Lincoln, NE, USA) was used to detect the ﬂuorescent
signal.
Glycerol gradient velocity sedimentation and
co-immunoprecipitation
Membranes were prepared by osmotic shock from HEK-
APPSwe cells transiently expressing either Flag-tagged or
untagged human APMAP1, as previously described (4). Next,
membrane proteins solubilized in 1% CHAPSO were loaded
onto an 18–28%glycerol gradient containing 11 × 950 ml frac-
tions prepared in 0.1%CHAPSO.After centrifugation for 15 h at
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220 000g, 950 ml fractions were collected and analyzed by
western blotting. For co-immunoprecipitation experiments, all
fractions collected after glycerol velocity sedimentation were
diluted twice with 0.2% digitonin in Tris-buffered saline
(TBS) and incubated with 50 ml of M2 resin (Sigma-Aldrich)
at 48C overnight. The beads were then washed three times for
15 min in TBS with 0.1% digitonin and collected in 50 ml of
diluted (1:2 in water) Laemmli sample buffer.
Immunostaining
Mouse primary cortical neurons were prepared from embryonic
day17Of1 fetalmousebrains.Corticeswere digested inmedium
containing papain (20 U/ml, Sigma-Aldrich) and dissociated by
mechanical trituration. Cells were plated in the neurobasal
medium (Invitrogen) supplemented with B27 (Invitrogen) and
2 mMGlutamax (Life Technologies, Thermo Fischer Scientiﬁc)
on poly-L-ornithine (Sigma-Aldrich)-coated plates at 378C in a
humidiﬁed 5% CO2 atmosphere. At in vitro day 14, neurons
were ﬁxed with 4% paraformaldehyde and permeabilized in
phosphate buffered saline (PBS) containing 0.1% Triton
X-100 for 10 min. The cells were then incubated in citrate
buffer (10 mM sodium citrate, 0.05% Tween-20, pH 8.0) for
30 min at 95–1008C. After cooling at room temperature, non-
speciﬁc antibody binding was prevented by incubation in
0.25% cold water ﬁsh gelatin (Sigma-Aldrich) diluted in PBS
for 45 min. Following the blocking step, the cellswere incubated
with antibodies against APMAP (GTX46051, Gentex, Irvine,
CA,USA),APP-CTFs (4G8,AbCamCambridge,UK) orNicas-
trin (NCT164, BD Bio-Sciences, Franklin Lakes, NJ, USA).
Finally, the ﬁxed cells were incubated with anti-rabbit Alexa
488 and anti-mouse Alexa 568 (Invitrogen) secondary anti-
bodies. Image acquisition was performed with a Zeiss
LSM700 UP2 microscope using a 40× objective.
Immunoprecipitation-mass spectrometry (IP-MS) analysis
of Ab and APP-CTFs
Ab secreted fromHEK-APPSwe cells treatedwith scrambled or
APMAP siRNAs were immunoprecipitated overnight using the
monoclonal anti-Ab antibody 4G8 (AbCam) and protein
G-coupled agarose (Roche Applied Sciences). Ab was eluted
using a 1:20:20 (vol:vol:vol) mix of 0.1% (vol/vol) triﬂuoroace-
tic with acid:acetonitrile:H20 mixed 1:1 (vol:vol) with saturated
CHCA (a-cyano-4-hydroxycinnamic acid) and analyzed by
MALDI-TOF mass spectrometry in the reﬂectron mode on an
ABI 4800 MALDI-TOF/TOF mass spectrometer (Applied Bio-
systems, Thermo Fischer Scientiﬁc). Intracellular APP-CTFs
from whole protein extracts prepared from cells treated with
APMAP siRNA and/or DAPT were immunoprecipitated with
an antibody targeting the CTF portion of APP (CTF15; Sigma-
Aldrich GmbH, Buchs, Switzerland). Next, APP-CTFs were
washed two times in 1% NP40-HEPES and two more times
in deionized water, and then eluted in 0.1% (vol/vol)
triﬂuoroacetic acid with acetonitrile:H20 mixed 1:1 (vol:vol),
dried with a vacuum pump and ﬁnally resolubilized in the
same elution buffer saturated with sinapinic acid (3–4-
hydroxy-3,5-dimethoxyphenyl prop-2-enoic acid). All spectra
were acquired in the linear mode with an ABI 4800 MALDI-
TOF/TOFmass spectrometer.Molecular masses were accurately
measured and searched against known amino acid sequences of
human APP.
Puriﬁcation of APMAP in E. coli and CHO
For the puriﬁcation of recombinant human APMAP1-His6 in E.
coli, a pET21b vector encoding human APMAP1-His6 cDNA
was expressed in BL21(DE3) cells and induced with 1 mM
isopropyl-b-D-thiogalactopyranoside for 16 h at 248C at a
600 nm optical density of 0.8. For the puriﬁcation of human
APMAP1-His6, harvested bacteria were lysed with 10 mM Tris
pH 7.4, 150 mM NaCl, 1% CHAPSO and complete protease
inhibitor cocktail (Roche) and passed three times through a high-
pressure homogenizer (Emulsiﬂex-C5; Avestin, Inc.,Mannheim,
Germany) at a pressure greater than 1000 psi. The obtained lysate
was incubated for 1 h on ice and spun downat 5150g for 20 min at
48C, and the resulting supernatant was incubated for 30 min with
Ni-NTA agarose beads (Invitrogen) at room temperature. Bound
proteins were eluted ﬁve times in 10 mM Tris pH 7.4, 150 mM
NaCl and 1% CHAPSO containing 250 mM imidazole (pH 7.4)
and analyzed by Coomassie-stained SDS–PAGE.
For the puriﬁcation of mammalian APMAP-Flag, a total of
2.64 × 109CHOcells stably transfectedwith humanAPMAP1-
Flag were resuspended in MES buffer [50 mM MES pH 6.0,
150 mM NaCl, 5 mMMgCl2, 5 mM CaCl2 and protease inhibitor
cocktail (Roche)]. The cells were lysed by three passages in a
high-pressure homogenizer at a pressure greater than 1000 psi
and centrifuged at 3000g for 20 min. The supernatant was
further centrifuged at 100 000g for 1 h to pellet microsomes.
The pellet was resuspended by pipetting up and down 30 times
in bicarbonate buffer (0.1 M NaHCO3, pH 11.3) and incubated
for 20 min at 48C to remove non-integral proteins. The washed
microsomes were pelleted by centrifugation at 100 000g for
1 h. The supernatant was discarded, and the membranes were
solubilized in ice-cold 1% CHAPSO-HEPES lysis buffer
[50 mM HEPES, 150 mM NaCl, 5 mM MgCl2, 5 mM CaCl2, 1%
CHAPSO and protease inhibitor cocktail (Roche)] for 1 h at
48C. The lysate was centrifuged at 16 000g, saved and diluted
twice in HEPES buffer [50 mM HEPES, 150 mM NaCl, 5 mM
MgCl2, 5 mM CaCl2 and protease inhibitor cocktail (Roche)].
The lysate was further diluted six times in 0.1% digitonin-TBS
buffer (50 mM Tris–HCl pH 7.4, 150 mM NaCl) and bound to
M2 anti-Flag afﬁnity resin (Sigma-Aldrich) overnight. Follow-
ing three washes in 0.1% digitonin-TBS buffer, the bound pro-
teins were eluted in 1.5 ml of 0.1% digitonin-TBS buffer
containing 0.2 mg/ml Flag peptides and used for the in vitro
g-secretase assays. In both protocols, the purity of human
APMAP1-His6 and APMAP1-Flag was conﬁrmed by SDS–
PAGE using Coomassie staining.
g-Secretase activity assays
g-Secretase assays using recombinant human APMAP1 and
APP-C100-Flag were performed as previously reported (42–44).
Brieﬂy, g-secretase puriﬁed from SS20 cells was solubilized in
0.2% (wt/vol) CHAPSO, 50 mM HEPES (pH 7.0), 150 mM
NaCl, 5 mM MgCl2 and 5 mM CaCl2 and incubated at 378C for
4 h with 1 mM substrate, 0.1% (wt/vol) phosphatidylcholine
and 0.025% (wt/vol) phosphatidylethanolamine. The resulting
products, AICD-Flag and Ab, were detected with Flag-speciﬁc
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M2 antibodies (Sigma-Aldrich) and Ab-speciﬁc 6E10 (Covance),
respectively.
Mice
Male and female WT and APP/PS1 transgenic mice (obtained
from Prof. M. Jucker, HIH, Tu¨bingen, Germany) were used.
APP/PS1 animals co-express theKM670/671NLSwedishmuta-
tion of humanAPP and the L166Pmutation of human PS1 under
the control of theThy-1 promoter and showage-dependent accu-
mulation of parenchymal Ab plaques (45). Both WT and APP/
PS1 mice were generated on a C57BL/6J background. We con-
ducted all animal experiments in accordance with local and
federal directives for the care and use of laboratory animals.
Production and titration of AAV2/9 vectors
Theproductionand titrationofAAVvector particles pseudotyped
with a serotype 9 capsid has been described previously (46).
Brieﬂy, the vectors were obtained by transient co-transfection of
293-AAV cells (Agilent, Santa Clara, CA, USA) with the
shuttle plasmid and a pDP9rs.gck helper plasmid, which
encodes the REP and CAP adeno-associated viral genes, as
well as genes that are essential to the adenoviral helper function
(plasmid kindly provided by Dr J. Kleinschmidt, Deutsches
Krebsforschungszentrum, Heidelberg, Germany). Viral vector
particles were puriﬁed from cell lysates by centrifugation on
an iodixanol gradient (OptiPrep, Axis-Shield, Oslo, Norway)
followed by anion exchange afﬁnity chromatography on a
HiTrap Q-FF column (GE Healthcare Bio-Sciences AB,
Uppsala, Sweden). The suspension medium was replaced with
Dulbecco’s PBS (DPBS, Gibco), and the viral particles were
concentrated to a ﬁnal volume of 100 ml using Centricon
Plus-20 ﬁltration devices (regenerated cellulose, 100 000
MWCO, Millipore). Viral titers were determined by measuring
the number of viral genomes present in a given volume of the
vector suspension using real-time PCR. We used a primer and
probe set that anneals to the b-globin intron (fw: 5′-CGTGC
CAAGAGTGACGTAAG-3′; rv: 5′-TGGTGCAAAGAGGCA
TGATA-3′; TaqMan probe: 5′-FAM-TTGCCCTGAAAGAA
AGAGATTAGGGAA-BHQ-1-3′). The reactions were run in a
Corbett Rotor-Gene RG-3000 cycler (Qiagen Inc., Valencia,
CA, USA) using the following program: one cycle of 20 min at
958C for capsid denaturation followed by 40 cycles of 3 s at
958C and 10 s at 608C.
Injection of mice and Abmeasurements
The equivalent of 2.53 × 1010 and 1.10 × 1010 viral particles
were injected into 5-week-old WT and APP/PS1 mice, respect-
ively. Bilateral injection was performed at the following stereo-
taxic coordinates: (in mm, anterior, lateral, ventral to bregma)
22.1, 1.5, 1.7. After 4 weeks, the mice were euthanatized, and
the right hemisphere was homogenized in a buffer (1 ml
buffer/100 mg brain) containing 50 mM NaCl, 0.2% DEA and
complete protease inhibitor cocktail (Roche). After centrifuga-
tion at 200 000g for 35 min at 48C, soluble Ab peptide analysis
in WT and APP/PS1 brain lysates was performed using anti-
human/rat AbX-40 (Wako Chemicals, Richmond, VA, USA)
and anti-human Ab1-X (IBL International GmbH, Hamburg,
Germany), respectively, according to the manufacturer’s
instructions. Total proteins were subsequently extracted in 1%
NP40 and complete protease inhibitor cocktail (Roche) for
western blot analysis.
Statistical analyses
All data are presented as the mean+SD. Student’s t-test (two-
tailed) was applied for statistical analysis, and statistical signiﬁ-
cance is shown asP , 0.05 (one asterisks),P, 0.01 (two aster-
isks) or P , 0.001 (three asterisks).
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Mosser et al., Supplementary Figure 1 (related to Figure 1) 
 
 
 
Human RTN4 
Uniprot ID: Q9NQC3 
Sequence coverage: 5% 
 
MEDLDQSPLV SSSDSPPRPQ PAFKYQFVRE PEDEEEEEEE EEEDEDEDLE ELEVLERKPA 
AGLSAAPVPT APAAGAPLMD FGNDFVPPAP RGPLPAAPPV APERQPSWDP SPVSSTVPAP 
SPLSAAAVSP SKLPEDDEPP ARPPPPPPAS VSPQAEPVWT PPAPAPAAPP STPAAPKRRG 
SSGSVDETLF ALPAASEPVI RSSAENMDLK EQPGNTISAG QEDFPSVLLE TAASLPSLSP 
LSAASFKEHE YLGNLSTVLP TEGTLQENVS EASKEVSEKA KTLLIDRDLT EFSELEYSEM 
GSSFSVSPKA ESAVIVANPR EEIIVKNKDE EEKLVSNNIL HNQQELPTAL TKLVKEDEVV 
SSEKAKDSFN EKRVAVEAPM REEYADFKPF ERVWEVKDSK EDSDMLAAGG KIESNLESKV 
DKKCFADSLE QTNHEKDSES SNDDTSFPST PEGIKDRSGA YITCAPFNPA ATESIATNIF 
PLLGDPTSEN KTDEKKIEEK KAQIVTEKNT STKTSNPFLV AAQDSETDYV TTDNLTKVTE 
EVVANMPEGL TPDLVQEACE SELNEVTGTK IAYETKMDLV QTSEVMQESL YPAAQLCPSF 
EESEATPSPV LPDIVMEAPL NSAVPSAGAS VIQPSSSPLE ASSVNYESIK HEPENPPPYE 
EAMSVSLKKV SGIKEEIKEP ENINAALQET EAPYISIACD LIKETKLSAE PAPDFSDYSE 
MAKVEQPVPD HSELVEDSSP DSEPVDLFSD DSIPDVPQKQ DETVMLVKES LTETSFESMI 
EYENKEKLSA LPPEGGKPYL ESFKLSLDNT KDTLLPDEVS TLSKKEKIPL QMEELSTAVY 
SNDDLFISKE AQIRETETFS DSSPIEIIDE FPTLISSKTD SFSKLAREYT DLEVSHKSEI 
ANAPDGAGSL PCTELPHDLS LKNIQPKVEE KISFSDDFSK NGSATSKVLL LPPDVSALAT 
QAEIESIVKP KVLVKEAEKK LPSDTEKEDR SPSAIFSAEL SKTSVVDLLY WRDIKKTGVV 
FGASLFLLLS LTVFSIVSVT AYIALALLSV TISFRIYKGV IQAIQKSDEG HPFRAYLESE 
VAISEELVQK YSNSALGHVN CTIKELRRLF LVDDLVDSLK FAVLMWVFTY VGALFNGLTL 
LILALISLFS VPVIYERHQA QIDHYLGLAN KNVKDAMAKI QAKIPGLKRK AE 
 
Human HSPA5 
Uniprot ID: P11021 
Sequence coverage: 58% 
 
MKLSLVAAML LLLSAARAEE EDKKEDVGTV VGIDLGTTYS CVGVFKNGRV EIIANDQGNR 
ITPSYVAFTP EGERLIGDAA KNQLTSNPEN TVFDAKRLIG RTWNDPSVQQ DIKFLPFKVV 
EKKTKPYIQV DIGGGQTKTF APEEISAMVL TKMKETAEAY LGKKVTHAVV TVPAYFNDAQ 
RQATKDAGTI AGLNVMRIIN EPTAAAIAYG LDKREGEKNI LVFDLGGGTF DVSLLTIDNG 
VFEVVATNGD THLGGEDFDQ RVMEHFIKLY KKKTGKDVRK DNRAVQKLRR EVEKAKRALS 
SQHQARIEIE SFYEGEDFSE TLTRAKFEEL NMDLFRSTMK PVQKVLEDSD LKKSDIDEIV 
LVGGSTRIPK IQQLVKEFFN GKEPSRGINP DEAVAYGAAV QAGVLSGDQD TGDLVLLDVC 
PLTLGIETVG GVMTKLIPRN TVVPTKKSQI FSTASDNQPT VTIKVYEGER PLTKDNHLLG 
TFDLTGIPPA PRGVPQIEVT FEIDVNGILR VTAEDKGTGN KNKITITNDQ NRLTPEEIER 
MVNDAEKFAE EDKKLKERID TRNELESYAY SLKNQIGDKE KLGGKLSSED KETMEKAVEE 
KIEWLESHQD ADIEDFKAKK KELEEIVQPI ISKLYGSAGP PPTGEEDTAE KDEL 
 
 
Human APMAP1 
Uniprot ID: Q9HDC9 
Sequence coverage: 16% 
 
MSEADGLRQR RPLRPQVVTD DDGQAPEAKD GSSFSGRVFR VTFLMLAVSL TVPLLGAMML 
LESPIDPQPL SFKEPPLLLG VLHPNTKLRQ AERLFENQLV GPESIAHIGD VMFTGTADGR 
VVKLENGEIE TIARFGSGPC KTRDDEPVCG RPLGIRAGPN GTLFVADAYK GLFEVNPWKR 
EVKLLLSSET PIEGKNMSFV NDLTVTQDGR KIYFTDSSSK WQRRDYLLLV MEGTDDGRLL 
EYDTVTREVK VLLDQLRFPN GVQLSPAEDF VLVAETTMAR IRRVYVSGLM KGGADLFVEN 
MPGFPDNIRP SSSGGYWVGM STIRPNPGFS MLDFLSERPW IKRMIFKLFS QETVMKFVPR 
YSLVLELSDS GAFRRSLHDP DGLVATYISE VHEHDGHLYL GSFRSPFLCR LSLQAV 
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Human ATP1α1 
Uniprot ID: P05023 
Sequence coverage: 29% 
 
MGKGVGRDKY EPAAVSEQGD KKGKKGKKDR DMDELKKEVS MDDHKLSLDE LHRKYGTDLS 
RGLTSARAAE ILARDGPNAL TPPPTTPEWI KFCRQLFGGF SMLLWIGAIL CFLAYSIQAA 
TEEEPQNDNL YLGVVLSAVV IITGCFSYYQ EAKSSKIMES FKNMVPQQAL VIRNGEKMSI 
NAEEVVVGDL VEVKGGDRIP ADLRIISANG CKVDNSSLTG ESEPQTRSPD FTNENPLETR 
NIAFFSTNCV EGTARGIVVY TGDRTVMGRI ATLASGLEGG QTPIAAEIEH FIHIITGVAV 
FLGVSFFILS LILEYTWLEA VIFLIGIIVA NVPEGLLATV TVCLTLTAKR MARKNCLVKN 
LEAVETLGST STICSDKTGT LTQNRMTVAH MWFDNQIHEA DTTENQSGVS FDKTSATWLA 
LSRIAGLCNR AVFQANQENL PILKRAVAGD ASESALLKCI ELCCGSVKEM RERYAKIVEI 
PFNSTNKYQL SIHKNPNTSE PQHLLVMKGA PERILDRCSS ILLHGKEQPL DEELKDAFQN 
AYLELGGLGE RVLGFCHLFL PDEQFPEGFQ FDTDDVNFPI DNLCFVGLIS MIDPPRAAVP 
DAVGKCRSAG IKVIMVTGDH PITAKAIAKG VGIISEGNET VEDIAARLNI PVSQVNPRDA 
KACVVHGSDL KDMTSEQLDD ILKYHTEIVF ARTSPQQKLI IVEGCQRQGA IVAVTGDGVN 
DSPALKKADI GVAMGIAGSD VSKQAADMIL LDDNFASIVT GVEEGRLIFD NLKKSIAYTL 
TSNIPEITPF LIFIIANIPL PLGTVTILCI DLGTDMVPAI SLAYEQAESD IMKRQPRNPK 
TDKLVNERLI SMAYGQIGMI QALGGFFTYF VILAENGFLP IHLLGLRVDW DDRWINDVED 
SYGQQWTYEQ RKIVEFTCHT AFFVSIVVVQ WADLVICKTR RNSVFQQGMK NKILIFGLFE 
ETALAAFLSY CPGMGVALRM YPLKPTWWFC AFPYSLLIFV YDEVRKLIIR RRPGGWVEKE  
TYY 
 
 
Human Tspan6 
Uniprot ID: O43657 
Sequence coverage: 22% 
 
MASPSRRLQT KPVITCFKSV LLIYTFIFWI TGVILLAVGI WGKVSLENYF SLLNEKATNV 
PFVLIATGTV IILLGTFGCF ATCRASAWML KLYAMFLTLV FLVELVAAIV GFVFRHEIKN 
SFKNNYEKAL KQYNSTGDYR SHAVDKIQNT LHCCGVTDYR DWTDTNYYSE KGFPKSCCKL 
EDCTPQRDAD KVNNEGCFIK VMTIIESEMG VVAGISFGVA CFQLIIFLAY CLSRAITNNQ  
YEIV 
 
 
Human Vamp2 
Uniprot ID: P63027 
Sequence coverage: 21% 
 
MSATAATAPP AAPAGEGGPP APPPNLTSNR RLQQTQAQVD EVVDIMRVNV DKVLERDQKL 
SELDDRADAL QAGASQFETS AAKLKRKYWW KNLKMMIILG VICAIILIII IVYFST 
 
 
Human Vamp3 
Uniprot ID: Q15836 
Sequence coverage: 24% 
 
MSTGPTAATG SNRRLQQTQN QVDEVVDIMR VNVDKVLERD QKLSELDDRA DALQAGASQF 
ETSAAKLKRK YWWKNCKMWA IGITVLVIFI IIIIVWVVSS 
 
 
Sup. Fig. 1. Mass spectrometric identification of γ-secretase-interacting proteins. Peptides 
identified by LC-MS/MS after tryptic digestion of γ-secretase purified from CHO cells are highlighted in 
yellow in the primary human sequences. Trypsin cleavage sites are indicated in bold. 
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Mosser et al., Supplementary Figure 2 (related to Figure 1) 
 
 
 
                                                        
 
 
Sup. Fig. 2. Characterization by SDS-PAGE of purified γ-secretase used for the BN-PAGE 
analysis in Fig. 1a. γ-Secretase purified as described in the Methods section was analyzed by silver-
stained SDS-PAGE on a NuPAGE Novex® 4-12% Bis-Tris gel (Life technologies). Western blot and 
mass spectrometric analyses confirmed that predominant proteins are γ-secretase subunits (labeled 
bands). 
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Mosser et al., Supplementary Figure 3 (related to Figure 1) 
 
 
 
 
 
                            
 
                           
                             
 
Sup. Fig. 3. Partial depletion of APMAP by different siRNAs raises the levels of APP-CTFs. 
HeLa cells (a) or HEK-APPSwe cells (b) were treated for 3 days with either negative control scramble 
siRNA or APMAP siRNA 1 (5'-TTCACCGATTCTAGCAGCAAA-3'), APMAP siRNA 2 (5'-
UGAAGUAAAUCCCUGGAAA-3'), APMAP siRNA 3 (5'-GCAGAAAGGCUGUUUGAAA-3'), or APMAP 
siRNA 4 (5'-GGAAGAACAUGUCCUUUGU-3') duplexes. APMAP siRNA 1 was used for experiments 
described in Figs 1 & 3. β-Actin served as a protein loading control. mAPP-FL and iAPP-FL: mature 
and immature APP full-length.  
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Mosser et al., Supplementary Figure 4 (related to Figure 1) 
 
 
 
 
 
 
 
 
 
 
Sup. Fig. 4. Partial depletion of Tspan6, RTN4, and APMAP does not affect the maturation or 
protein levels of α-, β-, and γ-secretases. The exception to this result was RTN4, in which reduced 
levels are associated with increased ADAM10 levels. a) HeLa cells; b) HEK-APPSwe cells. β-Actin 
served as a protein loading control. mNCT and iNCT: mature and immature Nicastrin.  
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 Mosser et al., Supplementary Figure 5 (related to Figure 1) 
 
 
 
 
 
 
Sup. Fig. 5. APMAP is a negative regulator of Aβ  production. In HEK-APPSwe cells treated with 
APMAP siRNA, increased levels of APP-CTFs (a) are associated with increased secretion of total Aβ 
(Aβ1-x), Aβ1-40, and Aβ1-42, as determined by either ELISA (b) or Western blot on a urea gel (c). The 
mass spectrometric analysis of secreted Aβ revealed no changes in the profiles of these peptides (d). 
(a) Biological triplicates are shown. (b): Student’s t-test was applied for statistical analyses; mean +/- 
SD; *P<0.05; ***P<0.001; n=4/group. β-Actin served as a protein loading control. 
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Mosser et al., Supplementary Figure 6 (related to Figure 1)  
 
 
 
 
 
Sup. Fig. 6. The depletion of APMAP in HEK-APPSwe and HeLa cells does not affect the 
maturation or protein levels of α-, β-, and γ-secretases. Levels of ADAM10, BACE1, and γ-
secretase components are shown in HEK-APPSwe cells (a, c, e) or HeLa cells (b, d, f) treated with 
either negative control scramble siRNA or APMAP siRNA. Biological triplicates are shown. (c-f) Bands 
revealed by Western blot analysis (upper panels) were quantified by densitometry (lower panels). 
Student’s t-test was applied for statistical analyses (mean +/- SD), and revealed no significant 
differences in ADAM10, BACE1, γ-secretase, and sAPPα/β protein levels. 
49
 8 
Mosser et al., Supplementary Figure 7 (related to Figure 1) 
 
 
 
 
 
Sup. Fig. 7. APMAP1 purified from E. coli is not a substrate for γ-secretase and does not affect 
the processing of APP-CTFβ  by purified γ-secretase. a) Affinity purification of human APMAP-His6 
expressed in E. coli. The starting material (Start), unbound fraction (Unb), and five elution fractions 
(E1-5) were resolved by SDS-PAGE on a Tris-glycine gel stained with Coomassie blue. b) Cell-free γ-
secretase activity assays with increasing concentrations of purified hAPMAP1-His6 (2x, 4x), pre-
incubated (+) or not (-), at 37°C for 60 min before the addition of the substrate APP-C100-Flag. Bands 
detected by Western blot analysis (left panel) were quantified by densitometry (right panel). Student’s 
t-test was applied for statistical analyses (mean +/- SD; n=4/group), and revealed no significant 
differences in AICD-Flag or total Aβ levels. c) Purified hAPMAP1-His6 is not a substrate for γ-
secretase. Left panel: Increasing concentrations of purified hAPMAP1-His6 (1x, 2x), denatured at 
65°C in 0.5% SDS (+) or not (-), were incubated for 4 h at 37°C in the presence (+) or absence (-) of 
purified γ-secretase and phospholipids (PC+PE). Right panel: APP-C100-Flag served as a positive 
control for γ-secretase activity. E-S: Enzyme in the absence of substrate; -E+S: Substrate in the 
absence of enzyme; E+S: Enzyme in the presence of substrate; E+S+GSI: Enzyme in the presence of 
substrate and 10μM γ-secretase inhibitor (GSI) DAPT. Cleavage products were detected with an anti-
His6 antibody (hAPMAP1-His6) or anti-Flag antibody (APP-C100-Flag). 
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Mosser et al., Supplementary Figure 8 (related to Figure 1) 
 
 
 
Sup. Fig. 8. APMAP1 purified from CHO cells is not a substrate for γ-secretase and does not 
affect the processing of APP-CTFβ  by purified γ-secretase. a) Affinity purification of human 
APMAP1-Flag stably overexpressed in CHO cells. The starting material (Start), unbound fraction 
(Unb), and two elution fractions (E1-2) were resolved by SDS-PAGE on a Tris-glycine gel stained with 
Coomassie blue. b) Cell-free γ-secretase activity assays with increasing concentrations of purified 
hAPMAP1-Flag (1x, 3x), pre-incubated (+) or not (-) at 37°C for 60 min before addition of the substrate 
APP-C100-Flag. Bands detected by Western blot analysis (left panel) were quantified by densitometry 
(right panel). Student’s t-test was applied for statistical analyses (mean +/- SD; n=4/group), and 
revealed no significant differences in AICD-Flag or total Aβ levels. c) Purified hAPMAP1-Flag is not a 
substrate for γ-secretase. Left panel: Increasing concentrations of purified hAPMAP1-Flag (1x, 2x), 
denatured at 65°C in 0.5% SDS (+) or not (-), were incubated for 4 h at 37°C in the presence (+) or 
absence (-) of purified γ-secretase and phospholipids (PC+PE). Right panel: APP-C100-Flag served 
as a positive control for γ-secretase activity. E-S: Enzyme in the absence of substrate; -E+S: Substrate 
in the absence of enzyme; E+S: Enzyme in the presence of substrate; E+S+GSI: Enzyme in the 
presence of substrate and 10μM γ-secretase inhibitor (GSI) DAPT. Cleavage products were detected 
with an anti-Flag antibody. 
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Mosser et al., Supplementary Figure 9 (related to Figure 2) 
 
 
 
                                  
 
 
 
Sup. Fig. 9. APMAP interacts physically with γ-secretase, APP-FL, and APP-CTFs. Co-
immunoprecipitation with anti-Flag beads of all γ-secretase components, APP-FL, and APP-CTFs with 
a Flag-tagged version of hAPMAP1 (hAPMAP1-Flag) overexpressed in CHO cells (a) or HEK-
APPSwe cells (b). Untagged APMAP (hAPMAP1) served as a control for the specific co-precipitation. 
(c) Co-immunoprecipitation of endogenous APMAP with a Flag-tagged version of hAPP (hAPP-Flag) 
overexpressed in HEK cells. Untagged APP (hAPP) served as a control for the specific co-
precipitation. 
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Mosser et al., Supplementary Figure 10 (related to Figure 2) 
 
 
 
 
 
Sup. Fig. 10. Immunohistochemical co-localization of APMAP (green) with the γ-secretase subunit 
Nicastrin (red, panel a) or APP (red, panel b) in 14 days in vitro mouse primary cortical neurons. Scale 
bar: 10 μm. Both confocal images (left panels) and Z-stack projections (right panels) are shown with a 
microscopy objective magnification of 40X. Un-merged images for APMAP, NCT, APP-CTFs, and 
DAPI are also shown for comparison. 
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Mosser et al., Supplementary Figure 11 (related to Figure 3) 
 
 
 
 
 
 
 
 
 
 
Sup. Fig. 11. APMAP controls the stability of APP-CTFs. MALDI-TOF mass spectrometric analysis 
of endogenous APP-CTFs immunoprecipitated from HeLa cells treated with scramble or APMAP 
siRNAs, in the presence (+ DAPT) or absence (- DAPT) of 1 μM of the γ-secretase inhibitor DAPT. 
Main changes (increased APP-C71:APP-C80 and APP-C74:APP-C80 ratios) are highlighted in red.  
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Mosser et al., Supplementary Figure 12 (related to Figure 4) 
 
 
 
 
 
 
 
 
Sup. Fig. 12. Validation of shRNAs targeting mouse APMAP in HEK cells. (a) In this validation 
experiment, mouse APMAP-Flag was co-expressed in HEK cells (+) with a scramble shRNA (Scr) or 
with an AAV9-specific vector encoding six different shRNAs targeting mAPMAP (#1-6). After 48 h of 
culture, cells were collected, and the levels of mAPMAP-Flag were estimated by Western blot analysis 
with an anti-Flag antibody. (b) Sequences for all shRNAs targeting mAPMAP, tested in HEK cells. The 
shRNAs # 1 and 2 (labelled with an asterisk) were used for the in vivo experiments in WT and 
APP/PS1 mice, respectively (Fig.4). 
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Mosser et al., Supplementary Figure 13 (related to Figure 4) 
 
 
 
 
 
 
 
 
Sup. Fig. 13. APMAP does not affect Aβ  production in wild-type (a) or APP/PS1 transgenic (b) 
female mice. Five-week-old animals were injected bilaterally in the dorsal hippocampus with AAV9 
expressing APMAP shRNA or a scrambled shRNA, together with a GFP reporter. Four weeks post-
injection, wild-type (a) or APP/PS1 (b) females displayed a reduction in APMAP expression (mean +/- 
SD; *P<0.05; n=4-5/group), associated with unchanged Aβ levels. Student’s t-test was applied for 
statistical analyses. β-Actin served as a protein loading control. 
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Mosser et al., Supplementary Figure 14 (related to Figure 4) 
 
 
 
 
                                 
 
Sup. Fig. 14. Dose-dependent depletion of APMAP1 and accumulation of APP-CTFs. HEK-
APPSwe cells were treated for 3 days with either negative control scramble siRNA or increased 
concentrations of APMAP siRNA. The two upper panels show Western blots from two independent 
experiments. The densitometric analysis of APMAP and APP-CTF Western blot bands (lower panel) 
revealed a critical step for APMAP depletion at ~50% depletion (red arrow), above which small 
changes in APMAP expression are associated with big changes in APP-CTFs accumulation. β-Actin 
served as a protein loading control. 
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 Mosser et al., Supplementary Figure 15 (related to the discussion) 
 
 
 
 
 
                          
 
 
 
Sup. Fig. 15. APMAP does not affect the processing of the Notch-1 receptor or the synaptic cell 
adhesion proteins Neurexin3β  and Neuroligin1. In contrast to the γ-secretase inhibitor Compound 
E (Comp. E), APMAP knockdown did not interfere (a) with the processing of the γ-secretase substrate 
NotchΔE and Notch-intracellular domain (Notch-ICD) production in HEK-N7 stable cells, or (b, c) with 
the processing of the γ-secretase substrates Neurexin3β and Neuroligin1 transiently expressed in HEK 
cells. β-Actin served as a protein loading control. 
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Mosser et al., Supplementary Figure 16 (related to the discussion) 
 
 
 
 
 
 
 
Sup. Fig. 16. APMAP gene and protein expression patterns in mouse and human brains. (a) 
APMAP gene expression maps in the mouse brain, according to the Allen Brain Atlas (www.brain-
map.org/). (b) APMAP protein expression maps in the human brain, according to the Human Protein 
Atlas (www.proteinatlas.org/).  
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Abstract
An important pathological hallmark of Alzheimer’s disease
(AD) is the deposition of amyloid-beta (Ab) peptides in the
brain parenchyma, leading to neuronal death and impaired
learning and memory. The protease c-secretase is respon-
sible for the intramembrane proteolysis of the amyloid-b
precursor protein (APP), which leads to the production of the
toxic Ab peptides. Thus, an attractive therapeutic strategy to
treat AD is the modulation of the c-secretase activity, to
reduce Ab42 production. Because phosphorylation of pro-
teins is a post-translational modiﬁcation known to modulate
the activity of many different enzymes, we used electrospray
(LC-MS/MS) mass spectrometry to identify new phospho-
sites on highly puriﬁed human c-secretase. We identiﬁed 11
new single or double phosphosites in two well-deﬁned
domains of Presenilin-1 (PS1), the catalytic subunit of the
c-secretase complex. Next, mutagenesis and biochemical
approaches were used to investigate the role of each
phosphosite in the maturation and activity of c-secretase.
Together, our results suggest that the newly identiﬁed
phosphorylation sites in PS1 do not modulate c-secretase
activity and the production of the Alzheimer’s Ab peptides.
Individual PS1 phosphosites shall probably not be consid-
ered therapeutic targets for reducing cerebral Ab plaque
formation in AD.
Keywords: Alzheimer’s disease, amyloid-beta peptides,
phosphorylation, phosphosites, Presenilin, c-secretase.
J. Neurochem. (2015) 133, 409–421.
Alzheimer’s disease (AD) is characterized by two major
pathological hallmarks: the extracellular accumulation of
amyloid-beta (Ab) senile plaques and the intracellular
accumulation of Tau proteins leading to the formation of
the neuroﬁbrillary tangles. By initiating the toxic amyloid
cascade, Ab peptides either adopting oligomeric structures or
aggregated into senile plaques could be at the origin of the
formation of neuroﬁbrillary tangles (Hardy and Allsop 1991).
Production of Ab is the result of the successive enzymatic
processing of the amyloid-b precursor protein (APP) by
b- and c-secretases (Selkoe 1994). However, a deep under-
standing of the molecular mechanisms regulating the
enzymatic activities of these two secretases should allow us
to better understand the pathogenesis of AD.
c-Secretase is a large protease complex composed of four
components: Presenilin (PS1 or PS2), Nicastrin (NCT),
Anterior pharynx-defective 1 (Aph-1), and Presenilin
enhancer 2 (Pen-2) (De Strooper 2003). The proteolytic
activity of this secretase is critical for the processing of many
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type-I integral membrane proteins including APP and the
Notch receptor (Steiner et al. 1999; Kimberly et al. 2000).
Importantly, early-onset familial Alzheimer’s disease (FAD)
has been largely attributed to mutations in both PS1 (Rogaev
et al. 1997) or PS2 (Rogaev et al. 1995). The vast majority of
FAD mutations in Presenilins have been identiﬁed in PS1, with
around 200 different missense mutations in PS1, but only 30 in
PS2 (http://www.alzforum.org/mutations). Also, PS1 mutations
account for about half of all FAD cases (Schellenberg 1995).
Most of these mutations increase the production throughout life
of Ab42, the hydrophobic and main component of Ab senile
plaques (Iwatsubo et al. 1994). Several of these mutations also
increase the Ab42 to Ab40 ratio (from 0.1 to 0.2 in healthy
subjects up to 1 in AD patients), either by increasing Ab42 or
by decreasing Ab40 production, or a combination of both
(Bentahir et al. 2006; Cacquevel et al. 2012).
PS1 is an integral membrane protein with nine transmem-
brane domains (TMD) (Laudon et al. 2005); it forms the
catalytic subunit of c-secretase, in which two aspartate
residues (Asp257 and Asp385 in human PS1) located in TMD6
and TMD7 are crucial for the catalytic activity of the enzyme
(Wolfe et al. 1999). In the secretory pathway, PS1 undergoes
endoproteolysis, generating stable N-terminal and C-terminal
fragments (PS1-NTF and PS1-CTF, respectively). The three
other components (NCT, Aph-1, and Pen-2) act as scaffold
proteins for the assembly and activation of the c-secretase
protease complex (LaVoie et al. 2003; Takasugi et al. 2003;
Fraering 2007). c-Secretase is present in multiple cell
compartments including the Golgi (Baulac et al. 2003),
endosomes (Vetrivel et al. 2004), lysosomes (Pasternak
et al. 2003) and plasma membranes (Ray et al. 1999).
Interestingly, PS1 is a protein that can be phosphorylated
at different sites, by different protein kinases. These include
glycogen synthase kinase 3b (GSK3b), which phosphory-
lates PS1 on Ser353 and Ser357 (Kirschenbaum et al. 2001),
cyclin-dependent kinase 5/p35 (cdk5/p35) on Thr354 (Lau
et al. 2002), protein kinase C on Ser346 (Fluhrer et al. 2004),
and c-Jun N-terminal kinase on the Ser319Thr320 motif (Kuo
et al. 2008). Many different post-translational modiﬁcations of
proteins, including phosphorylation and palmitoylation, have
been reported to modulate the biological activity of enzymes
(Patterson 2002). However, the correlation between PS1
phosphorylation and Ab production was examined only by
very few groups. Some results have shown that the substitu-
tion of Ser353 and Ser357 residues greatly reduces the ability of
PS1 to associate with b-catenin (an intracellular signal
transducer in the Wnt signaling pathway) without having an
effect on Ab production (Kirschenbaum et al. 2001). In
contrast, results from another group indicated an increase in
the Ab42 : Ab40 ratio in cells treated with LiCl, an inhibitor of
GSK3b, which phosphorylates PS1 on Ser353 and Ser357
(Maesako et al. 2011). Finally, the deletion of amino acid
residues 304–371 in the PS1 hydrophilic loop, which is located
between TMD6 and TMD7 of PS1 and which harbors the
above-described PS1 phosphorylation sites, did not impact the
endoproteolysis of PS1 or Ab production (Saura et al. 2000).
With these opposite statements, we decided to take
advantage of our highly puriﬁed c-secretase preparation to
identify new phosphorylation sites in PS1, and to analyze
their impact on c-secretase assembly and Ab production.
Using electrospray (LC-MS/MS) mass spectrometry, we
have identiﬁed a total of 15 PS1 phosphorylated peptides,
including 11 new single or double phosphosites. These new
phosphosites were mainly located in the PS1 hydrophilic
loop between TMD6 and TMD7, with the others being found
in the hydrophilic N-terminal domain located at the
N-terminus of the TMD1. Because the new PS1 phosphosites
can potentially be associated with late or early-onset non-
familial AD, or with other diseases implicating receptor
processing by c-secretase (De Strooper et al. 1999; Uemura
et al. 2006; Bot et al. 2011), we have analyzed their effects
on c-secretase maturation and activity, and Ab production.
Methods
c-Secretase puriﬁcation and mass spectrometry analysis
The c-secretase complex puriﬁed as previously described (Alattia
et al. 2013) was ﬁrst run on a NativePAGETM Novex 4-16% Bis-
Tris gel for blue native-PAGE analysis (Invitrogen, Carlsbad, CA,
USA). Next, gel band corresponding to the complex (containing
PS1) was visualized by Coomassie staining and cut into small
pieces. Proteins were reduced, alkylated, and subjected to in-gel
digestion with either Glu-C or Trypsin. Brieﬂy, gel pieces were
destained, desiccated by incubating them twice in 200 lL of
ammonium bicarbonate 50 mM, 50% ethanol during 20 min and
dried with vacuum concentrator. Samples were then incubated
overnight at 37°C with either Glu-C or Trypsin (12.5 ng/lL). After
peptide extraction from gel slices, phosphopeptide enrichments were
performed on homemade titania tips (Thingholm and Larsen 2009).
Titania tips were ﬁrst equilibrated with 0.75% triﬂuoroacetic acid
(TFA), 60% acetonitrile (ACN), lactic acid (300 mg/mL) (solution
A) prior to loading peptide samples resuspended in 20 lL of the
very same solution A. Titania tips were then successively washed
Fig. 1 Identiﬁcation of new human Presenilin-1/c-secretase phospho-
sites. (a) The high molecular weight human c-secretase complex
resolved by blue native polyacrylamide gel electrophoresis (BN-PAGE)
and stained with Coomassie Brillant Blue (upper panel) was excised
and used for the analysis by electrospray (LC-MS/MS) mass
spectrometry and the identiﬁcation of Presenilin-1 phosphorylated
peptides (PS1, lower panel). Phosphosites are highlighted in red. (b)
Representative tandem MS spectrum conﬁrming the identiﬁcation of
the new phosphorylation site at position Ser366 in the sequence of
human PS1. All spectra of newly identiﬁed phosphosites are in
Figure S1. (c) List (left panel) and schematic positioning (right panel) of
the PS1 phosphosites identiﬁed in this study. The newly identiﬁed
phosphosites are highlighted in red, while previously reported phos-
phosites are in blue.
© 2014 International Society for Neurochemistry, J. Neurochem. (2015) 133, 409--421
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with solution A and a 0.1% TFA, 80% ACN solution. A two-step
elution was performed once with 0.5% ammonium hydroxide
followed by once with 5% piperidine. Eluted fractions were
immediately acidiﬁed with formic acid (FA) and dried under a
vacuum concentrator. For LC-MS/MS analysis, peptides were
resuspended in 2% ACN, 0.1% FA and separated by reversed-
phase chromatography on a Dionex Ultimate 3000 RSLC nano-
UPLC system connected in-line with an Orbitrap Elite (Thermo
Fischer Scientiﬁc, Waltham, MA, USA). The instrument was
operated in an information-dependent mode where peptide masses
were selected for collision-induced dissociation to generate tandem
mass spectra. Database search was performed using Mascot 2.3
(Matrix Science, Boston, MA, USA) and SEQUEST in Proteome
Discoverer v.1.3 against a human database (UniProt release
2013_01; 87613 sequences). All searches were performed with
Trypsin or Glu-C cleavage speciﬁcity, up to two missed cleavages
allowed and ion mass tolerance of 10 ppm for the precursor and
0.5 Da for the fragments. Carbamidomethylation was set as a ﬁxed
modiﬁcation, whereas oxidation (M), acetylation (Protein N-term),
phosphorylation (STY) were considered as variable modiﬁcations.
Data were further processed and inspected in the Scaffold 3 software
(Proteome Software, Portland, OR, USA). Peptide-spectrum
matches with Mascot score > 18 and/or SEQUEST score > 2 were
considered as correctly assigned. Phosphorylation site localization
was conﬁrmed by manual inspection of the spectra. Tandem MS
spectra of phosphorylated peptides identiﬁed in the c-secretase
catalytic subunit PS1 are shown in Figure S1.
Plasmid constructs
Human cDNA of wild-type (WT) PS1 was a gift from D. Selkoe.
WT PS1 cDNA with a Flag-tag at the N-terminus was subcloned
into the mammalian expression vector pcDNA3 (Invitrogen) and the
PCR quick-change site-directed mutagenesis kit (Stratagene, La
Jolla, CA, USA) was used to generate all PS1 Serine or Threonine to
Alanine point mutations tested in this study (see Figure S2).
Cell culture and transfection
Human embryonic kidney 293T (HEK293T) and HeLa cells were
cultured as previously described (Bot et al. 2011) and transfected
with 10 lg of DNA (plasmids with PS1 WT or mutants) using the
calcium phosphate precipitation method and Lipofectamine 2000
(Invitrogen), respectively.
c-Secretase immunoprecipitation and activity assays
HEK and HeLa cells transfected with PS1 phosphosite mutants were
lysed in 1% 3-([3-Cholamidopropyl]dimethylammonio)-2-hydroxy-
1-propanesulfonate (CHAPSO)/HEPES buffer containing protease
inhibitors (Roche Applied Sciences, Basel, Switzerland). M2 anti-
Flag beads pre-equilibrated with 1% CHAPSO/HEPES buffer were
added to the crude protein extract, incubated overnight at 4°C on a
wheel, washed multiple times, and resuspended in 47.5 lL of 0.2%
CHAPSO/HEPES buffer containing lipids (5 lL of phosphatidyl-
choline [0.01 mg/lL] and 2.5 lL of phosphatidylethanolamine
[0.005 mg/lL]) and substrate (1 lM of APP-C100F or Notch-
N100F) for on-beads activity tests. The mix was incubated 4 h at
37°C and recovered for Ab analysis by ELISA, or for western blot
analysis of the cleavage products Ab, APP intracellular domain
(AICD), and Notch intracellular domain (NICD).
SDS–PAGE and western blot analysis
Cell lysates were resolved on a NuPAGE Novex 4–12% Bis-Tris
gel (Invitrogen) or 12% Tris-Glycine sodium dodecyl sulfate–
polyacrylamide gel electrophoresis and, respectively, transferred
onto a polyvinylidene diﬂuoride membrane or a nitrocellulose
membrane. Membranes were incubated with blocking buffer
(Invitrogen) and probed with the following primary antibodies:
anti-PS1-NTF (Ab10281; Abcam, Cambridge, UK or MAB1563,
Chemicon, Temecula, CA, USA), anti-PS1-CTF (MAB5232; Chem-
icon), anti-NCT (N1660; Sigma-Aldrich, St Louis, MO, USA or
NCT164; BD Biosciences, Mississauga, ON, USA), anti-Pen-2 (UD-
1, a gift from H. Karlstrom), anti-Aph-1 (O2C2, Covance, Berkeley,
CA, USA), anti-APP (CT15; Sigma-Aldrich), anti-Ab (6E10;
Covance), and anti-Flag (M2; Sigma-Aldrich) for detection of PS1-
NTF + PS1-FL, PS1-CTF, NCT, Pen-2, Aph-1, APP-FL + APP-
CTF, Ab, or Flag-tagged proteins, respectively. Membranes were
incubated with the secondary antibodies (anti-mouse, rabbit, or rat
IgGs) conjugated to Alexa 680 (Invitrogen) and visualized with the
Odyssey infrared imaging system (LICOR, Lincoln, NE, USA).
c-Secretase limited trypsin digestion
Highly puriﬁed c-secretase (Dimitrov et al. 2013) was incubated
overnight on ice with trypsin (Thermo Fischer Scientiﬁc), with a
c-secretase to trypsin molecular ratio of 1 : 5.
Ab analysis
ELISA
Samples from c-secretase activity assays were assayed using ELISA
kits for human Ab1-40 and Ab1-42 (Invitrogen), as previously
described (Dimitrov et al. 2013).
Immunoprecipitation – mass spectrometry
Ab peptides from c-secretase activity assays were immunoprecipi-
tated overnight using the monoclonal anti-Ab antibody 4G8 and
protein G-coupled agarose (Roche Applied Sciences) and analyzed
bymatrix-assisted laser desoption/ionization-time-of-ﬂight (MALDI-
TOF) mass spectrometry as previously described (Dimitrov et al.
2013).
Statistical analyses
All values are presented as the mean  SE. Statistical analyses were
performed using an unpaired Student’s t-test. *p < 0.05; **p < 0.01.
n = X indicates X-independent experiments.
Results
Identiﬁcation of PS1 phosphosites by mass spectrometry
To identify human c-secretase phosphosites, active protease
complex puriﬁed from Chinese hamster ovary (CHO) cells
over-expressing the four subunits of the protease complex
(Alattia et al. 2013) was resolved by blue-native gel
electrophoresis (Fig. 1a, upper panel), and the c-secretase
complex band was excised for protein content analysis by
electrospray LC-MS/MS mass spectrometry.
This approach led us to the identiﬁcation of 15 PS1
phosphorylated peptides, corresponding to 12 single and three
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double phosphosites in PS1 (summarized in Fig. 1a, lower
panel). No phosphorylated peptides have been identiﬁed in
NCT, Aph-1, or Pen-2. Representative tandem MS spectra
conﬁrming the localization of all phosphorylation sites are
shown in Fig. 1(b) and Figure S1. Among the 15 PS1
phosphosites identiﬁed, 11 (eight single and three double) are
new (Fig. 1c, red), whereas four have previously been
reported (Fig. 1c, blue). Interestingly, almost all phosphosites
(13 of 15) are present in the biggest hydrophilic loop of PS1,
located between TMD6 and TMD7 (Fig. 1c). This loop
(residues 263–374) contains the site of PS1 endoproteolysis,
which is necessary for the formation of PS1-NTF and PS1-
CTF, and consequently for the full maturation and activation
of c-secretase. The two additional phosphosites are found in
the N-terminal hydrophilic domain, located at the N-terminus
of the TMD1.
PS1 phosphosite mutants do not affect the maturation of
c-secretase
To investigate whether absence of phosphorylation of the
newly identiﬁed phosphosites in PS1 can affect the assembly
and maturation of c-secretase, all newly identiﬁed PS1
(a) (b)
Fig. 2 Maturation in HEK and HeLa cells of c-secretase complexes
with mutated PS1 phosphosites. HEK (a and c) or HeLa (b and d) cells
were transiently transfected with Flag-tagged individual PS1 phospho-
site mutants. 48 h post-transfection, whole cell protein lysates were
prepared for western blot analysis and detection of mature (m) and
immature (i) c-secretase subunits (a and b, upper panels). In parallel,
c-secretase complexes containing Flag-tagged mutated PS1 individual
phosphosites were immunoprecipitated (IP) with an anti-Flag afﬁnity
resin, and c-secretase subunits were revealed by western blot analysis
(c and d, upper panels). Densitometric analysis was performed on
western blots generated from four different experiments to estimate the
iNCT : mNCT ratio (a–d, middle panels) and the PS1-NTF : PS1-FL
ratio (a–d, lower panels). Data are means  SE with n = 4, and
normalized to wild-type (WT) PS1. *p < 0.05, **p < 0.01.
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phosphosites were mutated by substituting serine or threo-
nine residues with an alanine (Figure S2). Next, HEK and
HeLa cells were transiently transfected for 2 days with
plasmids encoding for Flag-tagged WT PS1 or Flag-tagged
PS1 phosphosite mutants, and total protein extracts were
analyzed for their content in c-secretase subunits (Fig. 2a
and b, upper panels). As shown in Fig. 2, a densitometric
approach was next used to estimate the ratio between
PS1-NTF and the full-length non-endoproteolyzed PS1 (PS1-
FL), and the ratio between immature and mature NCT (iNCT
and mNCT, respectively). These ratios are indeed relevant
indicators for the maturation of the complex as the highly
regulated endoproteolytic processing of PS1 (to generate
PS1-NTF and PS1-CTF fragments) is associated with the
biological activity of c-secretase (reviewed in Fraering
2007). Also, NCT is a type-I membrane protein that is
associated with active c-secretase, in the early endosomes
and the plasma membrane, in a ‘mature’ fully N-linked
glycosylated form (Kimberly et al. 2002). In contrast, the
immature partially glycosylated form of NCT, a post-
translational modiﬁcation that occurs after entering the
endoplasmic reticulum and the Golgi apparatus, is associated
with inactive c-secretase. As summarized in Fig. 2(a) and
(b), the analysis by western blot of both HEK and HeLa
whole cell extracts revealed only minor, non-signiﬁcant
variations in the maturation of c-secretase. It has to be noted
that the few results statistically signiﬁcant in one speciﬁc cell
line are not reproducible in the two cell lines tested.
Next, c-secretase complexes with exogenous PS1 phos-
phosite mutants were isolated by immunoprecipitation of
Flag-tagged mutated PS1, with M2 anti-Flag agarose beads.
This procedure allowed us to distinguish between c-secretase
complexes containing endogenous PS1 and those made of
exogenous PS1 with different mutated phosphosites (Fig. 2c,
d and Figure S3). Similar to the results observed with the
whole cell extracts (Fig. 2a and b), the analysis of c-secretase
(c) (d)
Fig. 2 Continued.
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immunoprecipitated from HEK (Fig. 2c and Figure S4a) and
HeLa (Fig. 2d and Figure S4b) cells revealed only minor but
non-signiﬁcant variations in the PS1-NTF : PS1-FL and the
iNCT : mNCT ratios. Again, the very few results signiﬁcant
in one speciﬁc cell line are not reproducible in the two cell
lines tested.
Altogether, our results indicate that the absence of
individual phosphorylation of the newly identiﬁed phospho-
sites does not affect the maturation of c-secretase, when
compared to WT PS1. It further suggests that phosphoryla-
tion of the individual phosphosites is not required for the
assembly and maturation of the c-secretase complex. The
maturation of the complex being not disturbed, we next
decided to investigate whether the activity of c-secretase can
be modiﬁed by mutagenesis of the newly identiﬁed phos-
phosites.
PS1 phosphosite mutants do not modulate the activity of
c-secretase
Because our results have shown that PS1 phosphosite mutants
have a maturation pattern similar to that observed for the WT
PS1 (Fig. 2), we next veriﬁed if these mutants can affect the
enzymatic activity of the protease complex. To do so, HEK
and HeLa cells were ﬁrst transiently transfected for 2 days
with plasmids encoding for Flag-tagged WT PS1 or
Flag-tagged PS1 phosphosite mutants. Then, c-secretase
complexes with mutated PS1 phosphosites were immunopre-
cipitated with anti-Flag M2 beads, and used to perform
on-beads c-secretase activity assays with the APP-based
C100F substrate (APP-C100F) or the Notch-based N100F
substrate (N100F), and lipids (phosphatidylcholine and
phosphatidylethanolamine). The cleavage products AICD-
Flag, Ab peptides, and NICD-Flag were analyzed by western
blot (Fig. 3a and b) and the ratios AICD : PS1-NTF,
Ab : PS1-NTF, and NICD : PS1-NTF were estimated by
densitometry for each individual phosphosite mutant because
it reﬂects directly total activity of c-secretase (increased PS1-
NTF/mature c-secretase is associated with increased AICD/
NICD production). Control experiments with HEK cells
treated with the c-secretase inhibitor Compound-E (Seiffert
et al. 2000), the c-secretase modulator GSM-1 (Qin et al.
2011; Chavez-Gutierrez et al. 2012), or HEK cells over-
expressing Pen-2 were performed to show that the above-
described assay can detect both inhibition or enhancement of
c-secretase activity (Figure S5). The speciﬁc activity of
c-secretase and the speciﬁcity of APP-C99 processing at
the c-cleavage site within the TMD of APP were veriﬁed
by estimating the Ab42 : Ab40 ratio, using Ab1-40- and
Ab1-42-speciﬁc ELISAs (Fig. 3c and d).
As shown in Fig. 3(a–d), only minor but non-signiﬁcant
variations in the AICD : PS1-NTF, Ab : PS1-NTF, NICD :
PS1-NTF, and Ab42 : Ab40 ratios were observed, suggest-
ing an activity for c-secretase complexes with individual
mutated phosphosites similar to that observed for c-secretase
with WT PS1. Further supporting the latter, endogenous
levels of both APP-FL and APP-CTF remained unchanged in
both HEK and HeLa cells transfected with the PS1
phosphosite mutants (Figure S6), and Notch-ICD production
remained unchanged in a HEK cell line stably expressing
Notch1DE and transiently transfected with the PS1 phos-
phosite mutants (Figure S7).
To better recapitulate the neuronal genetic repertoire, the
effect of PS1 phosphosite mutants on c-secretase activity was
further tested in SH-SY5Y neuroblastoma cells. As shown in
Figure S8, we found that individual mutations of the newly
identiﬁed phosphosites do not affect APP processing.
Altogether, our data indicate that none of the PS1
phosphosite mutants, when tested individually, affect the
activity of c-secretase when compared to WT PS1. It further
suggests that phosphorylation of the individual phosphosites
is not a prerequisite for generating c-secretase activity.
The c-secretase substrate cleavage speciﬁcity is not affected
by mutated PS1 phosphosites
Total c-secretase activity can be associated with changes in
the speciﬁcity of substrate cleavage. For example, last
generation c-secretase modulators (in opposition to c-secre-
tase inhibitors) do not affect the production of total AICDs
and Ab peptides (as estimated by western blot analysis and
ELISA), but alter the Ab proﬁle, by reducing Ab42
production and increasing Ab38 production (Dimitrov et al.
2013). Because of that observation, we investigated whether
our newly identiﬁed PS1 phosphosites can affect the
speciﬁcity of APP-C99 cleavage. To do so, MALDI-TOF
mass spectrometry was used to analyze the Ab cleavage
products generated in our cell-free activity assays performed
with semi-puriﬁed c-secretase complexes bound to the M2
anti-Flag afﬁnity resin, and containing WT PS1 or individ-
ually mutated PS1 phosphosites. As shown in Fig. 4(a), none
of the phosphosites analyzed individually did affect the c-
secretase cleavage speciﬁcity, when compared to that
observed for c-secretase with WT PS1. In contrast, the
known c-secretase inhibitor Compound-E (Seiffert et al.
2000) led to the complete inhibition of total Ab production,
whereas reduced Ab42 production was associated with
increased Ab38 production in the presence of the potent
c-secretase modulator GSM-1 (Qin et al. 2011; Chavez-
Gutierrez et al. 2012) (Fig. 4b).
Proteolytic removal of the PS1 phosphorylated domains
does not affect c-secretase activity and Ab production
To support our ﬁndings that the phosphorylation status of
PS1 at the identiﬁed sites does not affect the activity of
c-secretase, we subjected the native puriﬁed c-secretase
complex to limited trypsin digestion, to proteolytically
remove the two phosphorylation domains in PS1. As shown
in Fig. 5(a), limited trypsin digestion of c-secretase
removed both the hydrophilic loop of PS1 located between
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TMD6 and TMD7 (residues 263–374) and the N-terminal
hydrophilic domain located at the N-terminus of the TMD1
(residues 1–80). The removal of these domains was
conﬁrmed by western blot analysis using antibodies target-
ing speciﬁcally the N-terminal hydrophilic loops of PS1-
NTF and PS1-CTF, respectively, MAB1563 targeting the
residues 21–80 and MAB5232 targeting the residues 263–
378 (Fig. 5b, middle panel). Next, equal amounts of
c-secretase complexes with or without the phosphorylation
domains were probed for speciﬁc activity. Western blot
analysis of APP cleavage products revealed no changes in
AICD and Ab production (Fig. 5c), and mass spectrometric
(a) (b)
(c) (d)
Fig. 3 Activity of semi-puriﬁed c-secretase complexes with mutated
PS1 phosphosites. HEK (a and c) or HeLa (b and d) cells were
transiently transfected with PS1 individual phosphosite mutants. 48 h
post-transfection, cell lysates were prepared and c-secretase
complexes with mutated PS1 phosphosites were immunoprecipitated
with an anti-Flag afﬁnity resin. Next, activity assays were performed
with c-secretase bound to the resin and puriﬁed amyloid-b precur-
sor protein (APP)-based substrate (APP-C100F) or Notch-based
substrate (N100F). Cleavage products APP intracellular domain
(AICD)-Flag, Notch intracellular domain (NICD)-Flag and Ab were
detected by western blot analysis (a and b, upper panels). AICD,
NICD and Ab production for all individual phosphosite mutants
were estimated by densitometric analysis of western blots from
three independent experiments (a and b, lower panels). AICD,
NICD and Ab productions were normalized to mature PS1-NTF
and thus expressed as AICD : PS1-NTF, NICD : PS1-NTF and
Ab : PS1-NTF ratios. Ab1-40 and Ab1-42 speciﬁc ELISAs were used
to estimate the Ab42 : Ab40 ratio (c and d). Data are means  SE
with n = 3, and normalized to wild-type (WT) PS1 (except for c
and d).
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(a)
(b)
Fig. 4 Mass spectrometric proﬁles of Ab peptides generated from
human c-secretase complexes with mutated PS1 phosphosites. (a)
MALDI-TOFmassspectrometricanalysisof totalAbpeptidesproduced in
cell-free activity assays performed with semi-puriﬁed c-secretase com-
plexes harboring the indicated mutated PS1 phosphosites and bound to
an anti-Flag afﬁnity resin. Molecular masses were accurately measured
and searched against known amino acid sequences of human amyloid-b
precursor protein (APP) for proﬁling theAb species. (b) Thewell-known c-
secretase inhibitor Compound-E (CompE) and c-secretase modulator
GSM-1 were used as controls for the speciﬁcity of APP processing.
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analysis of Ab revealed no changes in Ab proﬁle (Fig. 5d).
Together, these data suggest that the absence of the two
phosphorylated domains of PS1-NTF and PS1-CTF does
not affect the sequential and speciﬁc processing of APP by
c-secretase.
Discussion
In this study, we used a mass spectrometric approach and
highly puriﬁed c-secretase to identify a total of 11 new PS1
phosphorylation sites which, to the best of our knowledge,
(a)
(b)
(c) (d)
Fig. 5 Removal by trypsin digestion of the phosphorylated domains in
PS1 does not affect c-secretase activity and Ab production. (a)
Topologies of PS1 before ( Trypsin) and after (+ Trypsin) limited
digestion of the native c-secretase complex with the serine protease
trypsin. Red: newly identiﬁed phosphosites; blue: previously reported
phosphosites. (b) Analysis of the trypsin digested native c-secretase
complex by blue native polyacrylamide gel electrophoresis (BN-PAGE;
left), western blot (middle) and denaturing sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS–PAGE) followed by silver
stain (right). Antibodies used for the detection of the N-terminal
hydrophilic loops of PS1-NTF and PS1-CTF were MAB1563 (targeting
residues 21–80 of human PS1) and MAB5232 (targeting residues 263–
378 of human PS1), respectively. (c) Dose-dependent activity assays
performed with puriﬁed c-secretase before (Trypsin) and after
(+Trypsin) trypsin digestion. Dilutions of the c-secretase complex are
indicated. Amyloid-b precursor protein (APP) cleavage products APP
intracellular domain (AICD)-Flag and Ab were detected by western blot
with M2 anti-Flag and 6E10 anti-Ab antibodies, respectively. c-Secre-
tase protein normalization was conﬁrmed by western blot analysis of
Nicastrin (NCT). (d) MALDI-TOF mass spectrometric analysis of total
Ab peptides produced in activity assays performed with puriﬁed
c-secretase before ( Trypsin) and after (+ Trypsin) trypsin digestion.
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have never been reported in the literature. Then we generated
individual PS1 phosphosite mutants for all newly identiﬁed
phosphorylation sites, and completed detailed cell-based and
cell-free analyses of their effects on (i) the assembly and
maturation of the c-secretase complex, (ii) the activity of the
complex, and (iii) the speciﬁcity of APP processing by c-
secretase. Overall, we demonstrate here that none of the
newly identiﬁed phosphosite mutants affects the maturation
or the total and speciﬁc activities of c-secretase.
During the assembly and maturation in the secretory
pathway of the c-secretase complex, PS1 binds to the iNCT/
Aph-1 subcomplex and allows the trafﬁcking of the newly
formed trimeric intermediate subcomplex to the Golgi
apparatus (Fraering 2007). Next, the binding of Pen-2 to
PS1 triggers conformational changes in PS1 that initiate the
endoproteolytic cleavage to produce PS1-NTF and PS1-CTF,
and activate the whole complex in the late Golgi and early
endosomes (Fraering 2007). Thus, one could expect that
post-translational modiﬁcations caused, e.g., by individual or
multiple phosphorylation of amino acid residues could
modify the conformation of the PS1 protein and/or the
global structure of the c-secretase complex, and modify this
complex order of assembly and activation of c-secretase.
Based on our ﬁndings, mutagenesis of individual phospho-
sites does not affect the assembly and the maturation of the
complex, raising the question whether phosphorylation of
these sites appear during or after the maturation process.
Interestingly, we found that the vast majority of the newly
identiﬁed PS1 phosphosites are located in the loop between
TMD6 and TMD7, which contains the endoproteolysis site
(Wolfe et al. 1999). One could thus hypothesize that
phosphorylation, or absence of phosphorylation at the newly
identiﬁed sites, could modulate the endoproteolysis of PS1.
We found that this is not the case, raising again the question
whether phosphorylation of these sites occurs before PS1
endoproteolysis ‘by default’ in the non-processed loop
simply because it is the most accessible domain in the c-
secretase complex, or after endoproteolysis in the remaining
N- and C-terminal domains exposed to the cytosol.
We further found that individual mutations in the newly
identiﬁed phosphosites do not interfere with (i) the produc-
tion of total Ab, (ii) the Ab42 : Ab40 ratio, and (iii) the
proﬁle of Ab species generated by c-secretase complexes
puriﬁed from both HEK and HeLa cells. Taken together, it
suggests that the absence of phosphorylation at individual
sites does not alter the catalytic site of c-secretase. This is
consistent with the predicted topology and biophysical
properties of matured PS1 within the c-secretase complex.
Indeed, the positioning of the two catalytic aspartates in the
TMD6 and TMD7 contrasts with the positioning of the two
phosphorylated regions in PS1, namely the cytosolic N-ter-
minus of PS1-NTF (hydrophilic amino acid residues 1–81),
and the cytosolic N-terminus of PS1-CTF (hydrophilic amino
acid residues 291–374; see Fig. 1c). Our results are also
consistent with the work by Kirschenbaum et al. (2001),
showing that transient expression in HEK-APPSwe cells of
the PS1 phosphomutants S353A and S357A (a similar
approach was used in our study) did not affect Ab1-40 and
Ab1-42 production, or the Ab42 : Ab40 ratio. In contrast,
Maesako et al. (2011) found a decreased Ab42 : Ab40 ratio
associated to PS1 phosphorylation, by using the GSK3b
inhibitor LiCl to change the phosphorylation status of PS1 in
CHO-APPSwe cells. However, it remains possible that this
non-speciﬁc chemical-based strategy initiated off-target
effects, besides modifying the phosphorylation status of
Ser353 and Ser357 which would explain the observed apparent
contradictory results.
Next, about 200 point mutations in PS1 have been reported
to cause early-onset FAD, by changing the activity of c-
secretase. While some of these mutations cause a drastic
increase in total Ab production, most of them are associated
with a toxic gain of function by increasing the Ab42 : Ab40
ratio (De Strooper et al. 1998). Moreover, several of the
FAD mutations in PS1 are characterized by a loss of function
causing drastic reductions in AICD production (Bentahir
et al. 2006; Cacquevel et al. 2012). Very interestingly,
residues Thr354 and Ser365, both of which are among our
newly identiﬁed PS1 phosphosites, have also been reported
to be part of the FAD-causing double mutations Thr354Ile/
Ala431Glu (Lee et al. 2006) and Met146Val/Ser365Tyr
(Rogaeva et al. 2001). However, single mutations at posi-
tions 431 and 146 (Ala431Glu and Met146Val, respectively)
are also known to cause FAD (Rogaeva et al. 2001; Lee
et al. 2006), raising the question about the signiﬁcance of the
second mutations (Thr354Ile and Ser365Tyr, respectively).
Based on our mutagenesis data (Fig. 3), single mutations in
Thr354 or Ser365 are not expected to cause AD pathogenesis.
Finally, in this study, only one phosphosite was mutated at
the time. Although it remains very possible that multiple
phosphosite mutations are required to detect an effect on the
maturation and/or activity of c-secretase, this hypothesis has
already been partially challenged by Saura et al., who
demonstrated that the deletion of the PS1 hydrophilic loop
(HL-residues 304–371) does not affect Ab production (Saura
et al. 2000). Based on this observation, one can anticipate
that mutagenesis of multiple phosphosites in this HL domain
will give the same results. We indirectly challenged the
hypothesis that mutagenesis of multiple phosphosites does
not affect the activity of c-secretase by removing proteolit-
ically the two N-terminal hydrophilic loops of PS1-NTF and
PS1-CTF, which contain all identiﬁed phosphorylation sites.
Consistent with, but going further than the Saura study, we
found that the absence of the two phosphorylated domains
(residues 1–80 and 263–374) does not affect the speciﬁc
processing of APP by c-secretase (Fig. 5).
In conclusion, our results suggest that the c-secretase
complex can be phosphorylated at two well-deﬁned domains
within PS1, and that absence of phosphorylation at individual
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phosphosites does not modulate APP or Notch processing
and Ab production. From the latter observation, one can
speculate that individual phosphosites do not modulate
cerebral Ab plaque formation, and consequently will not
prove to be therapeutic targets for AD.
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5SUPPLEMENTARY FIGURE 1. Tandem MS spectra of phosphorylated peptides identified in 
the γ-secretase catalytic subunit PS1. The high molecular weight human γ-secretase complex 
resolved by BN-PAGE and stained with Coomassie Brillant Blue (Fig. 1) was excised and used for the 
identification by electrospray LC-MS/MS mass spectrometry of new phosphorylation sites in 
Presenilin-1. Tandem MS spectra of PS1 phosphorylated peptides are shown, confirming the 
identification of a total of 15 PS1 phosphorylated peptides, corresponding to twelve single and three 
double phosphosites in PS1, at the indicated amino-acid residues. Among these, eleven (8 single and 3 
double) are newly identified PS1 phosphosites (also summarized in Fig. 1C). 
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Oligonucleotide Sequence
FS28A AGC-AAT-ACT-GTA-CGT-GCC-CAG-AAT-GAC-AAT-AGA
RS28A TCT-ATT-GTC-ATT-CTG-GGC-ACG-TAC-AGT-ATT-GCT
FT74A GAA-GAT-GAG-GAG-CTG-GCA-TTG-AAA-TAT-GGC-GCC
RT74A GGC-GCC-ATA-TTT-CAA-TGC-CAG-CTC-CTC-ATC-TTC
FS310A,S313A GCT-CAA-AGG-AGA-GTA-GCC-AAA-AAT-GCC-AAG-TAT
RS310A,S313A ATA-CTT-GGC-ATT-TTT-GGC-TAC-TCT-CCT-TTG-AGC
FS313A AGA-GTA-TCC-AAA-AAT-GCC-AAG-TAT-AAT-GCA-GAA
RS313A TTC-TGC-ATT-ATA-CTT-GGC-ATT-TTT-GGA-TAC-TCT
FS324A AGC-ACA-GAA-AGG-GAG-GCA-CAA-GAC-ACT-GTT-GCA
RS324A TGC-AAC-AGT-GTC-TTG-TGC-CTC-CCT-TTC-TGT-GCT
FS337A GAT-GAT-GGC-GGG-TTC-GCT-GAG-GAA-TGG-GAA-GCC
RS337A GGC-TTC-CCA-TTC-CTC-AGC-GAA-CCC-GCC-ATC-ATC
FS365A GCT-GTC-CAG-GAA-CTT-GCC-AGC-AGT-ATC-CTC-GCT
RS365A AGC-GAG-GAT-ACT-GCT-GGC-AAG-TTC-CTG-GAC-AGC
FS366A GTC-CAG-GAA-CTT-TCC-GCC-AGT-ATC-CTC-GCT-GGT
RS366A ACC-AGC-GAG-GAT-ACT-GGC-GGA-AAG-TTC-TGG-AC
FS367A CAG-GAA-CTT-TCC-AGC-GCT-ATC-CTC-GCT-GGT-GAA
RS367A TTC-ACC-AGC-GAG-GAT-AGC-GCT-GGA-AAG-TTC-CTG
FS365A,S367A GCT-GTC-CAG-GAA-CTT-GCC-AGC-GCT-ATC-CTC-GCT
RS365A,S367A AGC-GAG-GAT-AGC-GCT-GGC-AAG-TTC-CTG-GAC-AGC
FS366A,S367A GTC-CAG-GAA-CTT-TCC-GCC-GCT-ATC-CTC-GCT-GGT
RS366A,S367A ACC-AGC-GAG-GAT-AGC-GGC-GGA-AAG-TTC-CTG-GAC
SUPPLEMENTARY FIGURE 2. DNA sequences used to generate Ser or Thr to Ala phosphosite 
mutations in PS1, the catalytic subunit of the γ-secretase complex. Oligonucleotide primers listed 
above and containing desired Serine or Threonine to Alanine mutations were purchased at Eurogentec 
(Liège, Belgium) and annealed to the template PS1 vector. Mutagenic primers were extended during 
temperature cycling of DNA polymerase, resulting in mutated plasmids containing nicked circular 
strands. Then vectors were treated with the endonuclease Dpn I, specific for methylated DNA. The 
endonuclease allowed the digestion of the non-mutated DNA template and thus selecting vectors with 
expected mutations. Finally, nicked DNAs were transformed into XL1-Blue supercompetent cells (E. 
coli), to repair nicks in the mutated plasmids. The production of 11 different PS1 phosphosite mutants 
was completed and all mutants were verified by sequencing (Microsynth AG, Balgach, Switzerland).
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SUPPLEMENTARY FIGURE 3. Endogenous and exogenous PS1 levels in HEK and HeLa cells 
of γ-secretase complexes with mutated PS1 phosphosites. HEK (A) or HeLa (B) cells transiently 
transfected with Flag-tagged individual PS1 phosphosite mutants were collected 48 hours post-
transfection, and whole cell protein extracts were prepared for Western blot analysis to detect both 
endogenous (PS1-NTF) and exogenous (Flag-PS1-NTF) PS1 with the MAB1563 anti-PS1 antibody 
(upper panels), or with the M2 anti-Flag antibody (middle panels). Untransfected cells are labeled 
WT-. β-actin served as a loading control. 
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SUPPLEMENTARY FIGURE 4. Quantification of γ-secretase subunits in HEK and HeLa cells 
expressing PS1 phosphosite mutants. HEK (A) or HeLa (B) cells were transiently transfected with 
Flag-tagged individual PS1 phosphosite mutants. 48 hours post-transfection, cell lysates were prepared 
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9and γ-secretase complexes with mutated PS1 phosphosites were immunoprecipitated with an anti-Flag 
affinity resin for Western blot analysis (see Figs. 2C and 2D, upper panels). Densitometric analyses to 
estimate iNCT, mNCT, PS1-NTF, PS1-CTF, PS1-FL, Aph-1 and Pen-2 protein levels were performed 
on Western blots from three independent experiments. Data are means ± S.E. with n = 3, and 
normalized to WT PS1. *, p<0.05; **, p<0.01. 
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Matz et al., Supplementary Figure 5 
SUPPLEMENTARY FIGURE 5. Controls for inhibition or enhancement of γ-secretase activity. 
Untransfected HEK cells (Ctrl-), HEK cells transiently transfected with Flag-tagged WT PS1, or HEK 
cells transiently co-transfected with WT PS1 and Pen-2 (control for enhanced γ-secretase activity) 
were first incubated for 48 hours. Next, cell lysates were prepared and γ-secretase complexes with 
Flag-tagged WT PS1 were immunoprecipitated with an anti-Flag affinity resin. Then, activity assays 
were performed with γ-secretase bound to the resin and purified APP-based substrate (APP-C100F), in 
the presence or absence of the well-known γ-secretase inhibitor Compound-E (CompE; control for 
inhibited γ-secretase activity) or the γ-secretase modulator GSM-1. Cleavage products AICD-Flag and 
Aβ were detected by Western blot analysis together with γ-secretase subunits. CompE and Pen-2
overexpression caused respectively γ-secretase inhibition and enhancement. 
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Matz et al., Supplementary Figure 6 
SUPPLEMENTARY FIGURE 6. Endogenous APP levels in HEK and HeLa cells of γ-secretase 
complexes with mutated PS1 phosphosites. HEK (A) or HeLa (B) cells transiently transfected with 
Flag-tagged individual PS1 phosphosite mutants were collected 48 hours post-transfection, and whole 
cell protein extracts were prepared for Western blot analysis to detect both APP-FLs and APP-CTFs 
with the CT-15 anti-APP antibody, and Flag-tagged PS1-NTF with the M2 anti-Flag antibody. β-actin
served as a loading control. 
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Matz et al., Supplementary Figure 7 
SUPPLEMENTARY FIGURE 7. γ-Secretase complexes with mutated PS1 phosphosites do not 
affect cellular Notch processing. HEK-N7 cells stably overexpressing the γ-secretase substrate 
Notch1ΔE (residues 1704-2184 of human Notch1) were transiently transfected for 48 hours with PS1 
phosphosite mutants. Next, protein extracts were prepared and probed by Western blot for γ-secretase 
subunits and Notch intracellular domain (NICD). Untransfected cells (Ctrl-) and cells transfected with 
WT PS1 served as controls for NICD production, while β-actin served as a protein loading control. 
When compared to the control cells expressing WT PS1, PS1 phosphosite mutants do not significantly 
alter NICD production.
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Matz et al., Supplementary Figure 8 
SUPPLEMENTARY FIGURE 8. Activity of γ-secretase complexes with mutated PS1 
phosphosites purified from SH-SY5Y neuroblastoma cells. SH-SY5Y cells were transiently 
transfected with PS1 individual phosphosite mutants. Cell lysates were prepared and γ-secretase 
complexes with mutated PS1 phosphosites were immunoprecipitated with an anti-Flag affinity resin. 
Next, activity assays were performed with γ-secretase bound to the resin by using purified APP-based 
substrate (APP-C100F). (A) Cleavage products AICD-Flag and Aβ were detected by Western blot 
analysis. (B) AICD and Aβ production for all individual phosphosite mutants were estimated by 
densitometric analysis of Western blots from three independent experiments. AICD and Aβ 
productions were normalized to mature PS1-NTF and thus expressed as AICD:PS1-NTF and 
Aβ:PS1-NTF ratios. Data are means ± S.E. with n = 3, and normalized to WT PS1. 
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Rapid remodeling of the actin cytoskeleton in the pre- and/or post-synaptic compartments is responsible for the
regulation of neuronal plasticity, which is an important process for learning andmemory. Coﬁlin1 plays an essen-
tial role in these processes and a dysregulation of its activity was associated with the cognitive decline observed
during normal aging and Alzheimer's disease (AD). To understand themechanism(s) regulating Coﬁlin1 activity
we evaluated changes occurring with regard to Coﬁlin1 and its up-stream regulators Lim kinase-1 (LIMK1) and
Slingshot phosphatase-1 (SSH1) in (i) human AD brain, (ii) 1-, 4-, and 10-months old APP/PS1 mice, (iii) wild
type 3-, 8-, 12-, 18- and 26-months old mice, as well as in cellular models including (iv) mouse primary cortical
neurons (PCNs, cultured for 5, 10, 15 and 20 days in vitro) and (v) mouse embryonic ﬁbroblasts (MEF). Interest-
ingly, we found an increased Coﬁlin1 phosphorylation/inactivation with age and AD pathology, both in vivo and
in vitro. These changes were associated with a major inactivation of SSH1. Interestingly, inhibition of γ-secretase
activitywith Compound-E (10 μM)prevented Coﬁlin1 phosphorylation/inactivation through an increase of SSH1
activity in PCNs. Similarly, MEF cells double knock-out for γ-secretase catalytic subunits presenilin-1 and -2
(MEFDKO) showed a strong decrease of both Coﬁlin1 and SSH1phosphorylation,whichwere rescued by the over-
expression of human γ-secretase. Together, these results shed new light in understanding the molecular mech-
anisms promoting Coﬁlin1 dysregulation, both during aging and AD. They further have the potential to impact
the development of therapies to safely treat AD.
© 2014 Elsevier B.V. All rights reserved.
1. Introduction
Alzheimer's disease (AD) is the most common form of dementia
among the elderly. Amyloid-β peptides (Aβ) form senile plaques,
which, together with hyperphosphorylated tau-based neuroﬁbrillary
tangles (NFT), are the hallmarks of AD neuropathology [1]. From a clin-
ical point of view, a decline in episodic memory is observed, often mis-
taken with normal aging-related cognitive deﬁciencies [1]. These
similarities raised questions about the role of aging in AD onset and pro-
gression, thus demanding major efforts to clarify the molecular mecha-
nisms underlying these processes [2].
Aβ is strongly suspected to play a major role in the development of
dementia. Elevated Aβ levels produce abnormalities in learning and
synaptic functions in amyloid precursor protein (APP) transgenic mice
[3,4]. Furthermore, studies in human [5,6] and 3×Tg-AD mice (triple
transgenic model of AD) [7] highlighted the importance of soluble
endocytosed intraneuronal Aβ as the initial mediator of Tau pathology
and cognitive decline. Indeed, although senile plaque-formation has
been widely proposed to be responsible of the Aβ toxic effects, meticu-
lous analyses of AD patients suggest that the soluble pool of Aβ42 corre-
lates better with cognitive decline than Aβ plaques [5,6,8]. Oligomers of
Aβ42 signiﬁcantly (i) diminish long-term potentiation (LTP), which is
needed for learning and memory [9], (ii) promote an increase of oxida-
tive stress [10–12], (iii) impair synaptic functions [9,12]. Whether these
effects are mainly due to the extracellular or to the endocytosed Aβ re-
main to be clariﬁed, although disturbances in the metabolism of Aβ
might regionally increase Aβ42 levels that negativelymodulate neuronal
activity and potentially lead to a decline in cognitive performance [13].
Aβ peptides are derived from APP, a type I membrane protein that
undergoes a ﬁrst cleavage by β-secretase leading to the production of a
99 amino-acid long APP-C99 (APP-C-terminal fragment). The latter is
further processed within the membrane bilayer by the intramembrane
aspartyl-protease γ-secretase to generate an APP intracellular domain
(AICD) released into the cytoplasm, and Aβ secreted in the extracellular
compartment [14]. Despite the prominent role of γ-secretase in driving
Aβ production, its involvement in the cellular pathways regulating cog-
nitive processes is controversial because both the increase and the lack
of γ-secretase activity were reported to impair synaptic function and
neuronal survival [15–18]. APP is not the unique substrate for γ-
Biochimica et Biophysica Acta 1842 (2014) 2500–2509
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secretase, which is responsible for the cleavage of a broad range of pro-
tein receptors playing a role in neuronal trafﬁcking and synaptic plastic-
ity [reviewed in [19]].
Recently, modiﬁcations of γ-secretase by nitrosative stress were
found to be responsible for an age-dependent increase of the Aβ42/Aβ40
ratio in rat hippocampal neurons, thus offering a new possible mecha-
nism linking aging and AD [20]. Indeed, the accumulation of Aβ42
would trigger a pathological mechanism leading to an aberrant neuritic
morphology, sprouting and breakdown [21], which affect the structure
of synapses and lead to (i) alteredneuronal electrophysiology [22], (ii) in-
hibition of long-termpotentiation [23] and (iii) transientmemory deﬁcits
[24].
These phenomena strictly involve the actin cytoskeleton, which ac-
tively participates in thematuration and in themaintenance of the syn-
apses by regulating spine morphology [25], receptor anchoring/
trafﬁcking and synaptic plasticity [26,27]. Among numerous actin-
binding proteins, the actin-depolimerizing factor (ADF)/coﬁlin family
proteins, comprising inmammals Coﬁlin1 (a non-muscle type), Coﬁlin2
(amuscle-type) andADF (also known as destrin), critically control actin
ﬁlament dynamics and reorganization by severing and depolymerizing
actin ﬁlaments [28]. A growing body of evidence lends support to a
link between neurite transport defects or impaired synaptic plasticity
observed with age or in neurodegenerative diseases, and alterations in
the organization and dynamics of the actin cytoskeleton initiated by
Coﬁlin1 [27,29–31]. Regulation of Coﬁlin1 activity is quite complex
and involves cross-talking pathways [30]. In particular, Coﬁlin1 is
inactivated by LIMkinase isoform1 (LIMK1)-mediated phosphorylation
at Serine 3 (Ser3), and is reactivated by Slingshot phosphatase isoform1
(SSH1)-mediated dephosphorylation [28]. Although other kinases and
phosphatases can affect Coﬁlin1 activity, LIMK1 and SSH1 show the
highest substrate speciﬁcity [30]. Remarkably, phosphorylation of Thre-
onine 508 activates LIMK1 whereas phosphorylation at Serine 937 and
978 inactivates SSH1 [28]. In addition, not only Coﬁlin1 but also LIMK1
is a substrate for SSH1 activity, which in thisway can control Coﬁlin1 ac-
tivation either directly or indirectly through an upstream regulation of
LIMK1 [32].
In this study, we show that a dysregulation of SSH1/LIMK1/Coﬁlin1
(hereafter, Coﬁlin1 pathway) occurs in the brain as an effect of both
age and AD pathological features. We further demonstrate that γ-
secretase activity is involved in the regulation of both Coﬁlin1 protein
levels and phosphorylation/inactivation, providing potential new in-
sights into the molecular mechanisms that link aging to AD.
2. Materials and methods
2.1. Human tissues
Post-mortem tissues from frontal cortex were obtained from the Jo-
seph and Kathleen Bryan Alzheimer's Disease Research Center, Duke
University Medical Center [33]. Controls were compared to patients
with moderate to severe Alzheimer's disease. The age of death, gender
and postmortem intervalwere comparable in both groups. Demograph-
ic and diagnostic features available for patients used in this study are
showed in the Supplementary Table 1.
2.2. Animals
All animal procedures were performed in accordance to Swiss au-
thority guidelines. Animals were sacriﬁced at the selected age, brains
were extracted, weighed, ﬂash-frozen, and stored at −80 °C until
total protein extraction from one hemibrain and further analyses. Fro-
zen brain specimens were obtained from 3-, 8-, 12-, 18- and 26-
months old wild type (WT) (C57Bl/6 J) mice and 1-, 4- and 10-
months old APPKM670/671NL/PS1L166P transgenic mice (APP/PS1) mice
[34] or APP knock-out (APPKO) mice [35], and their littermate controls.
APP/PS1 mice were studied at 1, 4 and 10 months of age, because this
is the time frame during which these mice develop all pathological AD
features [34]. Indeed, cerebral amyloidosis starts at 6–8 weeks, and
the ratio of human amyloid Aβ42/Aβ40 is respectively 1.5 and 5 in
pre-depositing (1 month-old) and amyloid-depositing mice (4 and
10 months-old). Consistent with this ratio, extensive congophilic pa-
renchymal amyloid but minimal amyloid angiopathy is observed [34].
Amyloid-associated pathologies include dystrophic synaptic boutons,
hyperphosphorylated tau-positive neuritic structures and robust gliosis,
with neocortical microglia number increasing threefold from 1 to
8 months of age. Global neocortical neuron loss is not apparent up to
8 months of age, but local neuron loss in the dentate gyrus is observed.
In addition, diffuse Aβ plaques are strongly increased at 8 month and
defects in cognition were observed only at 8 month [34]. Because the
age process in WT mice is much longer than that observed in APP/PS1
mice, we have decided not to limit the analysis of the Coﬁlin1 pathway
in WT mice to the time points selected for APP/PS1 mice. Indeed, ac-
cording to the American Federation of Aging Research criteria (http://
www.afar.org/research/funding/animal-use/), 2–3 months-old mice
can be considered young and they represent the biological equivalent
of teen-agers and college freshmen, whereas 26 months-old mice can
be considered old, taking also into consideration that a median survival
is of about 24 months. Finally APPKOmice [35]were studied at the same
time points selected for APP/PS1 mice to test whether the changes ob-
served in a model characterized by an accelerated APP cleavage (APP/
PS1) were different in the absence of APP protein.
2.3. Cell culture and treatments
Mouse primary cortical neurons (PCNs) were prepared from embry-
onic day 17 Of1 mouse fetal brains. Cortices were digested in a media
containing papain (20 U/ml, Sigma-Aldrich GmbH, Buchs, Switzerland)
anddissociated bymechanical trituration. Cellswere plated in neurobasal
medium (Invitrogen, LuBioScience GmbH, Lucerne, Switzerland) supple-
mentedwith B27 (Invitrogen, LuBioScienceGmbH, Lucerne, Switzerland)
and 2mM L-glutamine on poly-L-ornythine coated plates at 1 × 105 cells/
cm2 at 37 °C in a humidiﬁed 5% CO2 atmosphere. At day 5, 10, 15 and 20,
neurons werewashed twice with PBS and proteins were extracted as de-
scribed below. The criteria to univocally establish at what age in vitro
PCNs reﬂect aging neurons in vivo do not appear very clear due to diver-
gent interpretations. Indeed, from one side, it was reported that during
the ﬁrst week, in vitromouse PCNs establishmorphological and function-
al axons and dendrites; during the second week they establish synaptic
activity and from the third week on (14 DIV) they begin to show canon-
ical signs of aging, including (i) accumulation of ROS, (ii) lipofuscin gran-
ules, (iii) heterochromatic foci, (iv) activation of the c-Jun N-terminal
protein kinase (JNK) and (v) the DNA repair p53/p21 pathways as well
as (vii) cholesterol loss and (viii) increased cholesterol-24-hydroxylase
[36–38]. In addition, in vitro hippocampal neurons cultured for 3 weeks
(21 DIV) undergo a time-associated increase in tubulin acetylation simi-
lar to that observed in vivo, and a time-associated increase in the phos-
phorylation of the microtubule-associated protein Tau [38] similar to
those reported either in aged human brains [39] or in mouse models of
senescence [40]. On the other side, it has been shown that starting at 28
DIV, mouse PCNs present a time-dependent and signiﬁcant increase in
known features of the aging brain, including protein oxidation, creatine
kinase expression and calcium channel density [41,42]. In addition,
based on phase contrast microscopy and the evaluation of the neuronal
nuclear protein NeuN levels in mouse PCNs cultured from 5 to 60 DIV,
it seems that (i) 20–25DIV cultured neurons show typical signs of neuro-
nal maturation, while (ii) only a subset of the neuronal population sur-
vives through DIV60 [43]. Thus, this spontaneous age-related loss of
neurons supports an important distinction between DIV 20–25 neurons
(“matured neurons”) and DIV60 neurons (“aged neurons”). Based on
the above-cited information, 20 DIV neurons used in this study may bet-
ter reﬂect mature-to-old neurons in vivo, and not exclusively aging neu-
rons in the brain. To test γ-secretase activity-dependent changes of
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Coﬁlin1 pathway, the day before the selected time points, neurons were
treated overnightwithDMSO (0.25%) orγ-secretase inhibitor Compound
E (CpdE) (10 μM, Merck Millipore, Darmstadt, Germany) and then sub-
jected toWestern Blot analysis as described below. Mouse Embryonic Fi-
broblasts: (i) wild-type (MEF), (ii) double knock-out for presenilin-1
(PS1) and -2 (PS2) [MEFDKO, [44,45]] and (iii) double knock-out overex-
pressing the human γ-secretase complex [MEFDKO + hγ-secretase, [46]]
were grown in 10 cm dishes in DMEM, supplemented with 10% fetal bo-
vine serum (FBS) and penicillin/streptomycin (P/S) (Invitrogen,
LuBioScience GmbH, Lucerne, Switzerland).
2.4. Western Blot
Total protein extracts were prepared in 1% NP40–HEPES buffer
(50 mM HEPES, pH 7.0, 150 mM NaCl, 5 mM MgCl2, 5 mM CaCl2),
supplemented with protease inhibitor cocktail (Roche, Rotkreuz,
Switzerland), and were clariﬁed by centrifugation for 1 h at 16,000 ×g,
4 °C. Protein concentrations were determined using standard BCA
assay (Pierce, Rockford, IL, USA). Ten micrograms of protein were re-
solved on 4–12% Bis-Tris PAGE gels (Invitrogen, LuBioScience GmbH,
Lucerne, Switzerland), or on standard 12% acrylamide/bisacrylamide
Tris Glycine gels for SDS-PAGE analysis. For immunoblot analysis, gels
were transferred onto nitrocellulose membranes (Whatman, Dassel,
Germany), and incubated overnight at 4 °Cwith the following antibodies:
anti-Coﬁlin1 612144 (1:1000, Bd Transduction Laboratories, Allschwil,
Switzerland) anti-phospho(Ser3)-Coﬁlin1 3311 s (1:500, Cell Signaling,
Bioconcept, Allschwill, Switzerland), anti-phospho(Ser3)-Coﬁlin1
ab12866 (1:1000, abcam, Cambridge, United Kingdom), anti-LIMK1
ab87971 (1:1000, abcam, Cambridge, United Kingdom), anti-
phospho(Thr508)-LIMK1 ab38508 (1:500, abcam, Cambridge, United
Kingdom), anti-SSH1 ab107799 (1:1000, abcam, Cambridge, United
Kingdom), anti-phospho(Ser978)-SSH1 SP3901 (1:500, ECM Biosciences,
Versailles, KY, USA), anti-PS1 ab10281 (1:1000, abcam, Cambridge,
United Kingdom), anti-APP-C terminal fragments (CTFs) A87717
(1:10,000, Sigma-Aldrich, GmbH, Buchs, Switzerland), anti-Chronophin
4686 (1:500, Cell Signaling, Bioconcept, Allschwill, Switzerland) and
anti-β-actin A2066 (1:5000, Sigma-Aldrich GmbH, Buchs, Switzerland).
Membranes were developed by using anti-mouse/rabbit/rat IgG conju-
gated to Alexa 680 or 800 purchased from Invitrogen (LuBioScience
GmbH, Lucerne, Switzerland). The Odyssey infrared imaging system
(LICOR, Bad Homburg, Germany) was used to detect the ﬂuorescent sig-
nal. For each antibody used in this study, a dose–response analysis was
performed by loading 15–40 μg total proteins from 3 months-old WT
mouse brain whole homogenate — this is to correlate changes observed
in signal strength with changes observed at the protein levels (Supple-
mentary Fig. 1). As shown in Supplementary Fig. 1, all signals exhibit lin-
earity at the protein levels tested and the protein amount (30 μg)weused
for sample analysis all over the manuscript falls into this linear range.
2.5. Aβ quantiﬁcation
Cultures media from 5, 10, 15 and 20 days in vitro (DIV) neurons
were collected, protease inhibitor cocktail (Roche, Rotkreuz,
Switzerland) added, and Aβ peptides were quantiﬁed using mouse
Aβ40 and Aβ42 ELISA kits (KHB3481, KHB3441; Invitrogen, LuBioScience
GmbH, Lucerne, Switzerland).
2.6. Statistical analysis
All experiments were performed at least twice with comparable re-
sults, and all data are presented asmeans± SEMof n independent sam-
ples per group. Student's t test was applied for statistical analysis.
P b 0.05 was considered signiﬁcantly different from the reference value.
3. Results
3.1. The Coﬁlin1 activation state is altered in AD human brains
Hyperactive coﬁlin forming rod-shaped coﬁlin-saturated actin ﬁla-
ment bundles (rods) were previously reported over Aβ plaques in the
hippocampus of AD subjects, suggesting abnormal Coﬁlin1 aggregation
in response to neurodegenerative stimuli [47,48]. Because of the pivotal
role ofγ-secretase in drivingADpathology and based on a signiﬁcant in-
crease of its activity in the brain of sporadic AD subjects [49], we ana-
lyzed the Coﬁlin1 pathway in the frontal cortex of seven sporadic AD
subjects (average age 87.8 ± 1.6 years) and their age-matched controls
(average age 82.6±2.7 years) [33]. As shown in Fig. 1, a signiﬁcant ~1.6
fold-increase of the pCoﬁlin1/Coﬁlin1 ratio (Fig. 1-c) is observed in the
frontal cortex of AD subjects with respect to controls, suggesting that
Coﬁlin1 gets inactivated in diseased brains. To extend our knowledge
about the mechanisms responsible for Coﬁlin1 inactivation in AD, we
further demonstrated defects in SSH1 activity. As shown in Fig. 1-g, a
~45% signiﬁcant reduction of total SSH1 protein levels associated with
Fig. 1. Coﬁlin1 inactivation in the frontal cortex of sporadic human Alzheimer's disease.
Changes observed with regard to the Coﬁlin1 pathway in the frontal cortex of sporadic
Alzheimer's disease subjects (n = 7), relative to their age-matched controls (n = 5).
Top panels: Western blot analyses of total protein extracts. Bottom panels: densitometric
analyses of Western blot protein bands: (a) Total Coﬁlin1 protein levels; (b) pCoﬁlin1
levels; (c) pCoﬁlin1/Coﬁlin1 ratio; (d) Total LIMK1 protein levels; (e) pLIMK1 levels;
(f) pLIMK1/LIMK1 ratio; (g) Total SSH1 protein levels; (h) pSSH1 levels; (i) pSSH1/SSH1
ratio. Protein levels were normalized to the loading control β-actin. Densitometric values
shown in the histograms are given as percentage of Control samples set as 100%.Means±
SEM, *P b 0.05 vs Control.
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unchanged pSSH1 levels led to the signiﬁcant increase of the pSSH1/
SSH1 ratio (Fig. 1-i). The latter suggests an inactivation of SSH1 in AD
brains. No signiﬁcant changes were observed for LIMK1 protein levels
and phosphorylation (Fig. 1-d–f). Altogether, these observations sug-
gest that the increased Coﬁlin1 inactivation observed in our AD samples
could be mediated, at least in part by the loss of SSH1 activity.
3.2. AD pathology-associated inactivation of Coﬁlin1 in the brain of APP/
PS1 mice
To better understand the altered pattern of expression/activation of
Coﬁlin1 in AD, we analyzed changes of the Coﬁlin1 pathway in 1-, 4-,
and 10-months old APP/PS1mice [34], a well-knownmodel of AD char-
acterized by age-associated increase of pathological features including
Aβ senile plaques and cognitive deﬁcits [34]. As shown in Fig. 2A-a,
Coﬁlin1 protein levels are signiﬁcantly reduced by ~65% and ~50% at
4- and 10-months of age,with respect to 1month-oldmice. The analysis
of pCoﬁlin1 further revealed a signiﬁcant ~70% decrease at 4 months of
age, whereas an increase of about 70% was observed at 10 months
(Fig. 2A-b). Interestingly, 10-months old APP/PS1 mice showed a 7-
fold increase in the pCoﬁlin1/Coﬁlin1 ratio, with respect to the young,
1-month old mice (Fig. 2A-c). In order to assess whether alteration of
Coﬁlin1 phosphorylation can be explained by modiﬁcations of its up-
stream regulators, we next evaluated changes occurring for LIMK1 and
SSH1. As shown in Fig. 2A-d, total LIMK1 did not show any signiﬁcant
changes at 1-, 4- and 10-months. Conversely, pLIMK1 levels were dras-
tically increased (by ~ 200%) at 10-months of age, with respect to the
1 month-old mice (Fig. 2A-e). Consequently, the pLIMK1/LIMK1 ratio
showed a 3.5-fold increase at 10-months (Fig. 2A-f), suggesting an
overactivation of LIMK1 in agedmice.With regard to SSH1 phosphatase
the most drastic effect was observed for the inactive pSSH1 at 10-
months of age, with an increase of ~ 200% with respect to 1 month-old
mice (Fig. 2A-h). As a consequence, a 3.9-fold increase of the pSSH1/
SSH1 ratio was observed (Fig. 2A-i), suggesting an inactivation of
SSH1 in aged mice.
Finally, in order to evaluate whether the increased phosphorylation/
inactivation of Coﬁlin1 in 10months-old APP/PS1micewas the result of
AD-related pathology, the Coﬁlin pathway was examined in APP/PS1
mice and their littermate WT controls. As shown in Fig. 2B, Coﬁlin1
and pCoﬁlin1 protein levels were respectively reduced by ~ 45%
(Fig. 2B-a) and increased by ~80% (Fig. 2B-b) in AD mice, with respect
to the littermate matched WT controls. As a consequence of these
changes, the pCoﬁlin1/Coﬁlin1 ratio showed a signiﬁcant 6-fold in-
crease (Fig. 2B-c), suggesting again an inactivation of Coﬁlin1 in AD
mice. These lines of evidence parallel with changes observed with re-
gard to LIMK1 and SSH1. Indeed, in APP/PS1 mice both LIMK1 and
SSH1 protein levels were reduced by ~40% (Supplementary Fig. 2-a
and b), while pLIMK1 and pSSH1 levels were signiﬁcantly increased
by ~40% and ~140%, respectively (Supplementary Fig. 2-b and e). The
drastic increases of both pLIM1/LIMK1 (~2.5-fold, Supplementary
Fig. 2-c) and pSSH1/SSH1 (~5-fold, Supplementary Fig. 2-f) ratios sug-
gest again an activation of LIMK1 and an inactivation of SSH1 in the
brain of 10-months old AD mice.
3.3. Age-dependent Coﬁlin1 inactivation in the brain of WT mice
We next investigated whether aging, in the absence of AD, plays a
role in the Coﬁlin pathway alterations observed in AD human/mice
Fig. 2. Alzheimer's disease pathology-associated changes of the Coﬁlin1 pathway proteins
in the brain of APP/PS1 mice. (A) Age-dependent changes observed with regard to pro-
teins controlling the Coﬁlin1 pathway, in the brain of 1- (n = 3), 4- (n = 4) and 10-
months old (n= 3) APP/PS1 mice. Top panels: Western blot analyses of total protein ex-
tracts. Bottom panels: densitometric analyses of Western blot protein bands: (a) Total
Coﬁlin1 protein levels; (b) pCoﬁlin1 levels; (c) pCoﬁlin1/Coﬁlin1 ratio; (d) Total LIMK1
protein levels; (e) pLIMK1 levels; (f) pLIMK1/LIMK1 ratio; (g) Total SSH1 protein levels;
(h) pSSH1 levels; (i) pSSH1/SSH1 ratio. (B) Decreased total Coﬁlin1 protein levels and in-
creased pCoﬁlin1 levels in 10-months old APP/PS1 mice (n = 3), with respect to their lit-
termate WT controls (n = 3). Top panels: Western blot analyses of total protein extracts.
Bottom panels: densitometric analyses of Western blot protein bands: (a) Total Coﬁlin1
protein levels; (b) pCoﬁlin1 levels; (c) pCoﬁlin1/Coﬁlin1 ratio. Protein levelswere normal-
ized to the loading control β-actin. Densitometric values shown in the histograms are
given as percentage of 1 month-old mice (A) or WT mice (B) set as 100%. Means ±
SEM, *P b 0.05, **P b 0.01 and ***P b 0.001 vs Control (A) or WT (B).
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samples. To do so, we evaluated changes in the Coﬁlin pathway occur-
ring in the brains of 3-, 8-, 12-, 18- and 26-month old WT mice. When
compared to 3-month oldmice, Coﬁlin1 protein levels were signiﬁcant-
ly reduced by ~25% both at 8 and 26 months (Fig. 3-a). Yet, the major
change was observed for pCoﬁlin1, which was increased by ~76% in
the oldest 26months-oldmice (Fig. 3-b), leading to a ~2.3-fold increase
of the pCoﬁlin1/Coﬁlin1 ratio (Fig. 3-c). No signiﬁcant differences were
observed for LIMK1 total and phosphorylated protein levels (Fig. 3-d–
e). In contrast, an interesting trendwas observed for pSSH1. After a sig-
niﬁcant reduction at both 8 and 12 months (by ~45% and ~35%, respec-
tively), pSSH1 levels signiﬁcantly raised (by ~27%) at 26 months (Fig. 3-
h). Together, and despite the drastic increase of both pCoﬁlin1 levels
and pCoﬁlin1/Coﬁlin1 ratio, no signiﬁcant changes were found for
both pLIMK1/LIMK1 and pSSH1/SSH1 ratios in 26 months-old mice
(Fig. 3-f and i). At a ﬁrst glance, the latter observation does not explain
changes observed with regard to Coﬁlin1. However, an in-depth analy-
sis of the results suggests that 8 months possibly represents a turning
point in the aging process occurring in our mice. Indeed, from 8 to
26 months, a clear increase of pCoﬁlin1 occurs (Fig. 3-b), possibly
caused by an age-dependent inactivation of SSH1 revealed by the rise
of the pSSH1 levels (Fig. 3-h) and the pSSH1/SSH1 ratio (Fig. 3-i) in
the same time frame.
3.4. Inactivation of Coﬁlin1 during neuronal maturation in vitro
We next assessed whether changes in the Coﬁlin1 pathway could
be observed during neuronal maturation, in mouse PCNs cultured for
5, 10, 15 and 20 days. These time points were selected because (i) an
increase of synaptic density [50], (ii) a linear increase of Aβ produc-
tion [51] and (iii) a shift with regard to γ-secretase activity towards
more amyloidogenic pathways [20] occur within this time frame. Also,
primary neuronal cultures undergo a whole series of morphological
and functional maturation processes that reﬂect at least partially
those of their counterparts in vivo [20,36,37,41,42,52]. As shown in
Fig. 4-a and b, Coﬁlin1 and pCoﬁlin1 protein levels were respectively re-
duced and increased in an age-dependent manner from 5 to 20 DIV
(Fig. 4-a). These changes led to age-dependent increases in the
pCoﬁlin1/Coﬁlin1 ratio, starting at 10 DIV (~2.6 fold), increasing at 15
DIV (~3.3 fold) and reaching the maximum at 20 DIV (~4.5 fold), with
respect to 5 DIV (Fig. 4-c). Similarly, changes of total LIMK1 (Fig. 4-d)
and pLIMK1 (Fig. 4-e) protein levels lead to an age-dependent increase
in the pLIMK1/LIMK1 ratio, reaching about 75% at 20 DIV (Fig. 4-f). In-
terestingly, signiﬁcant and age-associated increases in SSH1 and
pSSH1 protein levels were also observed (Fig. 4-g and h), causing a
marked increase in the pSSH1/SSH1 ratio both at 15 DIV (~1.9-fold)
Fig. 3.Age-associated changes of the Coﬁlin1 pathway in the brain ofWTmice. Age-associated changes observedwith regard to proteins implicated in the Coﬁlin1 pathway, in the brain of
3- (n=5), 8- (n=4), 12- (n=5), 18- (n=5) and26-months old (n=4)WTmice. Representative gels obtainedwith 3 blind selected samples per group are shown. Top panels:Western
blot analyses of total protein extracts. Bottom panels: densitometric analyses of Western blot protein bands: (a) Total Coﬁlin1 protein levels; (b) pCoﬁlin1 levels; (c) pCoﬁlin1/Coﬁlin1
ratio; (d) Total LIMK1 protein levels; (e) pLIMK1 levels; (f) pLIMK1/LIMK1 ratio; (g) Total SSH1 protein levels; (h) pSSH1 levels; (i) pSSH1/SSH1 ratio. Protein levels were normalized
to the loading control β-actin. Densitometric values shown in the histograms are given as percentage of 3 months-old mice set as 100%. Means ± SEM, *P b 0.05, **P b 0.01 and
***P b 0.001 vs 3-months old mice; †P b 0.05, ††P b 0.01 and †††P b 0.001 vs 8-months old mice.
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and at 20 DIV (~2.7-fold), in comparison to the younger 5 DIV neurons
(Fig. 4-i). Altogether, both LIMK1 activation (Fig. 4-f) and SSH1 inactiva-
tion (Fig. 4-i) with age are very consistentwith the observed Coﬁlin1 in-
activation (Fig. 4-c).
3.5. γ-Secretase is a negative regulator of Coﬁlin1 activation
In agreement with previous results [20], we observed in our PCNs
cultures that increased secreted Aβ42 and Aβ40 levels (Supplementary
Fig. 3A) are associated with changes of the Aβ42/Aβ40 ratio, from 5 to
20 DIV (Supplementary Fig. 3B). These changes include a switch to-
wards the production of the more amyloidogenic Aβ42 peptides, possi-
bly suggesting age-dependent modiﬁcations of the γ-secretase speciﬁc
activity. Because of that observation, we further hypothesized that γ-
secretase activity can affect the Coﬁlin1 pathway, possibly in an age-
dependent manner. To challenge this hypothesis, 5, 10, 15 and 20 DIV
mouse PCNs were treated for 24 h with 10 μM of CpdE, a potent γ-
secretase inhibitor. First, we found that DMSO alone did not affect
Coﬁlin-1 protein levels and phosphorylation changes observed in un-
treated neurons with age (Fig. 5A-a–c). Conversely, inhibition of γ-
secretase activity promotes a signiﬁcant decrease (by about 35%) of
total Coﬁlin1 levels, only at 20 DIV with respect to DMSO-treated
PCNs (Fig. 5A-a). Importantly, pCoﬁlin1 levels were reduced at 10, 15
and 20 DIV (by ~40%, ~50% and ~50, respectively) in CpdE-treated neu-
rons, reaching statistical signiﬁcance at 15 DIV and 20 DIV (Fig. 5A-b).
Together, a signiﬁcant decrease of the pCoﬁlin1/Coﬁlin1 ratio was ob-
served in CpdE-treated neurons at 10 DIV (~1.5 fold), 15 DIV (~1.4
fold) and 20 DIV (~1.3 fold) (Fig. 5A-c). Since we observed a γ-
secretase dependent reduction of both total Coﬁlin1 and pCoﬁlin1 pro-
tein levels only in 20DIV neurons, and since older PCNs showed a signif-
icant increase in the Aβ42/Aβ40 ratio (Supplementary Fig. 3B), we
decided to further evaluate the effect of γ-secretase activity on LIMK1
and SSH1 in 20 DIV PCNs. As shown in Figs. 5B-d,e, inhibition of γ-
secretase did not affect LIMK1 protein levels or phosphorylation. Con-
versely, we observed a drastic ~50% decrease of pSSH1 levels in CpdE-
treated neurons, with respect to DMSO-treated cells (Fig. 5B-h). The
consistent reduction of pSSH1 levels together with no changes of
SSH1 levels resulted in a strong ~1.6-fold reduction of the pSSH1/
SSH1 ratio (Fig. 5B-i). Altogether, these results suggest that γ-
secretase activity could induce Coﬁlin1 phosphorylation through the in-
hibition of SSH1. To exclude any off-target phenotype caused by the use
of a chemical γ-secretase inhibitor, we next analyzed the Coﬁlin path-
way in MEFDKO cells characterized by a complete genetic inhibition of
γ-secretase activity, caused by the knock-out of both PS1 and PS2 cata-
lytic subunits [44,45]. In this cell line, and with respect to MEFs WT, we
found decreased total Coﬁlin1 (~50%, Fig. 5C-a) and pCoﬁlin-1 (~70%,
Fig. 5C-b) levels, as well as a reduced pCoﬁlin1/Coﬁlin1 ratio (~1.4-
fold, Fig. 5C-c). A signiﬁcant decrease was also observed for SSH1 pro-
tein levels (~30%, Fig. 5C-d) and phosphorylation (~45%, Fig. 5C-e), as
well as for pLIMK1 (~35%, Supplementary Fig. 4B-b). To conﬁrm that
changes observed in MEFDKO cells were indeed dependent on γ-
secretase activity, we took advantage of the MEFDKO + hγ-secretase stable
cell line previously generated in our laboratory [46], and that is charac-
terized by a rescued γ-secretase activity via the overexpression of
human γ-secretase. When compared to MEFDKO cells, restored γ-
secretase activity triggers a signiﬁcant increase of pCoﬁlin1 (~80%,
Fig. 5C-b), to levels comparable to those of the control MEFs WT cell
line. Furthermore, both SSH1 total protein levels and phosphorylation
were rescued in MEFDKO + hγ-secretase (Fig. 5C-d and C-e) and a net in-
crease of the pSSH1/SSH1 ratio with respect to MEFDKO cells was ob-
served (Fig. 5C-f). These results are in good agreement with those
obtained in mouse PCNs treated with CpdE and suggest a role for γ-
secretase in SSH1-mediated regulation of Coﬁlin1 phosphorylation/
inactivation.
4. Discussion
Themechanisms by which Coﬁlin1 regulates cognitive processes re-
main quite controversial, as either an excessive activation [47,48,53–56]
or inactivation [27,31,57–61] have been reported to contribute to the
actin-dependent impairment of synaptic plasticity, and thus learning.
Here we provide new data about changes in the Coﬁlin1 pathway
with age and AD. The signiﬁcant increase of the pCoﬁlin1/Coﬁlin1
ratio (Figs. 1, 2A-c and B-c) suggest that Coﬁlin1 gets inactivated in
the brain of AD patients and APP/PS1 mice as a consequence of AD pa-
thology. Furthermore, the age-associated changes observed in WT
mice (Fig. 3) andmouse PCNs (Fig. 4), indicate that Coﬁlin1 inactivation
could also be an age-dependent event. To unravel if Coﬁlin1 inactivation
is a cause or a consequence of AD pathology needs further investigation.
So far, based on our data, the signiﬁcant increase of pCoﬁlin1/Coﬁlin1
ratio in the brain of 10-months old APP/PS1mice compared to the litter-
mateWT controls (Fig. 2B-c), suggests that AD pathology could acceler-
ate the aging process via Coﬁlin1 phosphorylation.
Fig. 4. Coﬁlin1 pathway changes during mouse primary cortical neurons (PCNs) matura-
tion in vitro. Age-associated changes of proteins from the Coﬁlin1 pathway in mouse
PCNs at 5, 10, 15, and 20 days in vitro (DIV) (n = 3 independent cultures/group). Top
panels: Western blot analyses of total protein extracts. Bottom panels: densitometric anal-
yses of Western blot protein bands: (a) Total Coﬁlin1 protein levels; (b) pCoﬁlin1 levels;
(c) pCoﬁlin1/Coﬁlin1 ratio; (d) Total LIMK1 protein levels; (e) pLIMK1 levels;
(f) pLIMK1/LIMK1 ratio; (g) Total SSH1 protein levels; (h) pSSH1 levels; (i) pSSH1/SSH1
ratio. Protein levels were normalized to the loading control β-actin. Densitometric values
shown in the histograms are given as percentage of 5 DIV PCNs set as 100%.Means±SEM,
*P b 0.05, **P b 0.01 and ***P b 0.001 vs 5 DIV.
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Yet, Kim et al. recently reported a decrease of the pCoﬁlin1/Coﬁlin1
ratio in the frontal cortex of sporadic AD patients [56]. Interestingly,
and possibly explaining this apparent discrepancy, an in-depth analysis
of the latter study revealed a major difference with regard to our work,
concerning the age of the subjects analyzed. Indeed, brain samples ana-
lyzed in the Kim study came from younger patients (average age;
Controls: 59.6 ± 4.4; AD: 62.5 ± 0.6), when compared to the cortical
samples characterized in our study, and collected from older patients
(Controls: 87.8 ± 1.6 years; AD: 82.6 ± 2.7 years). Because the same
antibodies were used in both studies for the analysis by Western blot
of Coﬁlin1 levels, the apparent discrepancy cannot be attributed to the
use of different technical approaches (Supplementary Fig. 5), thus
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reinforcing our ﬁndings supporting a role of both age and AD pathology
in the Coﬁlin1 pathway regulation.
Interestingly, increased pCoﬁlin1 was also observed in maturing
mouse PCNs (Fig. 4-b,c), consistent (i) with the role of Coﬁlin1 in den-
dritic spine maturation [25,27,28,62] and (ii) the observed increase of
synapses density from 5 to 21 DIV [50,63]. Because either loss or inacti-
vation of Coﬁlin1 is associated with spine morphology alteration and
impaired associative learning and extinction memory [27,29,59,63,64]
as well as inhibition of long-term depression (LTD) of the N-methyl-D-
aspartate (NMDA) receptors [58], it is conceivable that an aberrant inac-
tivation of Coﬁlin1 observed in human AD brain and both agedWT and
APP/PS1mice (Figs. 1–3) could be responsible for thenegative effects on
synaptic plasticity and cognition [27,29,59,60,64–67]. This would repre-
sent an intriguing link between age and AD pathology (Fig. 6).
The mechanisms driving Coﬁlin1 activation or phosphorylation/in-
activation may be different and dependent, at least in part, on Aβ levels
and aggregation state [53–57]. Most importantly, soluble and ﬁbrillary
Aβmay differentially affect Coﬁlin1 by promoting either its activation
[53] or its inactivation [57]. Whether these events could happen simul-
taneously or sequentially still remains unclear. Based on our results in
APP/PS1 mice, it seems that — with the progression of AD pathology
an activation of Coﬁlin1 occurs at 4 months of age (Fig. 2A-b and
Supplementary Fig. 6B-b) followed by a strong inactivation at
10 months (Fig. 2A-b,c and B-c), probably associated with the different
pattern of Aβ deposition in the brain of these mice [34]. From a molec-
ular point of view, Aβ peptides can differentially impact LIMK1 [30,68]
whose activity was found dysregulated in AD and other neurodegener-
ative disorders [57,69,70]. The novelty of our work is to show for the
ﬁrst time the inactivation of SSH1 in AD brain (Figs. 1-i, 2A-h,i and B-
c), thus strengthening the hypothesis that the equilibrium between
LIMK1 and SSH1 activities is disrupted in AD.Within that frame, the sig-
niﬁcant correlations found between pCoﬁlin1 or pCoﬁlin1/Coﬁlin1 ratio
and (i) SSH1 inactivation or (ii) LIMK1 activation in APP/PS1 (Supple-
mentary Fig. 7A-a–g) and WT mice (Supplementary Fig. 8-a–d), as
well as in mouse PCNs (Supplementary Figs. 9-a–c and 4A-a–d) likely
account for a main role of these two upstream effectors in mediating
Coﬁlin1 dysregulation.
To better understand the molecular mechanisms underlying the ob-
served increase of Coﬁlin1 phosphorylation both in vivo and in vitro, we
assessed the involvement of γ-secretase (one of the main proteins re-
sponsible of Aβ production) in these processes. A striking ﬁnding was
that both chemical and genetic inhibition of γ-secretase activity promot-
ed a signiﬁcant decrease of pCoﬁlin1 and pCoﬁlin1/Coﬁlin1 ratio, and that
this effect was associated with a reduction of SSH1 inhibition (Fig. 5A, B
and C). This ﬁnding was further supported by the observation that over-
expression of humanγ-secretase inMEFDKO rescued the observed pheno-
type (Fig. 5C-b,c and C-e,f), suggesting that γ-secretase activity might
promote Coﬁlin1 phosphorylation through SSH1 inactivation. These
changes could result from the reduced processing of one or more γ-
secretase substrates whose cleavage products, in turn, regulate cell fate
decision [19]. In this regard, APP represents a good candidate substrate.
Indeed, the signiﬁcant decrease of both pCoﬁlin1 and relative pCoﬁlin1/
Coﬁlin1 ratio observed in APPKO mice versus WT mice (Supplementary
Fig. 10A-a and B-a) resemble the results obtained following chemical in-
hibition of γ-secretase activity in mouse PCNs (Fig. 5A and B), or genetic
inhibition γ-secretase in MEFDKO cells (Fig. 5C). Similarly, the increase of
both Coﬁlin1 and SSH1 phosphorylation/inactivation following APP over-
expression inMEF cells (Supplementary Fig. 11) recall what we observed
in AD brain (Figs. 1 and 2). To unravel whether these changes are directly
linked to the loss (APPKO mice) or to an increase (MEF overexpressing
APP) of the γ-secretase-dependent cleavage of APP needs further investi-
gations, especially because no signiﬁcant changes were observed with
regard to LIMK1 (Supplementary Fig. 10A-b and B-b), SSH1 (Supplemen-
tary Fig. 10A-c and B-c) or Chronophin phosphatase (Supplementary
Fig. 10A-d and B-d) in APPKO mice.
Finally, early-onset familial Alzheimer's disease (FAD)-linked PS1
mutants have been reported to cause a drastic loss of γ-secretase activ-
ity in cell-free [46], cell-based [71] and in vivo [15] experiments. As pre-
viously observed in vivo [72,73], this loss-of-function is asymmetrical as
all FAD-linked PS1 mutants seem to generate higher Aβ42/Aβ40 ratio
compared to PS1-WT. It consequently causes an increased production
of the longer and more hydrophobic Aβ species, namely Aβ, that accu-
mulates and aggregates early in the course of the disease. Thus, one
could anticipate that FAD-linked PS1 mutants would promote Coﬁlin1
phosphorylation, in line with (i) the observation that ﬁbrillary Aβ pro-
motes Coﬁlin1 phosphorylation [57], and (ii) our preliminary results
showing that PS1-L166P promotes Coﬁlin1 phosphorylation (see Sup-
plementary Fig. 12).
5. Conclusions
In conclusion, our work demonstrates an age-dependent increase of
Coﬁlin1 phosphorylation, both in maturating PCNs and in WT mice,
which resembles the Coﬁlin1 phenotype observed in sporadic human
AD brain. γ-Secretase seems to play a fundamental role in the proposed
mechanism by enhancing Coﬁlin1 phosphorylation via SSH1 inhibition
(Fig. 6). The implication of these results on understanding themolecular
mechanisms leading to impaired synaptic plasticity both during aging
and AD are profound, and offer a molecular bridge connecting age, AD
and the activity of γ-secretase. They further have the possibility to im-
pact the development of therapies to treat AD.
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Fig. 5. Chemical and genetic inhibition of γ-secretase activity is associatedwith Coﬁlin1 activation. (A) Inhibition of γ-secretase activity with 10 μMCompound E (CpdE) promotes Coﬁlin1 ac-
tivation inmouse PCN at 10, 15 and 20 DIV (n= 3 independent cultures/group). A representativeWB is shown. Top panels:Western blot analyses of total protein extracts. Bottom panels: den-
sitometric analyses ofWestern blot protein bands: (a) Total Coﬁlin1 protein levels; (b) pCoﬁlin1 levels; (c) pCoﬁlin1/Coﬁlin1 ratio. (B) Coﬁlin1 protein levels andphosphorylation are decreased
following γ-secretase activity inhibition with 10 μMCompound E (CpdE) in mouse PCN at 20 DIV (n= 4 independent cultures/group). Activation of Coﬁlin1 parallels with a decrease of SSH1
phosphorylation. A representativeWB is shown. Top left panels: Western blot analyses of total protein extracts. Bottom and right panels: densitometric analyses of Western blot protein bands:
(a) Total Coﬁlin1 protein levels; (b) pCoﬁlin1 levels; (c) pCoﬁlin1/Coﬁlin1 ratio; (d) Total LIMK1 protein levels; (e) pLIMK1 levels; (f) pLIMK1/LIMK1 ratio; (g) Total SSH1 protein levels;
(h) pSSH1 levels; (i) pSSH1/SSH1 ratio. (C) Coﬁlin1 protein levels and phosphorylation are decreased in mouse embryonic ﬁbroblast (MEF) cells lacking presenilin-1 and -2, the catalytic sub-
units of the γ-secretase complex (MEFDKO). These changes parallel with a decrease of SSH1 protein levels and phosphorylation. Overexpression of the human γ-secretase complex in MEFDKO
cells (MEFDKO + hγ-secretase) rescues Coﬁlin1 phosphorylation (pCoﬁlin1) through the increase of SSH1 inactivation (pSSH1) (n= 3 independent cultures/group). Left panels:Western blot anal-
yses of total protein extracts. Right panels: densitometric analyses ofWestern blot protein bands: (a) Total Coﬁlin1 protein levels; (b) pCoﬁlin1 levels; (c) pCoﬁlin1/Coﬁlin1 ratio; (d) Total SSH1
protein levels; (e) pSSH1 levels; (f) pSSH1/SSH1 ratio. Protein levels were normalized to the loading control β-actin. Densitometric values shown in the histograms are given as percentage of 5
DIV PCNs (Aa–Ac), untreated Control PCNs (Ba–Bi) and uninfected WT MEF (Ca–Cf) set as 100%. Means± SEM, *P b 0.05, **P b 0.01 and ***P b 0.001.
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Supplementary Table 1. Demographic and diagnostic features of the human brain 
samples used in this study.  
PMD, post mortem delay 
Age Gender Apo E PMD Braak
Control (CERAD 1B) 82 F 3/3 15:30 I
Control (CERAD 1B) 90 F 3/3 23:00 I
Control (CERAD 1A) 87 M 3/3 18:30 II
Control (CERAD 1A) 90 M 3/3 7:20 II
Control (CERAD 1B) 90 M 3/3 4:00 II
AD 82 F 4/4 7:30 III
AD 90 M 3/4 17:00 VI
AD 88 M 3/4 NA III
AD 75 M 3/4 2:30 VI
AD 88 F 3/4 2:00 VI
AD 71 M 3/3 25:09 VI
AD 84 F 3/4 13:25 VI
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Supplementary Figures 
  
 
 
 
 
 
 
Supplementary Figure 1. Linearity of dose-curve for Western blot analysis of antibodies 
used in our study. Signals displayed by antibodies targeting Cofilin, phospho-Cofilin, 
LIMK1, phospho-LIMK1, SSH1 and phospho-SSH1 were estimated on protein levels ranging 
from 15 to 40 μg of a wild-type 3-month-old mouse brain total protein extract. As estimated 
by densitometry, all signals exhibit linearity at the protein levels tested (lower panels), and the 
protein amount (30 ?g) we used for sample analysis all over the manuscript falls into this 
linear range. Plots display densitometric estimations from n=2 independent Western blots, for 
each antibody; β-actin is used as a loading control. 
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Supplementary Figure 2 (related to Fig. 2). LIMK1 activation and SSH1 inactivation in 
the brain of 10-months old APP/PS1 mice. Brain samples from 10-months old APP/PS1 
mice (n=3) show a significant decrease in LIMK1 (a) and SSH1 (d) protein levels, together 
with a significant increase of their phosphorylation (b and e) with respect to aged-matched 
WT controls (n=3). These changes resulted in a significant increase of both pLIMK1/LIMK1 
(c) and pSSH1/SSH1 (f) ratios. Top panels: Western blot analyses of total protein extracts. 
Bottom panels: densitometric analyses of indicated Western blot protein bands. Protein levels
were normalized to the loading control β-actin. Densitometric values shown in the histograms 
are given as percentage of WT mice set as 100%. Means ± SEM, *P<0.05, **P<0.01 and 
***P<0.001 vs WT.
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Supplementary Figure 3. The increase of Cofilin1 phosphorylation during neuronal 
maturation in vitro parallels with a more amyloidogenic A? production. (A) Changes of 
Aβ40 and Aβ42 production during neuronal maturation in vitro, as estimated by ELISA. (B) 
Quantitative measurements of the Aβ42/Aβ40 ratio during neuronal maturation in vitro show a 
cellular shift towards the more amyloidogenic pathway, possibly caused by a modified ?-
secretase specific activity. Means ± SEM of n=3 independent cultures/group. ** or ††P<0.01 
and *** or †††P<0.001 vs 5 DIV (B). *P<0.05 vs 10 DIV (C).
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Supplementary Figure 4 (related to Fig. 5). The decrease of Cofilin1 phosphorylaltion 
following γ-secretase inhibition is associated with an increased SSH1 activation. (A) In 20 
DIV mouse primary cortical neurons (PCNs) treated overnight with DMSO (n=4) or 10 μM of 
the γ-secretase inhibitor Compound E (CpdE) (n=4 independent cultures/group), positive and 
significant correlations were found between pCofilin1 levels or pCofilin1/Cofilin1 ratio and 
pSSH1 levels (a,c) or between pCofilin1 levels or pCofilin1/Cofilin1 ratio and the 
pSSH1/SSH1 ratio (b,d). (B) Mouse embryonic fibroblasts (MEF) lacking the catalytic γ-
secretase subunits presenilin-1 and -2 (MEFDKO) showed unchanged LIMK1 total protein 
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levels (a) and a decrease of pLIMK1 (b), resulting in a decrease of the pLIMK1/LIMK1 ratio 
(c). Overexpression of human γ-secretase in MEFDKO cells (MEFDKO+hγ-secreatse) promoted an 
increase of both LIMK1 (a) and pLIMK1 levels (b) associated with a further decrease of the 
pLIMK1/LIMK1 ratio (c), with respect to MEFDKO and MEF cell lines. Thus, the increase of 
pCofilin1 observed in MEFDKO+hγ-secreatse cells is likely independent on LIMK1 because a net 
reduction of its activation (decreased pLIMK1/LIMK1 ratio) was observed. These results 
suggest that the decrease of pCofilin1 observed following γ-secretase inhibition (Fig. 5C-b,c) 
can possibly be mediated by the observed activation of SSH1 (Fig.5C-e,f). Top panels: 
Western blot analyses of total protein extracts. Bottom panels: densitometric analyses of 
Western blot protein bands. Protein levels were normalized to the loading control β-actin. 
Densitometric values shown in the histograms are given as percentage of WT MEF set as 
100%. Means ± SEM of n=3 independent cultures/group. *P<0.05, **P<0.01 and ***P<0.001 
vs MEF WT or MEFDKO. PS1-FL, presenilin-1 full length; PS1-NTF, presenilin-1 N-terminal 
fragment.
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Supplementary Figure 5 (related to Figure 1). Cofilin1 phosphorylation/inactivation in 
the frontal cortex of human sporadic Alzheimer’s disease patients, evaluated by using 
the anti-phospho(Ser3)-Cofilin1 (#ab12866, 1:1000, abcam, Cambridge, United 
Kingdom) antibody as in (Kim, et al., 2013). Top panels: Western blot analyses of total 
protein extracts, showing increased phospho-Cofilin1 (pCofilin1) in the frontal cortex of 
sporadic Alzheimer’s disease subjects (n=7), relative to their age-matched controls (n=5). 
Similar results were found by using the anti-phospho-Cofilin1 antibody #3311s (1:500, Cell 
Signaling, Bioconcept, Allschwill, Switzerland) (Fig. 1-b). Bottom panels: densitometric 
analyses of Western blot protein bands. Protein levels were normalized to the loading control 
β-actin. Densitometric values shown in the histograms are given as percentage of Control 
samples set as 100%. 
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Supplementary Figure 6 (related to Figure 2). Changes in proteins of the Cofilin1 
pathway in brains of 1- and 4-months old APP/PS1 mice. (A) Brain total protein extracts 
from 1-month old APP/PS1 mice (n=4) show a significant increase of total Cofilin1 protein 
levels with respect to age-matched littermate WT controls (n=3). No significant changes were 
observed with regard to LIMK1 or SSH1 protein levels and activation state. Top panels:
Western blot analyses of total protein extracts. Bottom panels: densitometric analyses of 
Western blot protein bands: (a) Total Cofilin1 protein levels; (b) pCofilin1 levels; (c) 
pCofilin1/Cofilin1 ratio; (d) Total LIMK1 protein levels; (e) pLIMK1 levels; (f) 
pLIMK1/LIMK1 ratio; (g) Total SSH1 protein levels; (h) pSSH1 levels; (i) pSSH1/SSH1 
ratio.  (B) Brain samples from 4-months old APP/PS1 mice (n=4) show a significant decrease 
of total Cofilin1 protein levels and phosphorylation (pCofilin1) associated with a significant 
decrease of LIMK1 phosphorylation (pLIMK1), with respect to age-matched littermate WT 
controls (n=3). Top panels: Western blot analyses of total protein extracts. Bottom panels:
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densitometric analyses of Western blot protein bands: (a) Total Cofilin1 protein levels; (b) 
pCofilin1 levels; (c) pCofilin1/Cofilin1 ratio; (d) Total LIMK1 protein levels; (e) pLIMK1 
levels; (f) pLIMK1/LIMK1 ratio; (g) Total SSH1 protein levels; (h) pSSH1 levels; (i) 
pSSH1/SSH1 ratio. Protein levels were normalized per β-actin as loading control. 
Densitometric values shown in the histograms are given as percentage of 5 DIV set as 100%. 
Means ± SEM, *P<0.05 vs WT.
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Supplementary Figure 7 (related to Fig. 2). Age-dependent Cofilin1 phosphorylation is 
associated with LIMK1 activation and SSH1 inactivation in the brain of APP/PS1 mice. 
In the brain of 1-, 4- and 10-months old APP/PS1 mice, positive and significant correlations 
were found (A) between pCofilin1 levels or pCofilin1/Cofilin1 ratio and (a-c) pSSH1 levels 
or pSSH1/SSH1 ratio or (e-g) pLIMK1 levels or pLIMK1/LIMK1 ratio, or (B) between 
pSSH1 or pSSH1/SSH1 ratio and pLIMK1 or pLIMK1/LIMK1 ratio (a-d). Because SSH1 can 
dephosphorylate/inactivate LIMK1, the significant correlation found in (B) suggests that 
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SSH1 inactivation could promote Cofilin1 phosphorylation, both directly and indirectly, 
through an effect on LIMK1. 
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Supplementary Figure 8 (related to Fig. 3). The age-dependent increase of Cofilin1 
phosphorylation is associated with SSH1 inactivation in the brain of WT mice. In the 
brain of 3- (n=5), 8- (n=4), 12- (n=5), 18- (n=5) and 26-months old (n=4) WT mice, positive 
and significant correlations were found between pCofilin1 levels or pCofilin1/Cofilin1 ratio 
and pSSH1 levels (a and b). The absence of significant correlations between pCofilin1 or 
pCofilin1/Cofilin1 ratio and pLIMK1 levels (c and d) suggests a major involvement of SSH1 
inactivation in promoting Cofilin1 phosphorylation.
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Supplementary Figure 9 (related to Fig. 4). The increase of Cofilin1 phosphorylation 
during neuronal maturation in vitro is associated with SSH1 inactivation. pCofilin1 or 
pCofilin1/Cofilin1 ratio are positively and significantly associated with pSSH1 (a,b) or
pSSH1/SSH1 ratio (c) in mouse PCNs cultured from 5 to 20 DIV. A significant correlation 
was also found between pSSH1 and pLIMK1 (d), thus suggesting age-associated SSH1 
inactivation as an event promoting Cofilin1 phosphorylation during neuronal maturation.
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Supplementary Figure 10. Changes in Cofilin1 pathway proteins in the brain of APPKO
mice. (A) Age-associated decrease of Cofilin1 phosphorylation in the brain of 1- (n=4), 4- 
(n=4) and 10-months old (n=4) APP knock-out mice (APPKO). Top  panels: Western blot 
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analyses of total protein extracts. Bottom panels: densitometric analyses of Western blot 
protein bands: (a) pCofilin1/Cofilin1 ratio; (b) pLIMK1/LIMK1 ratio; (c) pSSH1/SSH1 ratio;
(d) Chronophin protein levels. (B) Brain samples from 10-months old APPKO mice (n=4) 
show a significant decrease of pCofilin1/Cofilin1 ratio with respect to their age-matched 
littermate WT controls (n=4). No significant changes were observed for both 
pLIMK1/LIMK1, SSH1/pSSH1 ratio or Chronophin levels. Top panels: Western blot 
analyses of total protein extracts. Bottom panels: densitometric analyses of Western blot 
protein bands: (a) pCofilin1/Cofilin1 ratio; (b) pLIMK1/LIMK1 ratio; (c) pSSH1/SSH1 ratio;
(d) Chronophin protein levels. (C, D) Analyses of Cofilin1 pathway proteins in brain samples 
from 1- (n=4) and 4-months old (n=4) APPKO mice showing the absence of significant 
changes with regard to aged-matched WT controls (n=4). Top panels: Western blot analyses 
of total protein extracts. Bottom panels: densitometric analyses of Western blot protein bands: 
(a) pCofilin1/Cofilin1 ratio; (b) pLIMK1/LIMK1 ratio; (c) pSSH1/SSH1 ratio; (d)
Chronophin protein levels. Protein levels were normalized to the loading control β-actin. 
Densitometric values shown in the histograms are given as percentage of 1 month (A) or WT 
(B-D) mice set as 100%. Means ± SEM, *P<0.05, **P<0.01 and ***P<0.001 vs 1 month-old 
mice (A) or WT mice (B). Interestingly, reduction of Cofilin1 phosphorylation (reduced 
pCofilin1/Cofilin1 ratio) in the brain of 10-months old APPKO mice (A-a), when compared to 
their age-matched littermate WT controls (B-a), resemble the reduction of Cofilin1 
phosphorylation observed following the inhibition of γ-secretase activity in mouse PCNs 
(Figs.5A and 5B) and MEFDKO (Fig.5C). The lack of significant effects on LIMK1 and SSH1 
activities with respect to WT mice could suggest that at the age of 10 months other 
mechanism(s) could occur, different than those involving LIMK1 and SSH1. In that frame the
Chronophin (or CIN) phosphatase has also been suggested to be able to promote Cofilin 
desphoshorylation (Gohla A et al, Nat Cell Biol, 2005; Huang TY et al, Curr Opin Cell Biol, 
2006). However, it has recently been reported that the knock-down of SSH1 was associated 
with a consistent and strong increase of Cofilin1 phosphorylation. That was not the case for 
the knock-down of Chronophin, further highlighting the dominant role for SSH1 as a specific 
regulator of Cofilin1 desphosphorylation (Yan-Ting Zhang et al, J Cell Biochem, 2013; 
Posadas Inmaculada et al, J Neurochem, 2012; Klygis K et al. J Biol Chem, 2007). Moreover, 
the pSSH1/SSH1 ratio remains unaffected in APPKO mice (Ac, Bc). Altogether, it suggests
that SSH1 fulfills its dominant effector function, over Chronophin, for which no changes 
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were observed at the protein levels (Ad, Bd) [anti-Chronophin antibody #4686 (1:500, Cell 
signalling, Bioconcept, Allschwill, Switzerland)]. 
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Supplementary Figure 11. Overexpression of full-length amyloid precursor protein 
(APP) or APP-C-terminal fragments (C99 and C83) promotes Cofilin1 phosphorylation 
in mouse embryonic fibroblast (MEF). Mouse embryonic fibroblasts (MEF) transiently 
transfected for 48 hours with a mammalian vector carrying the gene encoding for (i) full-
length amyloid precursor protein (APP), (ii) ?-secretase-dependent APP-cleavage product 
APP-C83 (C83), or (iii) ?-secretase-dependent APP-cleavage product APP-C99 (C99) were 
characterized by an increase of Cofilin1 and Slingshot-1 phosphorylation (pCofilin1 and 
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pSSH1, respectively). Top panels: Western blot analyses of total protein extracts. Bottom 
panels: densitometric analyses of Western blot protein bands: (a) Total Cofilin1 protein 
levels; (b) pCofilin1 levels; (c) pCofilin1/Cofilin1 ratio; (d) Total LIMK1 protein levels; (e) 
pLIMK1 levels; (f) pLIMK1/LIMK1 ratio; (g) Total SSH1 protein levels; (h) pSSH1 levels; 
(i) pSSH1/SSH1 ratio. Protein levels were normalized per β-actin as loading control. 
Densitometric values shown in the histograms are given as percentage of MEF set as 100%. 
Means ± SEM of n=3 independent cultures/group. *P<0.05 and ** or P<0.01 vs MEF.
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Supplementary Figure 12. The ?-secretase Presenilin-1 L166P mutation causing early-
onset familial AD is associated with an increase of pCofilin1 in mouse PCNs. Mouse
primary cortical neurons (PCNs) (n=2 independent cultures/group) infected from 6 to 20 DIV 
with increasing concentrations (0.5 – 5 ?L) of the lentiviral vector carrying the gene encoding
for the mutated human Presenilin-1 (PS1) L116P were characterized by an increase of 
pCofilin1 (b) and pCofilin1/Cofilin1 ratio (c). Left panels: Western blot analyses of total 
protein extracts. Right panels: densitometric analyses of Western blot protein bands: (a) Total 
Cofilin1 protein levels; (b) pCofilin1 levels; and (c) pCofilin1/Cofilin1 ratio. Protein levels 
were normalized to the loading control β-actin. Densitometric values shown in the histograms 
are given as percentage of Control uninfected PCNs set as 100%. 
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Chapter III 
Engineering new tools for the 
observation and repair of brain 
structure damages 
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III.1) Introduction 
III.1.a) Monitoring brain structure alterations in AD 
AD spreads in the central nervous system according to a well-defined pattern and leads to important 
brain shrinkage (see Fig. 2, chapter I), inducing the loss of cognitive functions. In order to 
understand better the propagation of the disease and to develop therapeutic strategies, transgenic 
mouse models that reproduce AD patterns including senile plaques, NFT and neurodegeneration 
have been generated (reviewed in 209,210). However the observation of such patterns require heavy 
and time-consuming procedures such as PET- / MRI-scans29,36, cranial window imaging211, CSF 
collection or sacrifice of the animal for histological analysis.  
 
Both senile plaques and NFT cause neurodegeneration that affects cellular organization and 
consequently brain structures. Because of these observations, we investigated the potential of 
electrical impedance measurements for detecting these structural alterations (see manuscripts pages 
120 and 131). Electrical impedance represents the electrical resistance of a tissue when an 
alternating current is applied. In this context, electrical impedance provides information concerning 
cellular/tissue organization and integrity. Although this method would require neurosurgery for the 
cerebral implantation of the electrode, electrical impedance recordings may be done at any time 
without interfering with the animal well-being. Finally this method may be used for visualizing the 
progression of pathological phenotypes and their repair in a wide range of neuropathologies, as 
soon as alteration in the tissue structure is observed. 
 
III.1.b) Rescue brain alteration in neurodegenerative processes 
The major brain shrinkage observed in neurodegenerative diseases including AD is linked to cell 
loss. While most therapies focus on pharmacological and immunological blockage of A?-mediated 
cell death, replacing dead neurons by newborn neurons has been suggested for rescuing cognitive 
functions176. Generating these new cells can be achieved by two strategies: 1) stimulating adult 
neurogenesis, or 2) neurosurgical injection of induced pluripotent stem cells directly at seizure sites. 
While the first strategy clearly lacks of specific molecules212,213, the second showed very promising 
results in human patients214,215. Indeed, previous studies showed the integration and propagation of 
engrafted material into living tissues216–218. However, the empty space left by dead cells – 
particularly large for stroke lesions – hardly recovers initial cell density216–218. To overcome this 
limitation and promote cell growth, several groups proposed polymers scaffold mimicking cellular 
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matrix219–221. These scaffolds shall fulfill numerous conditions to be used in clinics: stable, 
biocompatible, autoclavable, neurotrophic, injectable, hydrophilic and cheap. In the last study of 
this PhD thesis, we first optimized the synthesis of a polymer that meets all of these expectations. 
Next, we developed a procedure to culture primary cortical neurons on this polymer, in order to 
recreate an as physiological as possible brain tissue matrix (see manuscript page 140). 
 
 
III.2) Results 
III.2.a) Accurate Resistivity Mouse Brain Mapping Using Microelectrode Arrays  
In this manuscript, we optimized the detection of brain structures by electrical impedance 
measurements (see manuscript page 120). We implanted a microelectrode in WT euthanized mice 
brain (ex vivo) at precise stereotaxic coordinates, and recorded electrical impedance in various brain 
structures. We succeeded with our method in discriminating brain structures such as the cortical 
layers, ventricles, the corpus callosum and the thalamus. Furthermore, we showed that damaged 
tissue integrity can be observed with our method. 
 
In this study, I performed mice euthanasia, stereotaxic positioning of the electrodes, and participated 
in the experimental design. 
 
III.2.b) Detection of Alzheimer’s Disease Amyloid-beta Plaque Deposition by Deep Brain 
Impedance Profiling 
 As tissue integrity affects electrical impedance (see section III.2.a), we aimed at using this method 
for detecting A? plaques in AD brain (see manuscript page 131). We thus performed ex-vivo 
electrical impedance recordings in the cortex and the hippocampus of the AD mouse model 
APPPS1208. We detected a decrease in electrical impedance correlated with A? plaque loads. 
Analysis of our data suggested that our method does not directly detect A? plaques, but rather 
structural changes surrounding these plaques linked to cellular disorganization. 
 
In this study, I performed mice euthanasia, stereotaxic positioning of the electrodes, and participated 
in the experimental design. 
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III.2.c) A Compressible Scaffold for Minimally Invasive Delivery of Large Intact Neuronal 
Networks 
In the last study of this PhD thesis, we aimed at synthesizing a polymer-based neuronal scaffold, 
compatible with a therapeutic application (see manuscript page 140). We synthesized an 
extracellular matrix-like polymer scaffold (cryogel), and characterized its physical properties. We 
optimized the culture of mouse primary cortical neurons on our cryogel and visualized high axonal 
sprouting. Moreover, compressing the cryogel for injecting in patient’s brain did not disrupt 
neuronal integrity. In conclusion, we report the synthesis and characterization of a potent cellular 
scaffold chemically stable, biocompatible, autoclavable, neurotrophic, injectable, hydrophilic and 
cheap with high therapeutic potential. 
 
In this investigation, I prepared the mouse primary cortical neurons and participated in the 
optimization of cell culture conditions, as well as in the experimental design. 
 
 
III.3) Manuscripts 
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a b s t r a c t
Electrical impedance spectroscopy measurements were performed in post-mortem mice brains using a
ﬂexible probe with an embedded micrometric electrode array. Combined with a peak resistance frequency
method this allowed obtaining intrinsic resistivity values of brain tissues and structures with submilli-
metric resolution. Reproducible resistivity measurements are reported, which allows the resistivity in the
cortex, ventricle, ﬁber tracts, thalamus and basal ganglia to be differentiated. Measurements of brain slices
revealed resistivity proﬁles correlated with the local density of cell bodies hence allowing to discriminate
between the different cortical layers. Finally, impedance measurements were performed on a model of
cauterized mouse brain evidencing the possibility to measure the spatial extent and the degree of the
tissue denaturation due to the cauterization.
& 2014 Elsevier B.V. All rights reserved.
1. Introduction
Neurosurgery can be considered as a high-tech speciality which
is strongly dependent on technological innovations aiming at
improving patient treatment and clinical outcome. During the last
decades neurosurgery has improved substantially, thanks to the
introduction of applied imaging technologies such as computed
tomography and magnetic resonance tomography, and new surgical
modalities like brain navigation (Kikinis et al., 1994; Mohri et al.,
2012). In particular, accuracy of targeting is critical for the success of
numerous brain surgery techniques because brain damage has a
very negative impact on the patient's quality of life. For example, in
Parkinson disease, precise placement of electrodes for deep brain
stimulation (DBS) is an essential determinant of outcome: electro-
des have to be placed accurately in the hypothalamus in order to
stimulate the appropriate neurons and reduce side effects to a
minimum. Similarly, proper electrode placement is essential for the
correct interpretation of stereoelectroencephalography recordings
used to identify the area of the brain where epileptic seizures
originate. In operations involving resective surgery such as radio-
frequency ablation, thermal ablation or cryoablation for medically
refractory epilepsy (Gigante and Goodman, 2012), hypothalamic
hamartoma (Mittal et al., 2013) or metastatic brain tumors (Li et al.,
2010), precise localization but also precise information about the
extent of the ablated tissue is absolutely essential in order to
minimize the damage caused to the brain. Recently, it has been
estimated that around 10% of patients who had resective epilepsy
surgery have to undergo a second intervention (Surges and Elger,
2013). Causes of failure in the ﬁrst epilepsy surgery vary but they
include incorrect localization and incomplete resection of the
seizure focus. Finally, information about the extent and develop-
ment of local tissues abnormalities such as tumors and lesions are
also valuable for the medical diagnosis before and during surgery.
Standard magnetic resonance imaging and X-ray computed
tomography are typically used for imaging the brain and taking
landmarks for the later surgical operation before opening the skull
of the patient. As such, these techniques take into account neither
brain release at the moment of skull opening nor possible acciden-
tal movements during the surgery. Techniques such as intraopera-
tive magnetic resonance imaging (iMRI) and intraoperative
computed tomography (iCT) are used for brain imaging and needle
guidance during surgical operations, for example for deep brain
stimulation needle placement (Burchiel et al., 2013; Lim et al., 2013)
and recently also for tumor ablation with high-intensity focused
ultrasounds (Ellis et al., 2013). However these techniques imply
complex surgical conditions and organization and also require
complex data treatment and expensive equipment. Further, iCT
implies irradiation of the patient or use of radioactive contrast
agents, putting the patient’s health at risk when used too frequently.
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In addition, image quality in magnetic resonance imaging (MRI) is
degraded by the metallic objects such as the implanted electrodes.
In order to overcome these difﬁculties, the neurosurgical procedure
would beneﬁt from new simple instruments or techniques enabling
localizing directly and precisely brain structures or distinguishing
different types of tissues, such as for example healthy and tumor
tissues for proper resection of the latter with minimal damage to the
former. Furthermore, an “in situ” and “real time” technique allowing
obtaining information on the properties of tissues could open wide
possibilities for the research of the direct effects of drug delivery and
local stimulation on the long term evolution of diseased tissue.
The imaging of conductivity distributions gives valuable informa-
tion on physiological and pathological parameters, which are not
obtained by anatomical imaging. For example, conductivity measure-
ments can be used to classify different tissue types (Mayer et al.,
2006), and to detect edema (Merwa et al., 2004). Electrical
impedance tomography (EIT), in which surface potentials are
measured during application of currents via surface electrodes, has
been applied to obtain conductivity distributions in living bodies
(Metherall et al., 1996; Saulnier et al., 2001). However, EIT has
relatively low spatial resolution when using a limited number of
surface electrodes. Moreover, conductivity distributions of the brain
are difﬁcult to obtain with EIT because most of the current does not
penetrate the skull due to its low conductivity (Sekino and Ueno,
2002). Recently, Wang et al. (2008) proposed another method to
estimate conductivity from diffusion tensor MRI, though the applica-
tion of this method is limited to white matter tissues. An alternative
to EIT is electrical impedance spectroscopy (EIS), which has already
been used for detecting both local pathologies such as brain tumors
in rats (Jahnke et al., 2013) and global abnormalities such as hypoxic
ischemic encephalopathy of neonates (Seoane et al., 2012). It has also
been proven useful to monitor temporal changes such as the
evolution of the tissue reaction to neuroprostheses (Mercanzini
et al., 2009). Recently, impedance-based tissue discrimination for
needle guidance has been proposed (Kalvøy et al., 2009; Trebbels
et al., 2012). However, impedance measurements with very high
resolution enabling discrimination of submillimetric structures are
still missing.
In this report, we propose the usage of electrical impedance
spectroscopy (EIS) for a ﬁne discrimination in brain tissue structures.
By taking advantage of the latest advances in both microelectrode
fabrication and EIS analysis, we demonstrate that impedance spectro-
scopy can be performed in a minimally invasive fashion and that it
allows distinguishing ﬁne brain structures such as the cortical layers of
a mouse brain. The peak resistance frequency (PRF) analysis method
allowed obtaining intrinsic “tissue resistivity” values that depend
neither on the electrode size nor on the measurement frequency,
as soon as tissue structures of interest are larger than electrode
diameter. In this work, the term “resistivity” does not refer to the
classical conﬁguration in which homogeneous materials with deﬁned
dimensions are investigated but reports values for sub-millimetric
volumes of the brain surrounding measurement electrodes. Measure-
ments were performed ﬁrst on post-mortem mice brains and then on
brain slices for a better understanding of the mechanisms at play. We
demonstrate the distinction of brain structures such as different
cortical layers, ﬁber tracts, ventricles, thalamus and basal ganglia and
evidence the impact of cell density on impedance measurements.
In an application perspective, we further demonstrate that our method
can be used to discriminate healthy and cauterized tissue in the brain
and quantify the graduated cauterization effects. The developed
ﬂexible microelectrodes can be easily integrated on existing electrodes
already used for DBS or epilepsy issues. The integration of local
impedance measurements in real time during probe implantation or
tissue stimulation would also raise knowledge on tissue integrity and
on the propagation of electrical stimulation, i.e. lead to a better
knowledge of the passive electrical properties of the brain tissues.
2. Materials and methods
2.1. Probe microfabrication
Neural probes were fabricated using standard clean room proce-
dures. Fig. 1a and b shows the resulting microfabricated neural probe.
The fabrication process has been presentedin detail elsewhere
(Cheung et al., 2007; Mercanzini et al., 2008; Metz et al., 2004).
Fig. 1. Impedance measurement device and conﬁguration. a. Microscope image of the polyimide probe used for measurements consisting of an array of eight 50 mm
diameter platinum electrodes. b. Photograph image of the probe with glued connector and capillary. c. Electrical circuit model for the electrode/tissue/counter-electrode
system. d. Corresponding impedance modulus, phase spectra and peak resistance frequency measurement method.
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Brieﬂy, a sacriﬁcial aluminum layer is ﬁrst deposited on a silicon
wafer. A 20 mm thick layer of polyimide (PI2611, HD Microsystems
GmbH, Germany) is then spin coated. A Ti/Pt/Ti sandwich is sputter
deposited with thicknesses of 50/200/50 nm respectively. The ﬁrst
titanium layer serves as an adhesion layer whereas the second one
constitutes a protection layer for the platinum during subsequent
process steps and will be ﬁnally removed. The platinum layer is
photolithographically deﬁned and etched, thus determining the
microelectrode array. A 4 mm thick layer of polyimide is then spin
coated onto the metallic layer. Finally, both the device structure
outline and the openings for the electrodes are deﬁned by dry
etching the polyimide through a silicon oxide mask. Polyimide
devices are then detached from the silicon wafer by anodic dissolu-
tion of the sacriﬁcial aluminum layer. A surface mount connector is
glued to the bond pads at the end of the device using conductive
silver epoxy (EPO-TEK H20E, Epoxy Technology Inc., USA). Electrical
contacts are subsequently isolated with epoxy. In order to facilitate
insertion into the brain tissues, the probe shaft is stiffened by gluing a
fused silica capillary of an outer diameter of 150 mm on its backside,
as shown in Fig. 1b.
2.2. Electrical impedance spectroscopy measurements
Impedance is measured with an impedance analyzer (Agilent
4294A, Agilent Technologies, USA). A sinusoidal voltage of 50 mV is
applied between an electrode and a counter-electrode and the
current is measured simultaneously, giving the impedance. Fig. 1c
and d presents the electrical model of a tissue and the methodology
used for impedance measurements. For each measurement the
frequency is swept on a logarithmic scale from 100 Hz to 4 MHz.
At each frequency, impedance magnitude and phase are recorded.
The PRF method is applied to the obtained spectrum. This method
has been described in detail elsewhere (Mercanzini et al., 2009).
Brieﬂy, the measured system comprises a microelectrode device,
counter-electrode (platinum wire) and tissue. The interface between
microelectrode and tissue is modeled by a constant phase element
(CPE) whereas the counter-electrode contribution is neglected due to
its large surface. The tissue is modeled by a resistor placed in series
with the microelectrode CPE. Indeed, brain tissues are mostly
resistive at the frequencies of interest in this work, with a resistive
component being 20–100 times larger than the reactive one (Gabriel
et al., 1996). The dielectric capacitance through the polyimide
between metal trace and tissue is placed in parallel to these elements
(see Fig. 1c). The resulting spectrum, presented in Fig. 1d, shows a
decreasing impedance at low frequency due to the microelectrode
CPE followed by a plateau corresponding to the tissue resistance. At
higher frequencies, the dielectric capacitance becomes predominant.
The tissue resistance value is given by the impedance modulus at the
frequency at which the phase is closest to 01. According to the model
used here, the impedance at this frequency is a close approximation
to Rtissue. The resistivity of the tissue surrounding the microelectrode
is extracted from the tissue resistance using the relationship
Rtissue ¼ κρtissue ð1Þ
where ρtissue is the resistivity of the tissue surrounding the electrode,
d is the electrode diameter and κ is a constant factor, called cell
constant. For an ideal disc electrode (with a diameter d) the cell
constant is equal to 1/2d (Newman, 1966). In practice, every micro-
electrode has a slightly different cell constant, due to possible
impurities adsorbed on the electrode surface. However, this factor
is easily determined by measuring the impedance spectrum of the
microelectrode placed in a saline solution of known resistivity. Before
use, neural probes were rinsed with ethanol and plasma, and treated
(Femto, Diener Electronic GMbH, Germany) at a pressure of 0.6 mbar
and a power of 100W for 6 s. All experiments were carried out at
room temperature (24–25 1C).
2.3. Surgery and setup
2.3.1. ex vivo brains preparation
All experimental procedures were carried out according to the
Swiss federation rules for animal experiments. Eight 4–6 weeks
old mice were euthanatized through carbon dioxide inhalation;
brains were extracted and placed into dedicated machined poly-
mer molds in order to avoid any displacement during the experi-
ments. Phosphate buffered saline solution (PBS) was added to
avoid brains drying out. Measurements were carried out within
2 h of the death of the animal. The counter-electrode consisting of
a platinum wire was immersed in the PBS solution next to the
brain. The probe was mounted on a microcontroller and gradually
inserted vertically into the brain. The whole electrode array
composed of eight microelectrodes was used.
Measurements were also performed on brains remaining inside
the skull of the euthanatized animal. In this case, a stereotaxic
frame was used. Incisions were made in the skin and the perios-
teum overlying the skull, after which the periosteum was scraped
away from the bone. Several coordinates were investigated based
on a mouse brain atlas (Paxinos, 2004). Holes were drilled using a
dummy cannula (25G) bilaterally at the following stereotaxic
coordinates (anterior to bregma; medio-lateral in mm): 0.7;1
and 0.7;1.5. The counter-electrode was placed inside the brain
approximately 3 mm anterior to bregma. Care was taken to avoid
drying of the cortical surface and the skull was covered with PBS.
The cortex was never left exposed to air since transient drying can
alter the surface impedance. The probe was placed in the taxic
clamp of the stereotaxic frame and gradually inserted vertically into
the skull and brain. The whole electrode array composed of eight
microelectrodes was used.
2.3.2. Acute slices preparation
All experimental procedures were carried out according to the
Swiss federation rules for animal experiments. Five 12–16 days old
mice were rapidly decapitated and neocortical slices (sagittal;
300 μm thick, lateral between 1.56 mm and 2.28 mm) were cut
using a vibratome (Microslicer; DSK) ﬁlled with iced extracellular
solution (artiﬁcial cerebrospinal ﬂuid containing 125 mM NaCl,
25 mM NaHCO3, 2.5 mM KCl,1.25 mM NaH2PO4, 2 mM CaCl2, 1 mM
MgCl2, and 25 mM D-glucose). Slices were incubated for 30 min at
34 1C and then at room temperature (24–25 1C).
For impedance measurements, slices were placed in a petri dish
containing PBS solution under a 10 microscope objective. The
counter-electrode consisting of a platinum wire was placed in
contact with the brain slice. The tilted probe was inserted
vertically into different slice areas by using a manual microcon-
troller. All measurements were performed with the microelectrode
situated at the tip of the probe.
2.4. Cauterization
A short and rigid copper wire was ﬁrmly attached to a soldering
iron which was used as a constant heat source. The temperature at
the tip of the wire was monitored using a thermocouple and the
power on the heat source was regulated in order to reach a steady
temperature of 70–80 1C. Once this steady temperature was
reached, the wire was carefully implanted into the brain for 60 s
and then removed.
For slices cauterization, slices were placed in a petri dish and
covered by a thin layer of PBS to avoid drying of the slice. Again,
once a steady temperature of 70–80 1C was reached, the tip of the
wire was put in contact with the slice for 60 s. The color change
linked to the denaturation of the tissue following cauterization is
directly observed with a binocular.
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2.5. Histology and imaging
Standard coronal parafﬁn sections through the regions of
interest were selected for visualizing the localization of the
performed measurements (microtome Microm HM325). Small
recesses located at the probe implantation site conﬁrmed the
measurement sites. Series of 4 mm sections (20 mm interval) were
stained with hematoxylin–eosin and analyzed using light micro-
scopy (Leica DM5500).
2.6. Cell density quantiﬁcation
Fluorescence images were captured using a ﬂuorescent micro-
scope (ZEISS LSM 700 UPRIGHT). Quantiﬁcation of cell density for
each cortical layer was achieved by counting Dapi-stained nuclei.
Cells counting data were generated from the observation of ﬁve
independent ﬁelds using a pre-deﬁned template, for each cortical
layer.
2.7. Statistics
Statistical analysis was based on at least ﬁve independent series
of experiments. Standard deviations are indicated on the graphs.
By using a paired t-test, data were considered to be statistically
signiﬁcant when the two-tailed p-values were po0,001 (nnn),
po0.01 (nn) or po0.05 (n).
3. Results and discussion
3.1. Probe design
3.1.1. Microelectrodes diameter
Our measurement conﬁguration involves micrometric electro-
des and a counter-electrode measuring approximately 2 cm placed
at least at 1 cm from the measurement point. This asymmetric
geometry leads to a non-linear voltage drop between microelec-
trode and counter-electrode. In the case of a homogeneous tissue,
it has been shown that most of the voltage drop occurs within
short distance from the microelectrode. The order of magnitude of
this distance is a few times the microelectrode diameter d. At a
distance d, the voltage falls to 50% of its value on the microelec-
trode and at a distance 2d to 20% of it (Newman, 1966). Conse-
quently, the volume contributing mostly to the impedance
measurement (i.e. the volume of tissue of which the resistivity is
actually measured) is a half sphere of a diameter of a few times d
surrounding the microelectrode. This implies that microelectrode
dimensions have to be carefully determined taking into account
the size of the desired measurement volume. In this study, we
intended to distinguish structural and cellular organizations of
brain tissues having typical sizes of several hundreds of microns
and composed of several types of cells, whose cell bodies dia-
meters are in the range of 10 mm. To this end, we need to measure
the resistivity of small volumes so as to be able to differentiate
structures down to the scale of 100 mm. On the other hand, the
measurement volume has to be large enough to constitute a
representative sample of the investigated structure, i.e. it has to
contain the different constitutive elements such as neurons, glial
cells, ﬁbers, myelinated axons and extracellular matrix. For these
reasons, we chose a sampling volume on the order of 50–100 μm
size and consequently designed and fabricated disc microelec-
trodes measuring 50 μm in diameter.
3.1.2. Microelectrodes spacing
The probe design resulted from a compromise between a high
number of microelectrodes and a minimal invasivity. The total
shaft width is determined by the number of metal traces linking
the microelectrodes to the connector. In this work we chose to
pattern 8 electrodes on the probe, resulting in a total probe width
of 500 μm which was considered a reasonable induced invasivity
for future in vivo measurements on mice brains (one of the
smallest in vivo model brains) (Lee et al., 2013; Polikov et al.,
2005). The electrodes are placed in a vertical array (Fig. 1a). Inter-
electrode spacing has been chosen to measure impedances over a
large range of depths inside the brain without moving the device.
Considering these different requirements the chosen tradeoff
inter-electrode spacing was 400 mm, enabling measuring simulta-
neously impedance at 8 depths over a total range of 2.8 mm.
3.1.3. Probe stiffness
In order to minimize invasivity and to allow tissues enfolding
tightly the probe, it was microfabricated with a thickness of only
20 mm at its tip. It is thus ﬂexible and enables a good conformity
with the penetrated tissues.
3.2. Discriminating brain structures with impedance spectroscopy
3.2.1. Brain resistivity proﬁles
In order to observe the probe penetration into the brain tissues
during the measurements, impedance measurements were ﬁrst
performed on an extracted brain placed in a dedicated mold.
The probe equipped with a vertical array of aligned microelec-
trodes was gradually inserted vertically into the brain in the motor
area of the cortex (M1) and below for several mm, as shown in
Fig. 2a. Fig. 2b shows resistivity values obtained during probe
penetration. Since the inter-microelectrode distance is 400 mm,
successive measurements were performed each 400 mm. This
allowed recording several times the resistivity of the same tissue
(micro-)region, each time with a successive microelectrode of the
vertical array. Fig. 2c presents resistivity measurements performed
during the penetration of a probe into the brain at six different
depths separated by the inter-electrode distance of 400 mm.
For microelectrodes located outside the brain, we measured
extremely high resistivities, in the order of several hundreds of
ohm meters. In this situation, microelectrodes are in contact only
with a small ﬁlm of PBS attracted by capillary forces due to the
hydrophilicity of the plasma treated polyimide probe. When
microelectrodes penetrate the tissue, the resistivity drops abruptly
to values between 0.5 and 10 Ωm. This abrupt change in resistivity
correlates with the “real time” observation of the probe penetra-
tion in the brain. The resistivity value of each electrode corre-
sponds to a tiny volume of tissue (a half sphere of 50–100 mm
diameter in our case, as explained in Section 3.1) and is speciﬁc to
the structure in which the electrode is placed. This abrupt decrease
of resistivity when the electrode enters into the brain and the
subsequent increase of resistivity at higher depths are measured
by the different electrodes. Furthermore, we observe comparable
values for a same region for successive measurements performed
with successive microelectrodes of the array. This shows that the
resistivity measurement is electrode-independent and demon-
strates that the penetration of the developed neural probe inside
the brain tissues is minimally invasive. The progression of the
probe inside the brain was monitored the same way as that of its
penetration. Fig. 2d–f shows resistivity proﬁles obtained by pro-
gressing deeper in the mouse brain. We observe signiﬁcant
resistivity inhomogeneities inside the brain tissues that we can
repeatedly measure by descending the probe by steps of a distance
equal to the inter-electrode distance. This is important since it
shows that the brain has not been distorted while moving the
electrodes, such that the relationship between electrode positions
and tissue boundaries remains intact.
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These results lead us to investigate systematically the resistivity
of brain tissues along the vertical axis over several millimeters.
To this end, we determined the probe insertion coordinates by
stereotaxy and inserted it gradually thanks to the z-micromanipu-
lator of the stereotaxic frame, as illustrated in Fig. 2g. As before, we
cross checked resistivity values obtained at the same brain depth by
taking advantage of the speciﬁc conﬁguration of the microelectrode
array. Fig. 3 displays typical resistivity z-proﬁles obtained for two
different insertion coordinates. To relate the actual electrode posi-
tion to a particular cytoarchitectonic layer, histological sections were
performed after measurement sessions. By combining observations
of these sections and z-depth measurements thanks to the stereo-
taxic frame, we were able to position very precisely the measure-
ment points on the mouse brain atlas. This allowed linking
resistivity values to speciﬁc brain structures/areas. Fig. 3a–c shows
the resistivity proﬁle obtained at 0.7 mm anterior to bregma, and
bilaterally medio-lateral 1.5 mm. In the ﬁrst millimeters, the probe
progresses inside the cortex. We noted low resistivities, namely
1–2 Ωm, until a depth of 250 mm corresponding to the ﬁrst cortex
layers (layer I and beginning of layer II). Resistivity grows to values
of approximately 6 Ωm for the deeper cortex layers. After
the cortex, the probe penetrates inside the corpus callosum.
Fig. 2. Monitoring of probe penetration into the brain. a and d. Schematic representation of probe penetration and progression. b and e. Resistivity proﬁles measured with
8 different microelectrodes on the same probe while penetrating into the brain and while progressing inside the brain. c and f. Measurements grouped as a function of the
position of the electrode (mean7SD). g. Photograph image of a post-mortem stereotaxic implanted mouse.
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This structure forming a ﬂat bundle of neural ﬁbers and thus
connecting left and right cerebral hemispheres constitutes the largest
white matter structure in the brain. This ﬁber tract exhibits the
highest resistivity comprised between 8 and 9 Ωm. These values are
signiﬁcantly higher than those obtained for the gray matter of the
cortex. This trend is in accordance with those reported in the
literature where white matter tissues exhibit higher resistivity values
compared to the gray matter tissues. For example, Latikka et al.
(2001a, 2001b) reported that for gray matter the average resistivity
was 5.96 Ωm (standard deviation: 1.42 Ωm) whereas white matter
had an average resistivity of 9.02 Ωm (standard deviation: 2.61 Ωm).
Gabriel et al. (1996) as well as Bao et al. (1997) reported white matter
resistivity being respectively 1.25 and 1.65 times larger than that of
the gray matter. It is difﬁcult to compare absolute impedance values
with our results because different animal models were used and they
also can depend on the type of electrode used. Nevertheless, we
observed the same tendency. The brain is not a homogeneous
medium. There are important differences in the histological proper-
ties of the gray and white matter, and it comes as no surprise that
they also differ in electric impedance. The higher impedance of the
white matter is often explained by the fact that this area is mostly
composed of myelinated ﬁbers exhibiting much higher electrical
resistance (Nicholson, 1965).
Cortical impedance measurements have been discussed with
two perspectives: frequency dependence and inhomogeneity/
anisotropy. Regarding frequency dependence, in this study, we
always used the PRF to determine the tissue resistivity from the
impedance measurements done on the electrode–tissue system as
described in Section 3.2.2 and demonstrated by Mercanzini et al.
(2009). The PRF method is particularly recommended in the case
of microelectrodes because the electrode capacitance is small and
dominates the impedance values at low frequencies whereas the
parasitic capacitance dominates at high frequencies. The plateau,
corresponding to the actual resistivity value of the tissue sur-
rounding the electrode, is consequently located in a short fre-
quency window. The PRF method enables locating precisely this
window and obtaining resistivity values close to the tissues
intrinsic values. It is more efﬁcient than conventional impedance
measurements at 1 kHz because such measurements performed
with microelectrodes would lead to values corresponding mostly
to the interfacial capacitance between electrode and tissue.
This value is strongly electrode dependent, contrarily to the values
presented in this work. The PRF is consequently a pertinent
method to combine the advantages of micrometric electrodes
with impedance measurements and allowed us to obtain intrinsic
resistivity values of the tissues with sub-millimetric resolution. For
a more detailed explanation of the PRF, see Mercanzini et al.
(2009). The frequency window of actual tissue resistivity measure-
ment can vary slightly depending on the local resistivity value.
As a consequence, the measurements are not always performed at
the exact same frequency. Nevertheless, the frequency depen-
dence of the brain tissue at the frequencies of interest in this
work (10–500 kHz) is far less pronounced than dependency on the
measured structure, i.e. on the electrode localization in our case.
Several studies report impedance measurements performed at
different frequencies in the brain. Logothetis et al. (2007) con-
cluded from their measurements on the cortex of macaque
between 10 Hz and 50 kHz that the impedance is almost purely
resistive, and thus almost independent of the frequency. Nicholson
(1965) measured the resistivity of ﬁber tracts of cats between
20 Hz and 20 kHz. He reported a very strong dependency on the
direction of measurements but almost no dependency on the
frequency. Gabriel et al. (1996) measured impedance of white and
gray matter in bovine brains. For frequencies between 10 kHz and
Fig. 3. Post-mortem measurements of vertical resistivity proﬁles within the mouse brain. a–c. Resistivity proﬁle for same positions in both hemispheres (bregma 0.7 mm,
lateral 1.5 mm). d–f. Resistivity proﬁle for bregma 0.26 mm, lateral 1 mm. a and d. Illustration of the probe progression in the brain on a coronal cross section map. b and e.
Illustration of each electrode position. Dashes on the map correspond to resistivity measurement positions. c and f. Measured resistivity as a function of the electrode depth.
Each measurement point in b and e corresponds to a resistivity value depicted at the corresponding height respectively in c and f.
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100 kHz they reported a resistivity of white matter changing from
16.5 Ωm to 14 Ωm (a drop of around 15%) whereas the resistivity
of gray matter at comparable frequencies is reported to be
approximately 8 Ωm (i.e. half of the white matter values). Some
studies reported a high anisotropy in the white matter (Güllmar
et al., 2010; Ranck and Bement, 1965). In our case we always
used the same measurement conﬁguration, thus measuring resis-
tivity always in the same direction.
Inside homogeneous structures like in the corpus callosum, we
did not note any variability of impedance, as shown in Fig. 3a–c.
Several measurement points are located inside corpus callosum and
gave same high values of resistivity (8.370.37 Ωm). Descending
the probe further inside the brain leads to an abrupt resistivity
decrease to values around 1 Ωm (mean value is 1.2870.12 Ωm).
This is explained by the penetration of the probe inside the lateral
ventricle, which is ﬁlled with cerebrospinal ﬂuid characterized by
an impedance of 0.7–0.8 Ωm. Indeed, Baumann et al. (1997)
reported values for the human cerebrospinal ﬂuid at room tem-
perature of around 0.7 Ωm at a frequency ranging from 10 Hz to
10 kHz. Latikka et al. (2001) obtained values of approximately
0.8 Ωm in humans at 50 kHz. Here again, we observed same
impedance values for all measurements performed inside the
ventricle. On the impedance proﬁle presented in Fig. 3a–c, we
observe a second abrupt impedance change (from 1 Ωm to 8 Ωm).
The probe is again localized in the corpus callosum, which is
situated below the ventricle in this brain region. For higher brain
depths, namely in the thalamus structure, we noted a high
distribution of impedance values. This can be explained by the
heterogeneity of this brain structure. Because of the small measured
tissue volume, resistivity values can reﬂect various parts of this
composition explaining the value distribution inside this area.
On the impedance proﬁle presented in Fig. 3f, below the lateral
ventricle (and corresponding low impedance values), we observe
an increase of impedance (around 7 Ωm and 8 Ωm deeper).
At these depths, measurements were performed in the basal gang-
lia. Probe insertion and impedance measurements were performed
in both brain hemispheres for the same stereotaxic coordinates.
As shown in Fig. 3c, we obtained same resistivity values for the
same depths for both hemispheres, demonstrating the reliability
and accuracy of the measurement method. Comparable proﬁles
were obtained three times for three different mice.
3.2.2. Cortex layers resistivity
The micrometric dimensions of our electrodes allowing small
volume resistivity measurements combined with high precision z-
displacements lead us to demonstrate inhomogeneities inside the
cortical gray matter (Fig. 2, depths from 0 to 1 mm and 0 to
1.5 mm). One would expect that these differences could be
related to the cortex organization in several layers. Although, as
mentioned before, numerous studies have shown resistivity differ-
ences between gray and white matter, the resistivity differences
within the gray matter have been less studied and no clear relation
to the histological structure has been shown. In order to investi-
gate the hypothesis that the resistivity proﬁles in the cortex are
related to histological structures, we measured impedance on
brain slices instead of a complete brain. Indeed, this new conﬁg-
uration allowed visualizing properly and in real time the measure-
ment localization. Fig. 4a presents the setup used. 300 mm thick
sagittal brain slices are placed in a petri dish ﬁlled with phosphate
Fig. 4. Resistivity measurements in the different cortical layers on acute brain slices. a. Experimental setup used for measurements on brain slices. b. Microscope image of a
slice with inserted probe tip for resistivity measurement c. Boxplot of the resistivity values obtained for the different cortical layers (mean7SD, n¼6). Paired t-test: po0.001
(***;), po0.01 (**) or po0.05 (*). d. Measured resistivity (mean7SD) as a function of the cell body density (mean7SD). Standard deviations in cell body density are too
small to be visible. Note that on the graphs, layers are depicted with equivalent weight whereas layers have different thicknesses in reality.
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buffered saline under an optical microscope. Differential interface con-
trast microscopy allowed distinguishing the different cortical layers.
Thanks to a micromanipulator, a probe tip was inserted precisely in
each cortex layer at middle height within the slice. Fig. 4b presents a
microscope image of the probe tip inserted within a slice. We can
distinguish the round electrode appearing black in the picture. The
counter-electrode is placed in contact with the slice at a distance of
approximately 1 cm from the measured region. The small thickness of
the probe and its ﬂexibility enabled an excellent contact between
tissue and electrodes which is observed in situ when the probe is
inserted and withdrawn from the tissue. This strong contact excludes
any impedance alteration due to the presence of a liquid ﬁlm or gap
between electrode and tissue, conﬁrming that our measurements
correspond to the actual electrical properties of the tissue region.
Combining microscopic observation and data from the mouse brain
atlas, measurements were performed in the ﬁve layers of the
somatosensory cortex and in corresponding layers in the cortex motor
area. Due to the thinness of layer II it was impossible to distinguish it
from layer III. We thus treated layer II and III as one single region.
Measurements were performed several times on the same slice and
on different slices, in the primary and somatosensory cortex.
Fig. 4c presents the measured resistivity for layers I–VI. Resistivity
values are between 0.7270.03Ωm for layer I and 5.2870.26Ωm for
layer VI. For each layer, we observed characteristic resistivity values.
Measurements were repeatable inside a layer for a same slice and for
different slices. Layer I exhibits a low resistivity (0.7270.03Ωm) and
layers II/III and V show a higher resistivity with respective mean values
of 3.7870.25Ωm and 4.1170.15Ωm. Layer IV reveals a lower
resistivity with a mean value of 2.4870.27Ωm. At the bottom of
the cortex, layer VI exhibits the highest resistivity with a mean value of
5.2870.26Ωm. Each layer has resistivity values statistically different
from its adjacent layer (po0.01 for each comparison between
neighbor layers and po0.001 in the case of layer I). Indeed, cortical
layers are different in function and structure. For instance, layer I
contains few neuronal cell bodies and consists mainly of ﬁber tracts
and glial cells. Other layers contain a higher number of neurons of
different types and sizes depending on the layer.
For describing rigorously the measured cortical layers, we
quantiﬁed cell body density for each layer. The graph presented
in Fig. 4d shows the resistivity as a function of the cell density for
each cortical layer. Layers with low cell body densities (layer I and
to a lesser extent layer IV) exhibit low resistivity values. Layers
II/III and V have higher and comparable cell body densities and
exhibit larger and comparable resistivity values. Layer VI has the
largest cell body density (180,000 cells/mm3) and the largest
resistivity. We observed that resistivity is linearly correlated with
cell density (correlation coefﬁcient is 0.96). Measurements per-
formed using a probe equipped with only one electrode would
lead to uncertainty and would not allow discriminating reliably
the electrode position in the in vivo situation. Using numerous
microelectrodes conﬁrms thus the opportunity of possible cross-
checking measurements on different electrodes placed at a
determined distance from each other. By comparing the cortex
resistivity values we obtained on slices with those obtained in
complete brains, we observe the same tendencies. In both conﬁg-
urations, we noted very low resistivity values for the ﬁrst cortical
layer and an impedance increase for layers II/III, V and VI.
However, at corresponding localizations in the “complete brain
conﬁguration”, layer IV does not exist or has a very low thickness
(o100 μm). The corresponding drop of resistivity measured in the
“slice conﬁguration” can consequently be hardly measured. Taking
this element into account, the results presented here on sagittal
slices are in good accordance with the measurements performed
in the cortex in the “complete brain conﬁguration”.
A few studies reported impedance differences inside the cortex.
Hoeltzell and Dykes reported relative vertical conductivities in the
somatosensory cortex of cats. Their data showed marked and abrupt
changes with cortical depth (Hoeltzell and Dykes, 1979). Goto et al.
evaluated the conductivity proﬁle in the somatosensory barrel cortex
of wistar rats and found impedance anisotropies. However, they did
not ﬁnd any correlation between the conductivity proﬁle and the
density of cell bodies, either for neurons and astrocytes, or for
oligodendrocytes (Goto et al., 2010). This can be potentially explained
by the fact that the authors investigated only the speciﬁc frequency
of 500 Hz. Besides these measurements on animal cortex, in vitro
models have also been developed in order to investigate tissue
reaction to inserted microprobes using impedance measurements.
Frampton et al. (2010) constructed an in vitro model of rat cortex
consisting of a three dimensional architecture of cells encapsulated in
alginate with an implanted microprobe, with which impedance
measurements were performed. They showed that cell density is
the critical factor in determining the resistance of the tissue
surrounding the electrodes.
3.3. Measurement of the spatial extent and gradation of brain tissue
denaturation induced by cauterization
The results presented so far demonstrate that our impedance
measurement setup can be used to perform repeatable measure-
ments in the brain with high spatial accuracy. In the following
sections, we aim at demonstrating that impedance spectroscopy
performed with microelectrode arrays can help to qualify brain
tissues modiﬁed during surgical procedures, as for example tissue
coagulation following thermal ablation. Thermal ablation is cur-
rently used in a wide range of diseases or disorders, like brain
tumors, or epilepsy. In each case, a very important focus is to limit
the ablation to the desired part. However, surgeons rarely get an
immediate feedback of their actions.
In order to imitate a local thermal ablation, we locally cauter-
ized the somatosensory cortex of an ex vivo mouse brain using a
copper wire (300 mm in diameter) attached to a heating element.
During this operation, the 70–80 1C hot copper wire is placed
inside the brain for 60 s. The local heat of the wire dissipates,
inducing a temperature gradient from a central hot point in all
directions. This heating results usually in a radial wound with a
central part composed of necrotic tissue with a loss of cellular
integrity and a peripheral part with shrunken neurons and glial
cells with condensed nuclei (Miao et al., 2002). Fig. 5a shows a
histological section of the cauterized brain stained with hematox-
ylin–eosin (HE). We observe color changes of the HE-stained slice
in the cauterized area. The wound is not clearly demarcated from
the healthy tissue, but a penumbra surrounds it, in which the
tissue changes progressively from healthy to necrotic with a
progressive loss of cellular integrity (Hsu et al., 2000; Miao et al.,
2002). In Fig. 5a, the necrotic area and the penumbra are delimited
by gray dashed lines. Black dashes represent measurement posi-
tions located every 250 μm inside the cauterized brain region,
surrounding penumbra and healthy tissue located more deeply in
the brain.
Fig. 5b shows the obtained resistivity proﬁle. We observe a low
resistivity (values are between 0.5 and 2 Ωm) for depths corre-
sponding to the wound region. In the penumbra, resistivity values
grow steadily from the wound region to healthy tissues. For depths
corresponding to corpus callosum region we note a high impe-
dance increase that was already observed in healthy brains, thus
meaning that corpus callosum is not affected by the cauterization
in this experiment.
In order to investigate more precisely the cauterization effect and
its spatial extent, we repeated the cauterization and resistivity
measurements on brain slices (see Fig. 6). This planar conﬁguration
allowed observing the slice directly with a microscope and thus
determining precisely where to measure the impedance. As before,
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cauterization was executed by heating a speciﬁc point of the slice
with a copper wire at a temperature of 70–80 1C for 60 s. Cauteriza-
tion was performed on the right hemisphere of a 300 μm thick
coronal brain slice while the left hemisphere was kept intact. The
heat dissipated and propagated within the slice, creating a radial
thermal gradient from the heating point in all directions. At the
center of the heated area, the tissue appeared visually clearer than
normal, showing strong denaturation. Most of the cell membranes
were lysed, leading to local necrosis (Hsu et al., 2000). Microscope
observation of the slice showed that damages caused on the tissue
decreased gradually with increasing distance from the insertion site
of the heat source. For large distances, the tissue appeared intact.
Fig. 5. Resistivity proﬁle of a locally cauterized ex vivo mouse brain. a. Microscope image of a histological section in the cauterized area of the brain. Cauterized portion of the
brain and penumbra are delimited by dashed lines. Electrode position for each measurement of the vertical proﬁle is represented by a bold dash. b. Resistivity values as a
function of depth. Black dots representing resistivity values in b and corresponding black dashes representing the electrode position are depicted at the same heights.
Fig. 6. Resistivity measurement of a locally cauterized coronal brain slice a. Schematic representation of the slice. Cauterization point is represented by the black dot in the
left hemisphere. The right hemisphere was kept intact. Resistivity is represented by gray scale in the cortex, dark gray corresponds to high resistivity. b. Resistivity values
obtained for various radial distances across the cortical layers (z-axis in a) from the center of the cauterization in the right hemisphere (black dots) and from the
corresponding point in the left hemisphere (clear dots). c–f. Resistivity along cortical layers (x-axis in a) for different distances from the center of cauterization (arc lines in a)
in the cauterized (black dots) and intact (clear dots) hemisphere. The zero point on the x-axis corresponds to the point at the minimal distance of the center of cauterization
(intersection of the arc lines with the dotted line in a).
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A schematic view of the brain slice summing up these observations is
presented in Fig. 6a. In order to determine the impact of the
cauterization on the resistivity and characterize its spatial extent,
impedance measurements were performed in the direction of the
arrows depicted in Fig. 6a, i.e. i) orthogonally to the layers (resulting
graph is presented in Fig. 6b) and ii) along the cortical layers at
different distances from the heated point (resulting graphs are
presented in Fig. 6c–f). In order to obtain control values, impedance
measurements were done at the corresponding symmetric points
in the intact hemisphere.
Resistivity values measured along an orthogonal line to cortical
layers in both hemispheres are presented in Fig. 6b. On the intact
hemisphere, we noted variations of the resistivity inherent to
the layer organization of the cortex. However, resistivity proﬁle on
the cauterized hemisphere differs strongly evidencing the effect
of the cauterization on the tissue. From Fig. 6b, we observe a
signiﬁcant decrease of the resistivity in the heated area which does
not appear in the intact hemisphere. Values change from 3.5 to
4 Ωm in the intact hemisphere to around 0.5 Ωm for symmetrical
coordinates in the cauterized hemisphere. In this region, the tissue
is strongly denatured: cell membranes have lost their integrity and
the remaining tissue is composed uniquely of lysate comparable to
cerebrospinal ﬂuid and with corresponding measured resistivity.
For radial distances from the insertion site of the heat source
comprised between 0 and 600 mm, the resistivity increases steadily
on the cauterized side from 0.6 to 3.2 Ωm. On the healthy side, it is
clearly layer dependent. For larger distances, both hemispheres show
similar, layer dependent values. The resistivity proﬁle obtained for
the cauterized side results from two types of contribution: inherent
resistivity and modiﬁcation induced by the cauterization. With
increasing radial distance, the difference between values for cauter-
ized and intact hemispheres decreases gradually. For radial distances
superior to 600 μm, both hemispheres exhibit comparable resistivity
values and cauterization effects are not measurable anymore. Resis-
tivity results presented in Fig. 6b can be consequently considered as
an accurate measurement of the radial extent and the gradation of
the progressive wound caused by the thermal treatment.
As observed previously (see Fig. 4), resistivity is homogeneous
inside each cortex layer and differs between them. In order to
overcome the issue of inherent resistivity variability due to the
layer organization of the cortex and to measure impedance
changes only due to the cauterization, measurements were also
performed inside layers at different distances from the heated
point (along the arc lines of Fig. 6a). Results are presented in
Fig. 6c–f. In the intact hemisphere (clear dots on the graphs), we
observe again that resistivity is homogeneous within layers and
differs between them. On the contrary, in the cauterized hemi-
sphere, we clearly observe an impedance decrease in the vicinity
of the cauterization point source. For layers located in the direct
vicinity of the heated point (100–300 μm distance), the impedance
drop is strong and resistivity values are comparable to those of
cerebrospinal ﬂuid. Values become comparable to those obtained
in the intact hemisphere only at high distances from the heated
point (approximately 1 mm along the layer, see Fig. 6c). On the
layers placed gradually further from the heated point (300 and
500 μm), the resistivity drop decreases gradually both in depth
and in extent (Fig. 6d and e). No drop has been measured on the
farthest layer (Fig. 6f). Here again, the impedance measurements
enable qualifying the extent and gradation of the wound and
induced penumbra area caused by the cauterization. Thus, these
measurements demonstrate the possibility of using impedance
measurements performed with an implantable microelectrode
array in order to determine the extent of the denaturation caused
during surgery. Combined with existing surgical tools for perform-
ing thermoablation, this could enable checking in real time the
localization and propagation of the induced necrosis.
4. Conclusion
Impedance measurements in the brain using macroscopic needles
were reported by many researchers previously. They allowed obtain-
ing resistivity values of big structures, discriminating for example brain
gray and white matters. A few studies report the use of micrometric
electrodes for impedance measurements with higher spatial resolu-
tion. However, these measurements were performed at mostly speciﬁc
frequencies, leading to resistivity values dependent on both the
measurement frequency and electrode design. Here, we reported the
use of the PRF method to obtain intrinsic resistivity values of brain
tissues that are independent of the microelectrodes size. In this study
we could demonstrate that impedance spectroscopy measurements
with microelectrodes embedded in a speciﬁcally designed neural
probe is a suitable method to systematically identify tiny cerebral
structures. Thanks to a micrometric electrode array we were able to
distinguish and localize cortical layers measuring hundreds of micro-
meters inside the mouse brain, thus demonstrating high localization
and resistivity accuracy. We were further able to show that tissue
resistivity inside the cortex is positively correlated with cellular
density. To the best of our knowledge, such measurements along with
a clear correlation with the underlying histological cortical structures
have never been reported elsewhere. In addition, impedance spectro-
scopy based real-time measurement on a cauterized mouse model
revealed impedance spectra characteristics that could be used for the
discrimination of healthy tissue from cauterized tissue and also for
measuring the spatial extent of the induced wound.
Ultimately such a technique can be used in several clinical
applications. For example, it could be potentially used to monitor
in real time the extent of a radiofrequency ablation, with the
advantage that the electrode array required for the measurement
could be placed directly on the radiofrequency ablation device.
The ﬂexible microelectrode array could also be easily integrated on
existing neural probes used clinically for deep brain stimulation.
As such, it could be a simple, precise and real-time localization
device used in addition to conventional imaging techniques. For
research and more fundamental studies, this method can bring
information about the evolution of tissue integrity or structural
modiﬁcations related to the local administration of a drug or to
tissue stimulation for example. In the case of studies of dynamical
effects involving animal models, using this real time monitoring
could also help to reduce the number of animals euthanized at
different time points.
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Abstract
Objective. Alzheimer disease (AD) is the most common form of neurodegenerative disease in
elderly people. Toxic brain amyloid-beta (Aß) aggregates and ensuing cell death are believed to
play a central role in the pathogenesis of the disease. In this study, we investigated if we could
monitor the presence of these aggregates by performing in situ electrical impedance spectroscopy
measurements in AD model mice brains. Approach. In this study, electrical impedance
spectroscopy measurements were performed post-mortem in APPPS1 transgenic mice brains.
This transgenic model is commonly used to study amyloidogenesis, a pathological hallmark of
AD. We used ﬂexible probes with embedded micrometric electrodes array to demonstrate the
feasibility of detecting senile plaques composed of Aß peptides by localized impedance
measurements. Main results. We particularly focused on deep brain structures, such as the
hippocampus. Ex vivo experiments using brains from young and old APPPS1 mice lead us to
show that impedance measurements clearly correlate with the percentage of Aβ plaque load in
the brain tissues. We could monitor the effects of aging in the AD APPPS1 mice model.
Signiﬁcance. We demonstrated that a localized electrical impedance measurement constitutes a
valuable technique to monitor the presence of Aβ-plaques, which is complementary with existing
imaging techniques. This method does not require prior Aβ staining, precluding the risk of
variations in tissue uptake of dyes or tracers, and consequently ensuring reproducible data
collection.
Keywords: impedance spectroscopy, neural probe, microelectrodes array, mouse brain,
Alzheimer’s disease, Aβ plaques, APPPS1 model
(Some ﬁgures may appear in colour only in the online journal)
1. Introduction
Alzheimer’s disease (AD) is one of the most widespread and
cognitively devastating neurodegenerative diseases (Nestor
et al 2004). In this disease, cognitive deﬁciencies include
early clinical hallmarks that consist of difﬁculties in learning
and recent memory storage. AD is also characterized by a
number of organic pathological features, in particular extra-
cellular senile plaques composed of 4 kDa beta-amyloid
peptides (Aß). These amyloid plaques are believed to play a
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central role in the pathogenesis of the disease (Hardy and
Higgins 1992), and their preferential localization in the cortex
and hippocampus (Ball 1977, Ball et al 1985, Hyman
et al 1990) correlates with the primary cognitive and memory
disturbances (Killiany et al 2002). Aß aggregates into toxic
plaques up to several years before ﬁrst clinical symptoms
appear, and their detection and monitoring is of primary
interest, both for diagnostic purposes, and for fundamental
research. The amyloid plaques are formed by the progressive
deposition and transformation of soluble Aß monomers into
insoluble and ﬁbrillar aggregates that contain Aß in a beta-
pleated plaque conformation. Soluble Aß monomers are
present in the cortical extracellular space and in the cere-
brospinal ﬂuid and can be detected by chemical analysis of
the ﬂuid composition (Portelius et al 2006).
A number of techniques have been developed for
detecting and monitoring the presence of insoluble Aß-
aggregates in vivo, although a lack of sensitive, label-free
techniques still exists, namely for the detection of senile
plaques in deeper structures such as the hippocampus. Indeed,
a number of relatively sensitive whole-brain or local imaging
techniques exist, such as positron emission tomography
(Mosconi et al 2010), single photon emission computed
tomography or molecular optical imaging (Bloudek
et al 2011), including multiphoton microscopy (Yan
et al 2009), but these techniques require the use of contrast
agents or dyes directed against speciﬁc molecular markers.
The delivery of contrast agents in animal models of AD is
typically carried out in an invasive fashion in the vicinity of
the plaques, due to the need to avoid the blood-brain barrier.
This, and direct molecular action of the contrast agents on the
actual formation and stability of the plaques, raises concerns
about the experimental results obtained with these techniques,
outlining the need for label-free approaches. Magnetic reso-
nance imaging (MRI) and computed tomography are such
label-free whole brain imaging techniques. These techniques
are currently limited by an insufﬁcient spatial resolution for
senile plaque detection, although in particular high-ﬁeld MRI
systems are approaching the necessary spatial resolution.
Senile plaques in the cortex can be detected via optical
coherence tomography (Bolmont et al 2012), but short of
taking a biopsy, no such option is as yet available for the
detection of plaques in deeper structures such as the
hippocampus.
Here we present a novel protocol that enables the
detection of amyloid plaques in the brain of an APPPS1
transgenic mouse model of AD in deep brain areas, typically
inside the hippocampus. In this study, measures were per-
formed post-mortem but the same tools and methods could be
applied in vivo for research purposes. APPPS1 mice constitute
a commonly used model for the study of AD characterized by
Aβ accumulation in the brain resulting in the formation of Aβ
plaques in the cortex and hippocampus, thus recapitulating
important aspects of AD pathogenesis in human brains
(Holcomb et al 1998). The density of plaques is directly
related to the age of the mouse: the ﬁrst plaques appear
between the second and the third month, the plaque density
then grows continuously at least until the eighteenth month of
the mouse life (Gordon et al 2002). In this work, we
demonstrate the feasibility of detecting Aβ plaque-pathology
by impedance measurements in a ﬁrst series of ex vivo
experiments using brains from 18-month-old Aβ depositing
APPPS1 transgenic mice, as well as from control, age-mat-
ched non-transgenic mice and 1-month-old pre-depositing
APPPS1 mice. We show that impedance measurement con-
stitutes a valuable technique to monitor the presence of Aβ
plaques in the hippocampus and more particularly in the
dentate gyrus.
2. Materials and methods
2.1. Probe design and microfabrication
The probe used in this work is presented in ﬁgures 1(b)–(c).
Eight 50 μm diameter platinum electrodes were patterned and
organized in a vertical array with inter-electrode distance of
400 μm. Both electrode size and inter-electrode distances
were speciﬁcally chosen considering the requirements of tis-
sue impedance spectroscopy, as detailed previously (Béduer
et al 2014). Indeed, the volume probed when measuring
impedance is determined by the electrode size. In general,
larger measurement volumes sample more tissue and thus
lead to better signal-to-noise ratio, but the measurement
volume also needs to be small enough to distinguish struc-
tures of a size of hundreds of micrometres. With a micro-
electrode diameter of 50 μm, the volume probed can be
estimated to be a half sphere measuring a few times the
microelectrode diameter (between 100 μm and 200 μm). The
inter-electrode distance is chosen in such a way that the eight-
electrode array cover a large range of depths within the mouse
brain (2.8 mm).
The ﬂexible multi electrode array was fabricated using
standard microfabrication techniques, presented in detail
elsewhere (Metz et al 2004, Cheung et al 2007). Brieﬂy, an
adhesion layer of a titanium tungsten alloy and a sacriﬁcial
layer of aluminium are sputter deposited on a silicon wafer. A
10 μm polyimide (PI2611, HD Microsystems) is then spin
coated. A sandwich layer of Ti/Pt/Ti (50 nm/200 nm/50 nm)
is sputter deposited and patterned through a photoresist layer
in order to deﬁne the electrodes and electronic tracks. This
layer is covered by a second 10 μm thick polyimide layer. A
ﬁnal etching step enables to open the electrode contacts and to
deﬁne the device outlines. The devices are detached by anodic
dissolution of the aluminium layer (Metz et al 2005). Con-
nectors are glued using conductive silver paste (EPO-TEK
H20E, Epoxy Technology, USA). A biocompatible epoxy is
used for encapsulation of the connector-device junction. The
total thickness of the ﬂexible probe tip 20 μm, enabling good
conformity with penetrated tissues.
2.2. Electrical impedance spectroscopy measurements
Impedance spectroscopy measurements were performed using
an impedance analyser (Agilent 4294A, Agilent technologies,
USA). A sinusoidal voltage of 50 mV was applied and the
2
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frequency was swept between 40 Hz and 4MHz. The
obtained spectrum reﬂects the different capacitive and resis-
tive elements of the measured electrical system: electrode-
tissue interfacial double layer, resistivity of the tissue sur-
rounding the electrode and parasitic capacitance between
platinum tracks and tissue through the polyimide. The other
elements of the system—the resistance of the platinum tracks,
the bulk tissue resistance and the counter electrode double
layer capacitance—have a negligible impact on the impe-
dance spectrum in the measured frequency range. We used
the peak resistance frequency (PRF) method in order to iso-
late the resistance of the tissue surrounding the electrode from
the other elements (Kasi et al 2011): the tissue resistance is
approximated by the value of the impedance modulus at the
frequency at which the phase is closest to zero. The resistivity
is then calculated by dividing the resistance by a constant
factor (called cell constant), depending of the microelectrode
diameter (Newman 1966) and determined by measuring the
impedance spectrum of the microelectrode placed in a saline
solution of known resistivity.
The probe was mounted on a stereotaxic frame and
inserted vertically into the mouse brain at determined ste-
reotaxic coordinates, as illustrated on ﬁgure 1(a). Figure 1(d)
presents the method used for resistivity recordings. Brain
resistivity proﬁles were obtained by inserting the probe within
the brain and by lowering it by steps of 100 μm. At each step,
the impedance spectrum was recorded and the surrounding
tissue resistivity was extracted for each electrode by PRF.
Thanks to the array conﬁguration, the resistance at a given
point was recorded several times (by each electrode passing
it). This method allowed to obtain a resistivity proﬁle for each
electrode, as presented in ﬁgure 1(e). By considering the
proﬁles obtained for the different electrodes together, we
Figure 1. Impedance measurement device and conﬁguration. (a) Photograph image of a post mortem stereotaxically implanted mouse. (b)
Photograph image of the probe with glued connector and capillary facilitating probe manipulation. (c) Microscope image of the polyimide
probe used for measurements consisting of an array of eight 50 μm diameter platinum electrodes. (d) Schematic representation of the probe
insertion into the brain tissues. Each geometrical shape (triangle, square, star and disc) represents one of the eight electrodes of the array.
Electrodes are gradually inserted into the brain and impedance spectra are recorded at every 100 μm step. (e) Typical impedance
characteristics measured in the mouse brain (example of a wild-type mouse). (f) Schematic representation of resistivity proﬁles resulting from
the recorded impedance spectra analysis. Each proﬁle is obtained from one electrode of the array. (g) Schematic representation of the ﬁnal
mean proﬁle and associated standard deviations.
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obtained a resistivity proﬁle with standard deviation for each
point probed, as presented in ﬁgure 1(f).
2.3. Mice
Male and female wild-type (WT) and APPPS1 transgenic
mice (kindly provided by Professor M Jucker, HIH, Tübin-
gen, Germany) were used. APPPS1 animals co-express the
KM670/671NL Swedish mutation of human amyloid pre-
cursor protein and the L166P mutation of human presenilin 1
under the control of the Thy-1 promoter and show age-
dependent accumulation of parenchymal Aβ plaques (Radde
et al 2006). Both WT and APPPS1 mice were generated on a
C57BL/6J background. All animal experiments were con-
ducted in accordance with local and federal directives for the
care and use of laboratory animals. Experiments were per-
formed on both male and female mice aged of 18-months (old
mice) or 1-month (young mice).
2.4. Surgery and setup
All mice were euthanatized by carbon dioxide inhalation, then
placed on a stereotaxic frame. Measurements were carried
within two hours of the death of the animal. Holes were
drilled in the skull using a dummy cannula (25 G) and
bilateral measurements were performed at the following ste-
reotaxic coordinates: −2.1, 1.5 (in mm, anterior, lateral to
bregma). The counter electrode consisting in a platinum wire
was placed inside the brain approximately 3 mm anterior to
bregma. Care was taken to avoid drying of the cortical surface
and the skull was covered with phosphate buffered saline
(Sigma Aldrich, Saint Louis, MO). The probe was placed in
the taxic clamp of the stereotaxic frame and gradually inserted
vertically into the skull and brain.
2.5. Histology and staining
Immediately after impedance proﬁling, mice brains were
removed and ﬁxed overnight using 4% paraformaldehyde
(PFA) in PBS, pH 7.4, followed by 48 h incubation in 30%
sucrose. Brains were frozen in optimal cutting temperature
compound and subsequently sectioned on a freezing-sliding
microtome to collect 30 μm coronal sections. Sections cor-
responding to spatial coordinates used for impedance mea-
surements were selected and stained. To visualize Aβ deposits
sections were immunostained using the Aβ monoclonal
antibody 6E10 and DAB for revelation. After washing the
cryoprotectant with PBS, sections were incubated for 10 min
in 3% H2O2 in PBS to inhibit endogenous peroxidase. No
further pretreatment was required. Sections were blocked in
1% BSA in PBS for 20 min. Mouse α-amyloid (clone 6E10,
Covance) diluted 1:750 in 1% BSA was incubated overnight
at 4 °C under agitation. After PBS washes, the secondary
antibody mouse Immpress (ready to use, Vector Laboratories)
was applied for 30 min at room temperature. Revelation was
performed with DAB (3,3′-Diaminobenzidine, Sigma-
Aldrich). Sections were mounted on slides and counterstained
with Mayer’s hematoxylin. Brain sections were also stained
with Cresyl violet and hematoxylin-eosin according to stan-
dard protocols.
2.6. Imaging and quantitative analysis
Large area images were obtained using a Leica DM5500
microscope in bright ﬁeld with an 20× objective and a
motorized stage. In order to quantify the load of Aβ plaques in
the probed brain areas, and the probed area was graphically
selected and binarized using image analysis software (Ima-
geJ). Since the DAB stained plaques appear dark brown in the
original image, they give rise to black pixels after binariza-
tion, while the rest of the image remains white. The percen-
tage of black pixels per surface unit was reported for each
depth. Likewise, local cell density was quantiﬁed by counting
stained cell nuclei per surface unit. We used identical squares
of 100 μm side length for the quantiﬁcation of both the pla-
ques and the cell density, and evaluated ﬁve such squares for
each experimental condition (APPPS1 versus WT, young
versus old mice, at each measurement depth).
2.7. Statistics
Statistical analysis was based on at least ﬁve series of
experiments. Standard deviations are indicated on the graphs.
By using a paired t-test, data were considered to be statisti-
cally signiﬁcant when the two-tailed p-values were p< 0001
(***), p< 0.01 (**) or p< 0.05 (*). No multiple testing cor-
rections were performed.
3. Results and discussion
For performing impedance spectroscopy measurements, a
ﬂexible probe equipped with a microelectrode array com-
prising eight 50 μm diameter disc electrodes vertically sepa-
rated by a distance of 400 μm was fabricated and implanted
post mortem into the mice brains (ﬁgure 1(a)). Figure 1(b)
presents a photograph of the complete probe before implan-
tation. On ﬁgure 1(c), a microscope image of the probe tip is
presented. The eight microelectrodes are visible on the right
side. The probe was inserted gradually inside the brain and
impedance measurements were performed at steps of 100 μm
with each electrode of the array against a distant reference
electrode. Each point of interest along the proﬁle is therefore
measured by each electrode passing it, as schematized in
ﬁgure 1(d). We therefore obtain 8 resistivity values measured
at the same brain coordinate allowing us to extract the mean
resistivity proﬁles along with the standard deviation as
schematized in ﬁgures 1(f)–(g). To extract the tissue resis-
tivity from the impedance measurements, we used the PRF
method (Mercanzini et al 2007, Béduer et al 2014).
Figure 1(e) shows typical spectroscopic data from which we
extract the value for obtaining resistivity values.
In order to check the correct insertion of the probe inside
the tissues, we ﬁrst compared the resistivity measured by the
different electrodes of the array for a given coordinate and
depth. Comparable values were obtained for a given region
4
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for successive measurements performed with successive
microelectrodes showing that the resistivity measurement is
essentially electrode-independent and demonstrating that the
penetration of the developed neural probe inside the brain
tissues creates minimal tissue damage.
Figures 2(a)–(c) presents the resistivity proﬁles obtained
in the hippocampus area for post-mortem WT mice and for
APPPS1 mice. For each mouse, measurements were per-
formed in both brain hemispheres. Figure 2(a) shows the
results obtained for two 18-months-old WT mice. We observe
that all the resistivity proﬁles are similar. For each proﬁle, we
note nearly constant resistivity values except in one area
corresponding to depths comprised between −1.7 mm and
−1.9 mm where resistivity values increase. In order to corre-
late these observations with anatomical features, brain his-
tology and consecutive Haematoxylin-Eosin as well as Cresyl
violet and anti-Aβ plaques stainings were performed in the
measurement area. Results are shown in ﬁgure 2(d). We
observed that the tissue resistivity increase corresponds to
ﬁbre tracts located below the cortex. This result is in accor-
dance with impedance measurements performed previously at
other stereotaxic coordinates (anterior to Bregma; medio-lat-
eral in mm: −0.7;1 and −0.7;1.5) (Béduer et al 2014).
Figure 2(b) presents the resistivity proﬁles obtained for
APPPS1 transgenic mice and gives a comparison with the
mean proﬁle obtained for WT mice. All proﬁles were
acquired at the same stereotaxic coordinates. We ﬁrst observe
that all resistivity proﬁles measured in AD mice brains exhibit
the same shape, namely stable resistivity values around 7Ωm
for depth smaller than −1.75 mm followed by a distinct
resistivity decrease for depths comprised between −1.75 mm
and −3.00 mm (minimal resistivity values are about
Figure 2. (a)–(c) Resistivity proﬁles obtained in the hippocampus of mice (2.1 mm anterior to Bregma; 1.5 mm medio-lateral in mm). (a)
Resistivity proﬁles obtained for 18-months-old WT mice. (b) Resistivity proﬁles obtained for 18-months-old AD mice compared to the mean
proﬁle obtained for the WT mice. (c) Control proﬁle obtained for a 1-month-old AD mouse in comparison to 18-months-old AD mice and
18-months-old WT mice. (d)–(f) Microscope image of histological sections of mice brains in the measurement region. Cell nuclei appear in
blue and Aβ plaques are revealed with DAB, in brown. Black rectangles indicate the measurement area. (d) Brain of an 18-months-old WT
mouse. (e) Brain of a 18-months-old APPPS1 mouse. (f) Brain of a 1-month-old APPPS1 mouse. (g) Zoomed area on Aβ plaques observed in
the hippocampus of an 18-months-old APPPS1 mouse.
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1.75Ωm). In the last 500 micrometres (from −3.00 mm to
−3.5 mm), we observe a resistivity increase, back to values
7Ωm. As we can see from the mean proﬁle obtained for WT
mice brains, the distinct resistivity decrease observed in AD
mice hippocampus was not observed in the WT mice brains,
where resistivity values consistently remained high, namely
between 6.8Ωm and 7.8Ωm, along the whole measurement
depth. We thus observed a signiﬁcant difference between
resistivity proﬁles from 18-month-old, Aβ depositing
APPPS1 transgenic mice and from age-matched non-trans-
genic mice. In order to check that the differences of resistivity
values observed are not linked to non-speciﬁc structural
alterations induced by the APPPS1 genetic modiﬁcation, we
measured resistivity proﬁles in young, predepositing APPPS1
mice. Figure 2(c) gives a comparison between proﬁles
obtained from old and young AD mice and from old WT
mice. There was no resistivity drop for the young APPPS1
mice, and also no signiﬁcant difference between resistivity
proﬁles of old WT mice and young APPPS1 mice. This
indicates that prior to the onset of the deposition of the pla-
ques, there is no structural difference between the APPPS1
and WT brains detectable via impedance proﬁling. Thus, we
can conclude that the observed resistivity shift is speciﬁc to
aged APPPS1 mice.
In order to correlate the alteration of the resistivity proﬁle
to pathological features in the APPPS1 mice, we obtained
histological sections of the measured brain areas and stained
for Aß plaques, known to be the hallmark of aged APPPS1
mice. Figures 2(d) and (e) show microscope images of the
measured area in both WT (d) and AD (e) mice brains. As
expected from the genetic modiﬁcation present in APPPS1
mice, histopathological assessment shows an accumulation of
Aß plaques in the APPPS1 mice; also as expected, young
APPPS1 mice show no detectable Aß aggregates (ﬁgure 2(f)).
We further observe that the density of plaques is parti-
cularly high in the middle layer of the hippocampus (lacu-
nosum moleculare). This layer corresponds to the observed
resistivity decrease, suggesting that the drop in resistivity is
correlated with the presence of Aß plaques. To further check
this assertion, we quantiﬁed from the histological sections the
local Aß plaque load, that we compared to measured local
resistivity values for the three APPPS1 mice as well as the
age-matched WT controls examined in this study.
Figure 3 shows the results of this quantiﬁcation.
Figures 3(a) and (c) illustrate the typical visual aspect of the
areas where the Aβ plaque load quantiﬁcations was per-
formed, for WT and AD mice respectively. Figures 3(b), (d)–
(f) depict the quantiﬁcation results, for a WT mouse brain and
for three different APPPS1 brains, respectively. The plaque
load proﬁle on ﬁgure 3(b), obtained on a WT mouse brain,
serves as a negative control for the Aβ plaque load quantiﬁ-
cation protocol, and indicates that in the absence of clearly
visible plaques, only a small background plaque load signal is
observed. On the plaque load proﬁles obtained for all three
AD brains, the area of high plaque density in the hippo-
campus is clearly identiﬁable. Also, by comparison with the
corresponding resistivity values, an inverted correlation
between Aβ plaque load and resistivity values can be detected
for all three AD brains. Indeed, relative depths corresponding
to low impedance values consistently exhibited high Aβ
plaque load. These results conﬁrmed that resistivity proﬁles
are linked to the presence of Aβ plaques, and further
demonstrate that this dependency is quantitative. In the cortex
located just above the ﬁbre tract, we can see some Aβ pla-
ques, albeit at a much lower density than in the hippocampus.
However, their presence does not appear to be correlated to
particularly low resistivity values. This observation raises the
question of the sensitivity of the resistivity measurement. It
appears that a minimal density of Aβ plaques is needed to be
detected through resistivity measurement. We estimate the Aβ
plaques detection threshold to correspond to a score of about
17% positive pixels, as it can be observed in the proﬁles
presented in ﬁgure 3(d). This threshold depends on the tissue
volume probed with the microelectrodes, depending itself on
the microelectrode diameter. In order to reduce this threshold
and to be able to detect small Aβ plaques, it should be pos-
sible to reduce the probed tissue volume by reducing the
microelectrode diameter.
We recently demonstrated that resistivity in the mouse
brain cortex is linearly correlated with cell density (Béduer
et al 2014). To further explain the resistivity drop observed in
AD mice hippocampus, we therefore quantiﬁed cell density in
this particular area. We detected a decrease of 12% in the total
number of cells in this area for the AD mice relative to WT
mice. This is consistent with the known phenotype of
APPPS1 mice (Radde et al 2006), in which minor neuronal
loss has been demonstrated in close proximity to the plaques.
We also assessed the inﬂuence of the plaques on the local cell
density by quantifying both the cell density and the plaque
loads in squares of 100 μm side length, in histological
sections of the hippocampal area of both AD and WT mice.
Figures 4(a) and (b) present the distribution of squares in
function of the number of cells they comprise for both WT
and AD mice. For WT mice, scores of squares comprising
0–5 cells, 5–10 cells and 10–15 cells are in the same range,
showing a certain degree of homogeneity in the cell dis-
tribution. This is not the case in AD brains, where most of the
squares either show a very low (0–5) or a large number of
cells (more than 10), while very few squares comprise an
intermediate number (5–10), indicating a strong heterogeneity
in the cell density. We also quantiﬁed the percentage of Aβ
plaque load in the same picture squares. The results are shown
in the graph of ﬁgure 4(c). We clearly see that when the
number of cells is low, Aβ plaque load is high: for squares
comprising 0–5 cells, the mean Aβ plaque load is 62 ± 7%.
Conversely, when the cell number is high, Aβ plaque load is
reduced, even null. Indeed, when cell density was comprised
between 20 cells/square and 25 cells/square, Aβ plaque load
raises by only 2 ± 1%. Taking into account the results pre-
sented in ﬁgures 4(a)–(c), we deduce that the presence of Aβ
plaques results in a reduction of the cell density in the vicinity
of the plaques coupled with a general heterogeneity of the cell
density. These results conﬁrm the hypothesis that Aβ plaques
tend to push the cells away, creating alternating regions of
low and high cell densities according to their presence or
absence (Spires-Jones and Hyman 2014).
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Figure 4(d) is a schematic representation that sums up the
observed phenomena and gives an interpretation to explain
the resistivity drop in the hippocampus of aged AD mice. The
previously described results are taken into account, namely:
(i) the hippocampal region where the resistivity drop was
observed contains a high density of Aβ plaques, (ii) tissue
resistivity is correlated with the cell density, (iii) AD hippo-
campus shows a reduced number of cells around plaques and
an increased heterogeneity in the cell distribution and (iv)
areas with high Aβ plaques load exhibit very low cell density.
These results converge to unravel that tissue loaded with Aβ
plaques in vivo (post mortem, inside brain tissues) exhibit a
lower resistivity than healthy tissue. Indeed, areas occupied
by the Aβ plaques have a low cell density and as a
consequence a low resistivity. Amit et al (2012) investigated
Aβ peptide conductivity and showed that Aβ peptide
sequence and assembly conditions can lead to different con-
ductivities. This underlines that synthetic Aβ aggregates
cannot be directly compared with in vivo plaques. Moreover,
in the in vivo conﬁguration, the plaques are embedded in the
extracellular matrix and in a diffusive medium which, beside
the proteins, also contains a large amount of cerebrospinal
ﬂuid exhibiting a lower resistivity than tissue regions popu-
lated by cells (Béduer et al 2014). As a consequence, the
plaques and the surrounding tissue regions where cells are
missing have a lower resistivity than the healthy tissue. These
regions of low resistivity are distributed over the hippo-
campus and form a ‘percolating system’, as schematized by
Figure 3. (a), (c) Microscope image examples of measurement areas analysed to get the percentage of Aβ-plaques. (b), (d)–(f) Corresponding
resistivity proﬁles plotted with percentage of area occupied by Aβ-plaques. (a), (b) 18-months-old WT mice. (c)–(f) 18-months-old AD mice.
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the current lines of ﬁgure 4(d), such as shown by Seoane et al
(2005). This ‘percolating network’ results in a low resistivity
for the complete tissue region affected by Aβ plaques. In
contrast, in the case of wild-type and young APPPS1 trans-
genic mice, the cell density is homogeneous over the whole
tissue due to the absence of Aβ plaques. This results in the
absence of a percolating system of low resistivity regions. As
a consequence, the measured resistivity values are sig-
niﬁcantly higher in both WT mice as well as young APPPS1
transgenic mice.
4. Conclusion
Altogether, the data presented in this study demonstrate that
in situ resistivity measurement with implanted microelectrode
array is a good method to detect the presence of cerebral Aβ
load ex vivo and monitor the effects of aging in the AD
APPPS1 mice model. This method does not require prior Aβ
staining, precluding the risk of variations in tissue uptake of
dyes or tracers, and consequently ensuring reproducible data
collection. Furthermore, the ﬂexible minimally invasive probe
allows to measure Aβ load in deep brain structures such as the
hippocampus that is not possible using other label free tech-
niques. To the best of our knowledge, such measurements
have never been reported elsewhere. We anticipate that the
use of this technique will help to improve the diagnosis and
monitoring of Aβ loads in vivo after having ﬁrst evaluated the
long-term integration of the probe inside the brain tissues.
This technique will further enable the continuously monitor-
ing of Aβ plaque progression avoiding thus the use of
extensive numbers of animals for time point studies and also
giving new information about unravelled dynamic phenom-
ena in the disease progression. As such, it can be used to
evaluate the efﬁciency of Aβ-targeting therapeutic strategies.
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Figure 4. Analysis of cells and Aβ plaque-distribution in the hippocampus of aged WT and AD mice. For each condition, quantitative data
result from the analysis of three independent areas. Pictures of the hippocampus area were divided into squares of 100 × 100 μm in which the
number of cells was counted. (a) Distribution of cells in the hippocampus of aged WT mice. (b) Distribution of cells in the hippocampus of
aged AD mice. (c) Aβ plaque load related to the number of cells. (d) Schematic representation of the passive electrical behaviour of the
hippocampus of WT (left) and AD (right) mice.
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 Millimeter to centimeter-sized injectable neural scaffolds based on macropo-
rous cryogels are presented. The polymer-scaffolds are made from alginate 
and carboxymethyl-cellulose by a novel simple one-pot cryosynthesis. They 
allow surgical sterility by means of autoclaving, and present native laminin as 
an attachment motive for neural adhesion and neurite development. They are 
designed to protect an extended, living neuronal network during compression 
to a small fraction of the original volume in order to enable minimally inva-
sive delivery. The scaffolds behave as a mechanical meta-material: they are 
soft at the macroscopic scale, enabling injection through narrow-bore tubing 
and potentially good cellular scaffold integration in soft target tissues such 
as the brain. At the same time, the scaffold material has a high local Young 
modulus, allowing protection of the neuronal network during injection. Based 
on macroscopic and nanomechanical characterization, the generic geometri-
cal and mechanical design rules are presented, enabling macroporous cellular 
scaffold injectability. 
procedures involved in implanting com-
plex and large solid grafts into the brain 
are very invasive and can easily lead to 
further tissue damage rather than the 
desired reconstruction outcome. [ 4 ] A 
number of minimally invasive delivery 
methods have been proposed, allowing to 
apply in situ gelling formulations, micro-
particulate scaffold suspensions, partially 
dissociated tissue, or neural stem cell 
suspensions through narrow-bore nee-
dles. [ 5–15 ] Unfortunately, without the guid-
ance of a large-scale organized scaffold, 
the cells typically build chaotic structures 
rather than repairing the native tissue 
architecture as desired. [ 14 ] As a result, the 
associated functional recovery is never 
complete and data from successful human 
clinical studies are extremely scarce. [ 15 ] 
We propose here to address this current 
major bottleneck of neural tissue engi-
neering by the use of a smart cellular scaffold system, which 
is highly and reversibly compressible, allowing for minimally 
invasive implantation of large, potentially preorganized con-
structs. To achieve this goal, several requirements must be met: 
The scaffold material must be highly compressible, such that 
mL-scale volumes can be delivered through narrow-bore tubing 
or needles, yet it should recover its original shape, volume and 
organization after the injection process. It should protect dif-
ferentiated neurons with their extended neurites during the 
compression associated with the delivery process, but neverthe-
less behave as a globally soft material to minimize glial scarring 
reactions in the brain. [ 16 ] For the long-term culture necessary 
to develop differentiated neuronal networks, and in light of 
potential clinical translation, the scaffolds need to be reliably 
sterilized, preferentially by autoclaving. Last but not least, it is 
desirable to be able to provide native extracellular matrix (ECM) 
proteins to guide cell adhesion and differentiation. Macropo-
rous scaffolds with shape memory amenable to injection 
through narrow-bore tubing can be fabricated by different tech-
niques, such as emulsion polymerization, lyophilization, and 
cryogelation. [ 17–19 ] We base our scaffolds on the process of cryo-
gelation, involving polymerization of a hydrogel precursor at 
subzero temperature, since this has been observed to produce 
particularly robust gels, and since the possibility of neuronal 
tissue engineering with cryogels has been reported. [ 19–21 ] We 
provide a novel cryogel fabrication paradigm, consisting of a 
 1.  Introduction 
 It is a clinical observation that the adult human brain typically 
fails to repair large-scale tissue damage. [ 1 ] This contrasts with 
the observation that neurons are continuously generated in 
the subventricular zone and dentate gyrus, [ 2,3 ] and it is indeed 
the hope and aim of cell-based therapies to extend the brain’s 
regeneration capacity to large-scale lesions. A major limitation 
on the path to successful neural tissue engineering and deep 
brain transplantation is the development of minimally inva-
sive surgical techniques and scaffolds. Indeed, the surgical 
Adv. Healthcare Mater. 2015, 4, 301–312
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simple one-pot carbodiimide-based cryosynthesis, and a coating 
method for native cell-adhesive proteins applicable after auto-
clave sterilization of the scaffolds. The newly developed protocol 
is the ﬁ rst to simultaneously address the requirement for auto-
clave sterilization, native ECM protein presentation, and scaf-
fold injectability; at the same time, it avoids tedious precursor 
synthesis. It provides mL-scale scaffolds that can be injected 
through 1 mm needles while indeed protecting a live-extended 
neural network at cell densities approaching the one of native 
cortical gray matter. We also investigate the precise mechan-
ical and geometrical properties providing for injectability and 
cell protection, by means of a novel atomic force microscopy 
(AFM) sample preparation technique and mechanical testing of 
the scaffolds. The shape-memory properties, ﬁ nally, will allow 
adapting exactly the scaffold shape and volume, as well as cell 
density and neural growth to the tissue to be reconstructed, 
before in vivo injection. The system is therefore an ideal candi-
date for personalized tissue engineering. 
 2.  Results 
 To prepare macroporous scaffolds suitable for 3D cell culture, 
we used a cryogelation process, which consists in hydrogel 
polymerization at subzero temperatures, using ice crystal 
formation to deﬁ ne the pore space. Hydrogels presented in 
this work consisted in sodium alginate and carboxymethyl-
cellulose (CMC), selected for their known biocompatibility and 
potentially favorable effects on neurons in culture. [ 22–25 ] We ini-
tiate the polymerization via carbodiimide activation of the car-
boxylic acid residues on the carbohydrate moieties of the gel 
prepolymers, followed by amide bond formation with adipic 
dihydrazide, which results in the covalent crosslinking of the 
gels (details about the process are available in Supporting Infor-
mation 1). Carrying out this process at subzero temperature 
allows creating macroporous hydrogels, referred to as cryogels, 
characterized by large interconnected pores, as schematized in 
 Figure  1 A. These scaffolds are sterilized by autoclave, coated 
with appropriate cell-adhesive molecules (poly- L -ornithine, PLO, 
and laminin), and ﬁ nally seeded with neuronal cells. The cell-
laden cryogels can be partially dehydrated, reducing the scaffold 
size, and allowing for injection of the cellular scaffold through a 
syringe needle, as shown in Figure  1 A. After injection, cellular 
scaffolds retrieve their initial size and shape, by uptake of liquid 
injected along with the cryogel. Cell integrity and morphology 
are preserved throughout the injection process. Figure  1 B pre-
sents scanning electron microscope (SEM) images showing 
the microscopic architecture of the cryogel scaffolds, made 
either from alginate or CMC. The cryogelation process resulted 
in highly porous structures for both polymers. The pore 
Adv. Healthcare Mater. 2015, 4, 301–312
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 Figure 1.  Structure, neuronal cell adhesion, and injection principle for macroporous alginate and carboxymethyl-cellulose (CMC) cryogels. A) Scaffold-
protected injection of adherent cells: The cells are seeded on a macroporous cryogel scaffold coated with suitable adhesion motifs (poly-L-ornithine 
and laminin), and allowed to adhere and spread. The scaffold is then partially dehydrated, losing up to 90% of its volume without cell damage, and can 
be passed through an injection device such as a syringe before swelling back to its original volume. Cell integrity is protected throughout the process 
due to the particular mechanical and structural properties of the cryogels. B) Structure of alginate (3%) and CMC (1%) cryogels by scanning electron 
microscopy. C,D) Confocal micrographs of the human neuronal cell line SHSY-5Y (Figure  1 C) and primary mouse cortical neurons (Figure  1 D) on 
alginate and CMC cryogels. E) Closer view of a mouse primary neuron culture on a cryogel, showing the extensive neurite network visible on areas not 
covered by the cell bodies. For Figure  1 C–E, the nuclei are blue (DAPI), the gel is labeled green (aminoﬂ uorescein, incorporated covalently), and the 
actin cytoskeleton is labeled red (rhodamine-phalloidin); all gels were coated with PLO/laminin.
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dimensions are comprised between 20 and 500 μm and depend 
on the exact cryogelation process parameters (details about pore 
volumes are given below). Cryogel formation using alginate as 
a starting material allowed obtaining 3D scaffolds with rela-
tively thin walls (ca. 1–5 μm). They were somewhat thicker in 
the case of CMC-scaffolds (Figure  1 B). After coating with PLO 
and laminin, the 3D scaffolds were seeded with neuronal cells 
(human neuroblastoma neuronal cell line SH-SY5Y or primary 
cortical mouse neurons). Seeding was carried out by ﬁ rst par-
tially dehydrating cryogels (by pressing them against a sterile 
gauze) and rehydrating them with the cellular suspension. At 
the initial time of 3D plating, the dissociated neural cells had 
a spherical morphology, without visible neurites. Over time in 
culture, there was considerable process outgrowth resulting 
in the formation of 3D, interconnected neural networks. After 
7 d of culture, cellular scaffolds were ﬁ xed and observed by con-
focal microscopy. Figure 1C,D present 3D confocal images of 
the resulting cellular scaffolds for the human neural cell line 
SH-SY5Y (1C) and primary cortical mouse neurons (1D). The 
analysis demonstrates a complex and dense cellular 3D archi-
tecture for both the human cell line and the mouse primary 
cortical neurons, for both alginate and CMC-based cryogels, 
with an approximately homogeneous cell density throughout 
the 1 mm thick scaffolds. In addition, the mouse primary neu-
rons also presented a widespread and dense neural network, as 
exempliﬁ ed in the zoomed view given in Figure  1 E. Thus, the 
3D cryogels developed here allow to obtain high cell density 3D 
cellular scaffolds on the millimeter size scale when coated with 
appropriate cell-adhesive motives. The process is versatile with 
respect to the choice of hydrogel and cell types. 
 In order to further characterize the interaction between cells 
and cryogel scaffolds, in particular regarding cell adherence, 
spreading and development, we further investigated the role 
of scaffold coating, mean pore volume, and polymer concen-
tration. To do so, we quantiﬁ ed cell densities obtained on the 
scaffolds after 7 d of culture of the human neuronal cell line 
SH-SY5Y on different cryogel and control substrates, distin-
guishing “round cells” exhibiting rounded cell bodies without 
visible neurites, from “spread cells” exhibiting at least one 
sprouting neurite. 
 Figure  2 A shows how different combinations PLO, a syn-
thetic positively charged polyelectrolyte, and laminin, an ECM 
protein known to favor neurite development, affect the cell 
density and morphology on the cryogel scaffolds. Applying 
either PLO or laminin alone provides a statistically signiﬁ cant 
increase in overall cell adhesion (the total cell densities were 4.5 
± 0.9 × 10 6 cells mL −1 for PLO coating, 3.7 ± 0.4 × 10 6 cells mL −1 
for laminin coating versus 1.5 ± 0.3 × 10 6 cells mL −1 for the 
control condition consisting in pristine alginate cryogels,  P < 
0.001 vs control in both cases), but the majority of the cells 
remained rounded. Only the combination of PLO followed 
by laminin allowed to obtain a high density of spread cells 
43 ± 6 × 10 6 cells mL −1 ( P < 0.001 vs control) while keeping the 
round cell density low (4.6 ± 6 × 10 6 cells mL −1 , which is compa-
rable to the round densities found for other coating conditions). 
Hence in the remainder of this report, the speciﬁ c coating com-
bination consisting in PLO, followed by laminin, was used for 
all cell culture experiments. Next, we investigated the role of 
scaffold mean pore volume on cell density and morphology. For 
this, we employed scaffolds with a mean pore volume ranging 
Adv. Healthcare Mater. 2015, 4, 301–312
www.advhealthmat.de
www.MaterialsViews.com
 Figure 2.  Parameters inﬂ uencing cell adhesion and growth for the human neuronal cell line SH-SY5Y on the cryogels and 2D controls. A) The com-
bination of PLO and laminin coating efﬁ ciently promotes cell attachment and spreading. B) Relation between pore volume and cell adhesion; the 
different pore volumes were obtained by varying the cryogelation substrate. C) Cell adhesion and spreading as a function of the original alginate or 
CMC concentration prior to cryogelation. D) Growth kinetics. With the exception of the speciﬁ c conditions in Figure  2 A, all cryogels as well as the 2D 
control substrates (Figure  2 D) were coated with PLO/Laminin.
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from 0.2 to 0.9 nL, obtained by modifying cryogel gelatin speed 
and polymer types . Figure  2 B shows that the total cell density 
decreases signiﬁ cantly for pore volumes lower than 0.6 nL, with 
a concomitant relative increase in the ratio of round to spread 
cells. This indicates that the cryogel synthesis conditions should 
be chosen to achieve a mean pore volume of 0.6 nL or above. 
Figure  2 C shows the effect of the polymer concentration in the 
initial reaction mixture on the cell density and morphology. We 
observe a slight decrease in cell density for the lowest polymer 
concentrations, most likely related to the difﬁ culty encountered 
in manipulating the resulting very soft gels. 
 Next, we studied the effects of the cryogel scaffolds on cell 
duplication of the human neuronal cell line SH-SY5Y. Since 
both the scaffold material and the speciﬁ c 3D conﬁ guration 
could potentially affect cell growth, we compared the growth 
curves obtained for 3D alginate cryogel scaffolds both to a con-
trol consisting of a plain coverslip, and a 2D alginate hydrogel 
(all PLO/Laminin coated). The results are summarized in 
Figure  2 D. The sustainable cell density is higher on 3D scaf-
folds than on the 2D surfaces. The effect can clearly be ascribed 
to the 3D structure, since the mere presence of a 2D alginate 
substrate does not inﬂ uence the sustainable cell density com-
pared to the plain glass control. The growth rates on the other 
hand are comparable forall three conﬁ gurations. This indicates 
that although the 3D cryogel conﬁ guration permits to achieve 
higher ﬁ nal cell densities, it has no inﬂ uence on the replication 
rate per se. We obtained similar results for 2D and 3D CMC 
gels (data not shown). 
 The purpose of the cryogel scaffolds developed here is spe-
ciﬁ cally to enable injection of preformed neural engineered 
tissue through narrow-bore tubing such as syringe needles. It 
is therefore of primary interest to analyze survival once cellular 
constructs have been injected through a syringe needle. For 
doing this, we quantiﬁ ed cell survival using the trypan blue test 
at 7 d post-seeding, for both the human neuronal cell line SH-
SY5Y and mouse primary cortical neurons. We then performed 
syringe injections through a 16G needle (1 mm inner diam-
eter), and quantiﬁ ed the cell viability again at 24 h and 48 h 
post-injection (the tests are performed on different samples 
to avoid artifacts due to trypan blue toxicity). Survival results 
obtained for human neural cell line and for primary mouse 
neurons are, respectively, presented in  Figure  3 A,B. Control 
conditions consisted in 2D surfaces made of alginate and CMC 
and also in plain glass coverslips. Viabilities for control condi-
tions were quantiﬁ ed at the same time points with respect to 
the beginning of the culture as for the cryogel conditions but 
without the injection step. 
 Figure  3 A indicates that cell survival scores did not decrease 
signiﬁ cantly following the cellular scaffold injection step for 
the SH-SY5Y cell line ( P = 0.86 for alginate scaffolds 48 h after 
injection,  P = 0.92 for CMC scaffolds 48 h after injection). Like-
wise, Figure  3 B indicates that the injection step does not affect 
the viability of the mouse primary neurons on the 3D scaffolds, 
neither for the alginate nor for the CMC cryogels ( P = 0.90 for 
alginate scaffolds 48 h after injection,  P = 0.86 for CMC scaf-
folds 48 h after injection). This means that the cryogel scaffolds 
are able to protect not only the human cell line SH-SY5Y during 
the injection step, but also the more delicate primary neurons 
with their extended neurites. Figure  3 A also indicates that the 
SH-SY5Y cells show very high and comparable survival rates 
regardless of the substrate (Alginate and CMC 3D scaffolds, 2D 
polymer substrates and glass coverslip control). In contrast, for 
the mouse primary cortical neurons, survival is signiﬁ cantly 
better on the 3D scaffolds than on the 2D controls (for example, 
cell survival on the 3D alginate scaffolds was 82 ± 8% compared 
to only 57 ± 7% on 2D alginate surfaces,  P < 0.001). Indeed, 
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 Figure 3.  Cell survival and integrity during scaffold injection. A) Quantiﬁ cation of cell viability for the neuronal cell line SH-SY5Y before, 24 and 48 h 
after injection through a syringe. B) Quantiﬁ cation of cell viability for mouse primary neurons before, 24 and 48 h after injection through a syringe. 
The viabilities for the 2D controls in Figure  3 A,B are taken at the same time points, but without the injection procedure. C) Representative images of 
mouse primary neurons on a cryogel before and 48 h after injection. Actin is labeled by means of rhodamine-phalloidin. D) Average neurite length 
extracted from images before and 48 h after injection. The cryogels used are synthesized in glass molds; both the cryogels and the 2D controls were 
PLO/Laminin coated.
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the cell density obtained on 2D surfaces correspond to a high 
degree of conﬂ uence, which is apparently not very favorable for 
the survival of these primary cells under our culture conditions. 
In the 3D conﬁ guration, the resulting volumetric density is 
reduced, potentially explaining the better survival scores. 
 To assess the long-term outcome of CMC and alginate 3D 
scaffolds seeded with primary neural cells (40 × 10 6 cells mL −1 ) 
were also maintained in culture during 21 d, with half-media 
change twice weekly from 7 d on. The survival scores on 
the cryogels remained comparable to the ones obtained for the 
7-d culture: 87 ± 4% for alginate cryogels and 84 ± 6% for CMC 
cryogels. 
 Beyond cell survival, we also require the scaffolds to protect 
cell morphology during the scaffold injection step. Indeed, pri-
mary neurons develop dense neurite networks on the scaffolds, 
typically connecting clusters of neurons together; breakage of 
these networks must be avoided. Figure  3 C presents z-projec-
tions of confocal images (observation thickness: 50 μm), before 
and 48 h post-injection, indicating qualitatively that no major 
damage to the neural network occurs. To quantitatively assess 
the neurite network before and 48 h after scaffold injection 
through a 1-mm syringe needle, we measured neurite mean 
lengths before and after the injection step for both type of cel-
lular scaffolds (primary neurons grown on alginate and CMC 
cryogels) (Figure  3 D). We observe that the injection step has 
no signiﬁ cant inﬂ uence on neurite length ( P = 0.94 for alginate 
scaffolds,  P = 0.95 for CMC scaffolds). Furthermore, neurite 
lengths on 3D cryogels are comparable to those measured for 
neurons cultured on glass coverslips (control condition). Like-
wise, we measured the neurite length at 24 h and 7 d post-injec-
tion, and also found no signiﬁ cant difference to the respective 
controls. The successful protection of both cell viability and dif-
ferentiated morphology despite the extensive volumetric com-
pression of the scaffolds during syringe injection is a key result 
of the present study, underpinning the great potential of the 3D 
cellular injectable cryogels for neural tissue engineering and 
transplantation strategies. 
 In order to explain the observed neural protection during 
the compression associated with syringe injection, we charac-
terized the mechanical properties of the cryogels both experi-
mentally and theoretically. The characteristic highly porous 
structure of the cryogels (Figure  1 B) suggests that they should 
behave as mechanical meta-materials, [ 26,27 ] with potentially very 
large differences between a locally stiff, cell-protective environ-
ment, and a low apparent macroscopic bulk stiffness, enabling 
extensive scaffold compression and ultimately syringe injec-
tion. Indeed, adapting a model from foam mechanics, [ 26,28 ] we 
obtain a simple relation between the apparent macroscopic 
stiffness, described by the bulk modulus B ulk and the local 
stiffness of the cryogel wall material, described by the Young 
modulus  E wall . The development is given in Supporting Infor-
mation 4, and yields (Equation S21, Supporting Information):
 E E F2 * * *bulk wall
3
structΦ=   (1) 
 where  Φ is the volume fraction occupied by the scaffold walls, 
and  F struct is a dimension-less structural factor, on the order of 
unity, and depending on the polymer-type. Equation  1 outlines 
the crucial importance of the wall volume fraction: with a wall 
volume fraction  Φ in the range of 1%–10%, one may expect the 
cryogels to be 3 to 6 orders of magnitude softer globally than 
locally. 
 Atomic force microscopy has recently been identiﬁ ed as a 
useful tool to evaluate the local stiffness of cryogels. [ 27 ] Using 
this technique in conjunction with a speciﬁ cally developed 
sample preparation method, we evaluated the wall Young 
modulus  E wall in an aqueous environment on covalently immo-
bilized cryogel fragments on a glass coverslide (experimental 
details are given in Supporting Information 2).  Figure  4 A 
shows the topography of the immobilized cryogel fragments, 
whereas Figure  4 B,C show close-up views of a ﬁ ber-shaped 
fragment along with the local Young modulus. The cryogel 
fragments appear as elevated areas on the topography image 
(Figure 4A,B), and as soft areas on the comparatively hard glass 
substrate in the Young modulus image (Figure  4 C). Figure  4 D 
shows the average Young modulus of the cryogel fragments as 
a function of the polymer type (alginate or CMC) and initial 
concentration used to synthesize the cryogels. While we ﬁ nd 
the alginate cryogels to be locally stiffer than the CMC cryogels 
( E wall = 117 vs 4.2 MPa,  Table  1 ), we also ﬁ nd the local stiffness 
to be independent of the initial polymer concentration ( P = 0.52 
for the alginate gels,  P = 0.39 for the CMC gels). 
 Next, we determined the wall volume fraction  Φ by weighing 
the cryogels in the fully hydrated state, and after forceful dehy-
dration. The result is shown in Figure  4 E. To a ﬁ rst approxi-
mation, we can consider the wall volume fraction to be pro-
portional to the initial polymer concentration. This conﬁ rms 
that during the cryosynthesis, an approximately constant ﬁ nal 
polymer concentration is reached within the cryogel wall, [ 32 ] 
explaining the approximately constant Young modulus for each 
cryogel type (alginate and CMC, Figure  4 D). Further, from the 
slope of the regression lines in Figure  4 E, we can estimate the 
ﬁ nal polymer concentration in the scaffold walls for each of 
the two cryogel types. The results are given in Table  1 . They 
indicate that while very high local polymer concentrations 
are reached indeed, the walls should still be considered to be 
hydrogels, since they contain more than 70% water by weight. 
 Finally, we examined apparent bulk modulus of the cryogels 
by means of compression of macroscopic samples (disks of 
4 mm diameter and 1 mm height) with a mechanical testing 
device (details are given in Supporting Information 3). The 
resultant macroscopic Young moduli  E bulk were found to be in 
the kPa range (Figure  4 F) rather than the MPa range observed 
for the local Young moduli. Furthermore, Equation  1 quantita-
tively links the bulk moduli to the local Young moduli (linear 
ﬁ t in Figure  4 F), and also allows to determine the structural 
strength factor  F struct for each of the two polymers (Table  1 ). It is 
noteworthy that the CMC cryogels, despite a lower local Young 
modulus, are macroscopically stiffer at a given polymer con-
centration than the corresponding alginate cryogels. This is in 
part due to a higher volume fraction, but mostly due to a higher 
structural constant  F struct . Finally, Equation  1 also quantitatively 
explains mechanical data on cryogels presented by others, pre-
viously explained only qualitatively (detailed discussion in Sup-
porting Information 4). [ 27 ] 
 Given the strikingly different local and bulk elastic properties 
of the cryogel scaffolds, we next investigated how the presence 
of relatively hard cryogel walls can protect the soft cells during 
Adv. Healthcare Mater. 2015, 4, 301–312
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the compression process. For this, we used ﬁ nite element mod-
eling (FEM, carried out in the COMSOL software suite) of a 
simpliﬁ ed cryogel structure, comprising a simpliﬁ ed pair of 
adherent neurons with neurites ( Figure  5 A). As a control, we 
also simulate the same cell geometry, but embedded in a homo-
geneous gel without pores (Figure  5 D). We chose the Young 
moduli of the different elements to reﬂ ect approximately the 
situation in a 1% CMC cryogel. According to Table  1 , the local 
Young modulus should be 4.2 MPa; the wall volume fraction 
is about 4.3% (Figure  4 E), so together with a structural factor 
of 0.92 (Table  1 ), one would expect an apparent global Young 
modulus on the order of 0.6 kPa for the cryogel (Equation  1 ). 
Hence, we used  E = 0.6 kPa for the homogeneous control gel. 
The cells, including the neurites, are modeled with a Young 
modulus of 0.2 kPa, taken from literature. [ 33 ] 
 For the cryogel structure and the homogeneous control, 
we attempted to simulate the deformation and corresponding 
mechanical stresses using COMSOL for a uniaxial compres-
sion of 25% and 75%. We report the resulting von Mises stress, 
since this measure has been shown to be a good indicator of 
the probability of material failure under various load condi-
tions. The cryogel structure easily admits 75% compression and 
beyond, the resulting von Mises stress distribution is shown in 
Figure  5 B,C, respectively. On the contrary, the simulations for 
the homogeneous gel do not converge beyond 30% compres-
sion, enabling us to estimate the von Mises stress only for 
the 25% compression case (Figure  5 E). The non-convergence 
for larger compression agrees with what would be observed if 
these experiments were carried out physically: while a cryogel 
would survive a 75% compression and beyond while main-
taining mechanical integrity, a bulk gel would burst if com-
pressed beyond some 20–30%. [ 19 ] 
 The distribution of the von Mises stress shows that in the 
case of the cryogel, the hydrogel absorbs almost all the elastic 
energy (Figure  5 B,C), whereas in the bulk gel, the elastic 
energy transmitted to the gel respectively the cells is similar 
(Figure  5 E). As a result, the cells are exposed to higher stresses 
in the bulk gel at similar compression ( Table  2 ). 
 Taken together, these results indicate that accumulation of 
elastic energy by the cryogel structure, rather than transmis-
sion to the cells, offers the mechanical protection enabling high 
compression fractions while preserving neurons and extended 
neurites during the injection procedure. The high pore fraction, 
the small wall thickness, and the locally high Young modulus 
all contribute to this phenomenon (see Supporting Information 
5 and discussion part for details). 
 In order to facilitate the use of the injectable cryogels scaf-
folds in different settings, we further investigated how different 
Adv. Healthcare Mater. 2015, 4, 301–312
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 Table 1 Estimated intrinsic local and apparent bulk mechanical parame-
ters of the alginate and CMC cryogels. The errors for the intrinsic Young 
modulus are the standard deviations of the means; the errors for the 
polymer concentration within the cryogel ﬁ bers are obtained from the 
linear regression (Figure  4 E); the error on the structural factor results 
from the associated linear regression (Figure  4 F) and propagated errors 
from the intrinsic Young modulus measurement as well as the estima-
tion of the polymer concentration within the cryogel ﬁ bers. 
Polymer Intrinsic Young 
modulus [MPa] 
(Figure  4 D)
Polymer concentration within 
the cryogel ﬁ bers [% w/w] 
(Figure  4 E)
Structural factor 
 F struct (Figure  4 F)
Alginate 117 ± 14 27.2 ± 1.9 0.013 ± 0.004
CMC 4.2 ± 1.4 19.4 ±1.5 0.92 ± 0.52
 Figure 4.  Microscopic and macroscopic mechanical properties of cryogels. A) Height image of CMC cryogel ﬁ bers immobilized on a glass substrate 
(1% initial CMC concentration) by atomic force microscopy (AFM). B) AFM Height image of a single alginate cryogel ﬁ ber (from a 1.5% initial alginate 
cryogel). C) AFM Young modulus map corresponding to Figure  4 B, as determined by the quantitativenanomechanicalmapping in PeakForce Mode 
(PeakForce QNM). D) Intrinsic Young moduli of cryogel ﬁ bers from alginate and CMC cryogels with different initial polymer concentration, measured 
by AFM. E) Fraction of the volume occupied by the cryogel walls as a function of the initial polymer concentration. F) Apparent bulk Young moduli 
as a function of initial alginate, respectively, CMC concentration, determined by mechanical testing of macroscopic cryogel samples, along with best 
ﬁ t theoretical lines relating intrinsic modulus, wall fraction and apparent bulk modulus. The range of Young moduli for brain tissue is taken from 
literature. [ 29–31 ] 
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synthesis parameters affect the ﬁ nal cryogel scaffold structure 
and performance. Results are presented in  Figure  6 . First, we 
compared three freezing strategies involving different sub-
strates (Figure  6 A): A ﬁ rst strategy consisted in pipetting the 
prepolymer solution onto a precooled Teﬂ on plate (row “Teﬂ on” 
in Figure  6 A); a second strategy consisted in sandwiching the 
prepolymer solution between two glass cover slides by means 
of 1 mm high plastic spacers, and then placing the assembly 
on a preooled aluminum plate (row “Glass” in Figure  6 A); the 
third strategy consisted in pipetting the prepolymer solution 
directly onto the precooked aluminum plate (row “aluminum” 
in Figure  6 A). In each case, we assessed the linear pore dimen-
sions and calculated the mean pore volume. We also calculated 
an anisotropy index, corresponding to the largest pore diam-
eter divided by the smallest one on 2D sections. The smallest 
and most isotropic pores are observed for the “aluminum” sce-
nario. This is expected, since aluminum has by far the highest 
thermal conductivity of the three substrates used, [ 34,35 ] and since 
it is well known that cryogels with smaller pores are generally 
obtained for the highest freezing rates due to the increased ice 
crystal nucleation rate. [ 36 ] Figure  6 B summarizes the maximum 
volumes that we succeeded to inject through a 16G syringe 
needle without breakage, for gels of different composition (algi-
nate or CMC, with and without PLO/Laminin coating) and pore 
volume. The maximum cryogel scaffold volume successfully 
injected was 3 mL, obtained with a coated CMC-cryogel, exhib-
iting the smallest pore size. Larger volumes have not been 
investigated. Contrary to Figure  6 B where we injected cryogel 
scaffolds a single time, for Figure  6 C, we injected a standard 
spherical cryogel scaffold of 100 μL through a 16G syringe 
needle (1 mm inner diameter), and quantiﬁ ed the number of 
times we could repeat the process before the cryogel would 
break into pieces. Since in practice, one would inject a cryogel 
only a single time, this gives a safety margin in terms of gel 
integrity. We ﬁ nd a relatively narrow optimum of prepolymer 
concentration for each polymer: 0.75% prepolymer concentra-
tion for the CMC cryogels and 2% prepolymer concentration 
for the alginate cryogels. In addition, we show that the PLO/
Laminin coating reinforces the gel and makes it more robust 
against breakage. Figure  6 D ﬁ nally shows pore interconnec-
tivity as assessed by the wicking test; [ 19 ] for CMC cryogels, we 
observe a drop in pore interconnectivity beyond 1% prepolymer 
concentration, while the alginate cryogels show high intercon-
nectivity throughout the entire concentration range. 
 3.  Discussion 
 In neural tissue engineering, the use of scaffolds serving as 
organized cell carriers is considered necessary due to the low 
cell survival and engraftment efﬁ ciency observed for cells trans-
planted in suspension. [ 37,38 ] The surgical procedures needed to 
place scaffolds of clinically relevant size are however associated 
with a high risk of further tissue damage. [ 6 ] To the best of our 
knowledge, there is still no solution able to simultaneously 
address large-size tissue reconstruction, potentially deep inside 
the brain, and to provide preorganized neural tissue constructs. 
Here, we present a novel type of highly compressible cryogel 
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 Figure 5.  Finite element simulation. A) simpliﬁ ed structural model of the cryogel with a pair of adherent cells. B) Finite element simulation of a 25% 
compression of the cryogel. The deformation is imposed and corresponds to 25% of the height of the cryogel structure; the colors code for the von 
Mises stress, a known overall measure for material loading. C) Finite element simulation of a 75% compression of the cryogel structure. D) simpliﬁ ed 
structural model of a corresponding bulk gel with identical cell geometry and a bulk Young modulus corresponding to the apparent bulk modulus of 
the cryogel. E) Finite element simulation of a 25% compression of the bulk gel with cells, with imposed deformation. The colors again code for the von 
Mises stress, although it should be noted that the scales are different for Figure  5 E as compared to Figure  5 B,C. F) For 75% compression, the FEM 
simulation for the homogeneous control gel does not converge.
 Table 2.  Maximum von Mises stress sustained by the cells. 
25% Compression 75% Compression
Cryogel 15 Pa 46 Pa
Bulk gel 222 Pa Not applicable (gel breaks)
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scaffold, speciﬁ cally adapted to minimally invasive delivery of 
differentiated neuronal networks by transient compression to 
about 10% of the initial volume. Based on a novel one-pot car-
bodiimide cryogel synthesis, the scaffolds advantageously com-
bine desirable properties: They allow attachment, spreading 
and neurite formation by primary neurons due to the presen-
tation of native laminin. [ 21 ] Their highly porous nature allows 
injection through narrow-bore tubing. [ 18,19 ] The scaffolds also 
present the advantage of reliable sterilization, of prime impor-
tance in light of potential clinical translation: By performing the 
deposition of the cell-adhesive coating only after cryogel syn-
thesis, we are able to avoid microbiologically unsafe washing 
with ethanol solutions, which had to be employed with cryogel 
scaffolds having laminin or RGD peptides incorporated already 
during the synthesis step. [ 19,21,39 ] Further, the scaffolds extend 
the domain of volumes injectable through a 16-Gauge (1 mm) 
needle into the mL-range. Taken together, these properties 
enable the development of an extended neuronal network made 
from primary cells that can subsequently be highly compressed 
for minimally invasive delivery into the central nervous system. 
It is, to the best of our knowledge, the ﬁ rst demonstration of a 
compressible living neural network. 
 We ﬁ nd the success of cell seeding, attachment, and spreading 
on the cryogel scaffolds to be critically dependent on the prior 
coating of the cryogels with suitable cell adhesive motives (here, 
the combination of PLO and laminate, Figure  2 A), conﬁ rming 
ﬁ ndings for neuronal culture on other substrates. [ 40 ] We also 
ﬁ nd a minimal pore volume of 0.6 nL to be required for optimal 
adhesion and spreading (Figure  2 B), corresponding to a mean 
pore diameter of about 100 μm, in line with results reported for 
neural tissue engineering. [ 21 ] Additional important architectural 
parameters are the total pore fraction (Figure  4 E: 1 – φ = 89% for 
the 3% alginate cryogels, and >90% for all other compositions, 
in accordance with literature recommendations) [ 41 ] and also 
the fraction of the pore space interconnected [ 42 ] to the outside 
world (>80% for all scaffolds except the CMC 1.25% and 1.5%, 
Figure  6 D) since only the accessible pores will be colonized. 
Provided suitable cell-adhesive coating, pore size, and inter-
connectivity, the cryogels support live cell densities up to 
50 × 10 6 cells mL −1 , for both the human neuronal cell line SH-
SY5Y (Figure  2 ) and mouse primary neurons (data not shown), 
for culture periods beyond 1 week. These cell densities approach 
the ones found in the mouse cortex (92 × 10 6 cells mL −1 ), and 
exceed the live densities achievable with homogeneous gels by 
about one order of magnitude. [ 43,44 ] The 3D structure, with its 
high available surface area and high pore space for nutrient dif-
fusion, rather than the speciﬁ c material, is responsible for sus-
taining high viability at these high cell densities (Figure  3 B). 
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 Figure 6.  Control and optimization of the structural parameters and injectability of the cryogels. A) Cryogelation on different substrates affects pore 
size and pore anisotropy. B) Maximum injectable volumes (spherical gel geometry, injection through a 16G needle). C) Injectability as a function of the 
initial polymer concentration and the coating. Cryogelation performed on glass substrates. D) Pore interconnectivity as a function of the initial polymer 
concentration. Cryogelation performed on glass substrates. The errorbars indicate standard deviations of the mean.
147
FU
LL P
A
P
ER
309wileyonlinelibrary.com© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
 Beyond attachment, the cryogel coating also provides cues for 
cell spreading (Figure  1 E), and neurite extension by the mouse 
primary neurons (Figure  1 E, Figure  3 C,D). At the same time, 
neural cells also need to communicate with their peers. [ 45–47 ] In 
the cryogel scaffolds, we ﬁ nd that the neurites largely follow the 
gel walls, but are also able to bridge small gaps (Figure  1 E). In 
addition, the somata of individual cells are found to adhere to 
the cryogel walls; but with higher cell density, organized multi-
layered structures are also formed (Figure  1 E). This suggests an 
equilibrium between strong cell–matrix interaction and cell–cell 
interaction, which is considered suitable for tissue formation. 
Indeed, if the cell–matrix interaction is too strong, the cells will 
line the scaffold surface with minimal 3D organization and 
potentially loss of cell functionality; [ 46 ] if the cell–matrix interac-
tion is too weak, the cells tend to adopt rounded morphology, 
and oftentimes undergo cell death due to lack of adhesion. [ 48 ] 
 In order to identify criteria to enable injection of the cellular 
scaffolds, we carried out bulk and nanomechanical characteri-
zation. By aligning the results obtained on the alginate and 
CMC cryogels, we are able to establish the following design 
rules for scaffold injectability (Supporting Information 5): 
minimal bulk Young modulus ( E bulk ≥ 0.1 kPa) and minimal 
microscopic Young modulus ( E wall ≥ 100 kPa) for appropriate 
manual handling, maximal wall volume fraction ( Φ < 10%) for 
limiting local strain (Equation S29, Supporting Information), 
and high pore interconnectivity for enabling ﬂ uid evacuation. 
The protection of the cells during the injection process is due to 
the concentration of the elastic energy within the cryogel mate-
rial (Figure  5 ). The nanomechanical analysis conﬁ rms the high 
local Young moduli necessary for this (Figure  4 D, Table  1 :  E wall = 
117 MPa for alginate-based cryogels, respectively, 4.2 MPa for 
CMC-based cryogels). The high local Young modulus may also 
be advantageous in terms of neurite formation, since stiffer 
substrates have been linked to the formation of both more 
numerous and more highly branched neurites. [ 49 ] 
 The macroscopic compression analysis on the other hand 
conﬁ rms the low bulk stiffness (Figure  4 F, 0.85 kPa for the 1% 
CMC vs 2.2 kPa for the 3% alginate cryogels used in the cell 
culture and live injection experiments), facilitating compres-
sion prior to injection with minimal force. In addition, the 
brain is a relatively soft organ, with elastic moduli reported in 
the 0.1–3 kPa range, depending on the region and measure-
ment technique employed. [ 29–31 ] Since it has been reported that 
mismatch between the local stiffness and implanted devices 
may be linked to a strong adverse glial reaction, [ 16 ] it may be 
necessary to match the bulk stiffness of the scaffold to the local 
brain tissue Young modulus for in vivo experiments. Given the 
strong dependence of the bulk modulus on the initial polymer 
concentration (Figure  4 F), it is straightforward to match to any 
desired Young modulus in the range reported for the brain; the 
necessary initial polymer concentration can indeed be calcu-
lated by Equation  1 . 
 Finally, we demonstrate that cryogels with neurons exhibiting 
already substantial neurite extension can be compressed and 
syringe-injected, without damaging the cells (Figure  3 ). To the 
best of our knowledge, these scaffolds are the ﬁ rst to combine 
macroscopic size and injectability through a narrow-bore con-
duit for neuronal tissue engineering applications. The results 
demonstrate that suitably designed macroporous scaffolds 
allow to protect morphologically differentiated primary cells, 
going a fundamental step beyond the demonstration of inject-
ability of cell suspensions or robust cell lines along with shape-
memory scaffolds. [ 18,19 ] Given that cell density, neurite develop-
ment and scaffold organization are preserved throughout the 
injection process, the scaffolds will allow to transfer in vivo not 
only the cells, but also their precise spatial organization. 
 4.  Conclusions 
 We present a novel neural engineering scaffold that can be 
injected through a syringe needle, while conserving cell via-
bility, morphology, and organization as well as scaffold integ-
rity, even in the presence of differentiated neurites. The system 
is an answer to a major dilemma encountered in neural tissue 
engineering for the central nervous system: scaffolds should 
be preorganized and potentially large, but at the same time 
they should be delivered in a minimally invasive fashion to 
avoid further tissue damage. The scaffolds developed here are 
both: organized at a large size scale, and nevertheless inject-
able thanks to their compressibility. They open up an avenue 
of experiments and approaches hitherto thought impossible: 
spatial localization of adhesion motives and cells could be used 
to organize the scaffold into physiologically relevant regions, 
while chemical gradients could be used to guide long range 
connections before implantation. The features obtained could 
be quality-checked before implantation, and then minimally 
invasively delivered while maintaining shape, volume, viability, 
and neural network organization. 
 5.  Experimental Section 
 Chemicals : The following chemicals were obtained from 
Sigma–Aldrich: Sodium alginate (catalog number A0682-100 G, 
molecular weight Mn = 110 kDa, Mw = 242 kDa, polydispersity 
2.2 by gel permeation chromatography), sodium CMC (419338-
100 G, 700 kDa according to the manufacturer’s datasheet),  N -(3-
dimethylaminopropyl)- N ’-ethylcarbodiimide hydrochloride EDC 
(E7750-25G), Morpholinoethanesulfonic acid MES hydrate (M2933-
100G), adipic acid dihydrazide (AAD) (A0638-25G), aminoﬂ uorescein 
(07980 Fluka-1G), NaOH (S8045–500G), ethylene-diamine-tetraacetic 
acid EDTA (EDS), phosphate buffered saline (PBS) (P4417-50TAB), 
laminin (L-2020), paraformaldehyde,(158127-500 g) Triton X-100 
(X100–100 mL), papain. Fetal bovine serum was obtained from PAA 
Laboratories, DMEM cell culture medium, penicillin streptomycin from 
GIBCO, neurobasal medium, and B27 from Invitrogen, and Glutamax 
from Life Technologies. 
 Cryogel Synthesis : Cryogels were synthesized based on established 
carbodiimide chemistry. [ 50 ] Details are given in Supporting Information 
1. Brieﬂ y, either alginate or CMC is dissolved in deionized water (DI) 
to the desired concentration, and crosslinking initiated by means 
of addition of AAD and a small excess of the carbodiimide EDC. The 
reaction mixture is rapidly placed at −20 °C in a mold, resulting in 
ice crystal formation prior to completion of gel crosslinking; if not 
speciﬁ ed otherwise, cryogels were formed on molds made from glass 
coverslides and suitable spacers (Supporting Information 1). After 24 h, 
the cryogels are thawed, washed in DI, EDTA 10 × 10 −3 M and PBS, and 
autoclaved in PBS; the space occupied by the ice crystals during the 
cryo-incubation now becomes pore space. If not speciﬁ ed otherwise, 
alginate cryogels were synthesized using the 3% composition as 
listed in Table S2 (Supporting Information 1), whereas CMC cryogels 
Adv. Healthcare Mater. 2015, 4, 301–312
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were synthesized according to the 1% composition listed in Table S3 
(Supporting Information 1). For visualization purposes, we also 
synthesized ﬂ uorescent cryogels by addition of aminoﬂ uorescein during 
the crosslinking reaction, since aminoﬂ uorescein will react with EDC-
activated carboxylic acid groups under the same conditions as AAD (for 
details, see Supporting Information 1). [ 51 ] 
 SEM : Cryogel samples were lyophilized, gold coated and imaged 
using a Zeus's Merlin SEM operated at 5 keV and secondary electron 
detection. 
 Pore Fraction and Interconnectivity : The pore fraction and 
interconnectivity can be estimated from the weight loss under different 
dehydration conditions. The interconnected pore space is assessed 
by the wicking test, that is by the relative amount of water that can be 
withdrawn from a fully hydrated cryogel by means of a paper towel. [ 19 ] 
Similarly, the total pore space can be assessed by force-full compression 
(estimated mechanical pressure on the order of 1 MPa). The wall 
volume fraction, ﬁ nally, is calculated as 1 minus the fraction occupied 
by the pore space. 
 Bulk Young Modulus : Bulk Young moduli were obtained by mechanical 
compression of cryogels with a deﬁ ned disk geometry (typically, 
4 mm diameter, 1 mm height). The measurements were performed on 
a TextureAnalyzer TA.XT plus (Stable Microsystems). Sample force–
distance curves and the ﬁ tting procedure to obtain the Young moduli are 
given in Supporting Information 2. 
 Local Young Modulus by Atomic Force Microscopy : The local Young 
modulus of the cryogel ﬁ bers was determined by AFM imaging using 
the PeakForce Quantitative Nanomechanical Mapping (QNM) mode 
(Bruker, FastScan). To enable AFM imaging and Young modulus 
quantiﬁ cation, cryogel ﬁ bers with a height ranging from 50 nm to 1 μm 
were immobilized on an otherwise ﬂ at substrate. Supporting Information 
3 provides the experimental details on the immobilization and imaging 
procedures; a comparison to Force–Volume imaging and COMSOL 
simulation of the hydrogel indentation process to evaluate the inﬂ uence 
of the underlying substrate and the tip geometry are also provided. 
 Syringe Injection : For systematic injection tests, roughly spherical 
cryogels of 100 μL (ca. 6 mm in diameter) were prepared for various 
concentrations of alginate and CMC according to the protocol given 
above and detailed in Supporting Information 1. The ﬁ nished cryogels 
were dehydrated by mechanical compression against a gauze, inserted 
into a syringe, and pushed through a syringe needle measuring 1 mm 
in inner diameter (16 Gauge). To investigate maximal injectable cryogels 
volumes, spherical cryogels of different volumes were fabricated and 
injected once through the same syringe needle. Injection was considered 
successful when the cryogels remained visually intact after the injection 
process. 
 Pore Volume and Anisotropy : Cryogels were cut into thin slices along 
two perpendicular directions while still frozen. After thawing, images 
were taken using a bright-ﬁ eld microscope (×10 objective), binarized, 
and the dimensions of at least 200 pores for each fabrication condition 
and cryogel composition were recorded using ImageJ software. The pore 
volume was estimated as the product of biggest, smallest, and mean 
pore diameter, whereas the pore anisotropy was calculated as the ratio 
between the biggest and the smallest pore dimension. 
 Cryogel Coating : Unless speciﬁ ed otherwise, autoclave-sterilized 
cryogels were coated prior to cell culture to allow the cells to adhere 
to the cryogel scaffolds. To do so, cryogel samples were ﬁ rst partially 
dehydrated by compressing them mechanically against a sterile gauze. A 
PLO (1 mg mL −1 diluted in sterile deionized water) droplet of 10 times 
the cryogel volume was then deposited on top of each cryogel and left 
for 1 h at 37 °C. The PLO droplet was then removed, and the cryogel 
samples rinsed with DI water. Finally, the cryogels were again partially 
dehydrated under sterile conditions, and laminin (1 μg mL −1 in sterile DI 
water) was added onto the cryogel samples (1× cryogel sample volume) 
and left for 4 h at 37 °C. Prior to initiation of cell culture, samples were 
rinsed with sterile DI water and compressed again immediately before 
cell seeding. 
 2D Control Substrates : 2D control samples for alginate and CMC 
substrates were fabricated on coverslips. To ensure permanent adhesion 
of the hydrogels to the glass slides, the coverslips are ﬁ rst coated with 
a molecular adhesion layer of alginate or CMC. The procedure coincides 
with the coverslide activation step used in the AFM sample preparation, 
given in Supporting Information 3. Once these molecular adhesion 
layers established, we deposited the bulk gel layers. To do so, we used 
the 1% recipe for the CMC and the 3% recipe for the alginate also used 
for the cryogel fabrication (Supporting Information 1), but rather than 
placing the reaction mixture at −20 °C, we dried a drop of the reaction 
mixture on the coverslides prior to completion of polymerization by 
using a stream of pressurized air. To ensure complete polymerization, 
we expose the dried slides to 170 °C dry heat for 20 min; to remove 
unreacted products, we sequentially washed them in NaOH 100 × 10 −3 M , 
EDTA 10 × 10 −3 M , and PBS, prior to 70% ethanol sterilization.  
 Neuronal Cell Line : The human neuroblastoma-derived cell line 
(SH-SY5Y) was grown in DMEM medium supplemented with 10% 
fetal bovine serum and 1% penicillin streptomycin in Petri dishes. Cells 
were subculture twice a week, and maintained at 37 °C and 5% CO 2 . 
All reported experiments were performed using cells with less than 20 
passages from purchase. 
 Primary Cortical Cells : All experimental procedures were carried out 
according to the Swiss federation rules for animal experiments. Mouse 
primary cortical neurons were prepared from embryonic day 17 Of1 fetal 
mouse brains. Cortices were digested in medium containing papain 
(20 U mL −1 ) and dissociated by mechanical trituration. Cells were 
plated in neurobasal medium supplemented with 2% B27 and 2 × 10 −3 M 
Glutamax. Unless otherwise speciﬁ ed, all substrates (cryogels, but also 
planar control substrates) were coated with PLO/Laminin as described 
above. All cells were kept in a humidiﬁ ed 5% CO 2 atmosphere at 37 °C. 
 Cryogel Seeding and Culture : SH-SY5Ycells or mouse primary cortical 
neurons were seeded onto cryogel and control substrates at a typical 
density of 4000 cells mm −3 . A droplet (volume equal to the cryogel 
volume) containing the cells is placed onto the partially dehydrated 
cryogel sample and incubated for 45–60 min. Cell culture medium 
(500 μL) was then added and cells were maintained at 37 °C, 5% CO 2 . At 
experimental endpoints, the cellular scaffolds or control substrates were 
ﬁ xed with 4% paraformaldehyde for characterization. Cell distribution 
was homogeneous throughout the 1 mm thick scaffold. For culture 
periods beyond 7 d, half-media were changed twice weekly. 
 Analysis of Cell Morphology : To observe cells and quantify their 
morphology, cells were ﬁ xed with 4% buffered formaldehyde during 
20 min. After PBS washes, actin cytoskeleton and cell nuclei were stained 
(permeabilization with Triton X-100 (0.3% in PBS), followed by phalloidin-
Atto565 (Sigma–Aldrich) at a dilution of 1:200 and 4′-6-diamidine-2-
phenyl indole (DAPI) used at 300 × 10 −9 M ). Fluorescence images were 
acquired using a confocal ﬂ uorescent microscope Zeiss LSM 700 with a 
−20× air objective or with a 40× oil objective. Images of at least 200 cells 
on four randomly chosen observation ﬁ elds were captured and analyzed 
for each experimental condition and for each experiment. Experiments 
were repeated at least three times. Cell density was quantiﬁ ed as the 
number of cell nuclei in a given volume. SH-SY5Y cells were designated 
as “spread” when they developed at least one sprouting neurite from the 
soma measuring at least 15 μm in length, otherwise, they are considered 
“round.” Based on confocal images, neurite length was measured using 
the plugin NeuronJ of ImageJ. For cell survival analysis, samples were 
rinsed with HEPES-buffered salt solution (HBS), and incubated in a 
trypan blue solution (0.4% in HBS) for 2 min at room temperature. The 
samples were then washed with HBS, and the cells of ﬁ ve independent 
observation ﬁ elds were observed and counted on the whole sample 
thickness using a bright-ﬁ eld microscope with ×20 objective (Leica 
DM5500). Cell viability (in%) resulted from the ratio between the 
number of non-stained cells and the total cell number. 
 Finite Element Simulation : Finite element modeling (FEM) was 
performed in COMSOL version 4.3b. The gel and the cells were 
modeled as nearly incompressible linear elastic materials, while the 
pore space was considered void. The boundary conditions were set 
to free movement for all boundaries except for the top and bottom 
boundary, which were used to impose the compression in  z direction. 
The simulations were run in 2D, using the SolidMechanics physics, with 
Adv. Healthcare Mater. 2015, 4, 301–312
www.advhealthmat.de
www.MaterialsViews.com
149
FU
LL P
A
P
ER
311wileyonlinelibrary.com© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
an in-plane stress 2D approximation. The materials were all supposed 
to be linearly elastic with appropriate local Young moduli, and a Poisson 
ratio of 0.48. 
 Statistical Analysis : Unpaired, two-sided  t -tests were used for 
direct comparison of pairs of outcome variables. To test whether the 
injection procedure had a signiﬁ cant effect on cell viability or neurite 
length, the difference between the outcome measures before and at 
a given time point after injection was compared to the difference at 
identical time points under control conditions by means of an adapted 
 t -test with a compound estimation of the standard deviation and a 
corresponding adjustment of the number of degrees of freedom. To 
assess the relation between the initial polymer concentration and the 
local Young modulus, F-tests were applied to the analysis of variance 
associated with the linear regression. No multiple testing corrections 
were used. Error bars indicate standard deviations, except where 
otherwise noted. 
 Supporting Information 
 Supporting Information is available from the Wiley Online Library or 
from the author. 
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Supporting Information 1: Cryogel Synthesis 
General remarks on the crosslinking and labeling chemistry 
The cryogels are synthesized by carbodiimide activation of the carboxylic acid residues and 
the carbohydrate moieties (alginate and carboxymethyl-cellulose), followed by amide bond 
formation with adipic dihydrazide, which results in the covalent crosslinking of the gels. 
Although stabilizers of activated esters such as N-hydroxysuccinimide (NHS) or 
hydroxybenzotriazole (HOBT) are sometimes used for this type of amino- to carboxyl 
coupling, we found it easier to directly take advantage of the particularly low pKa of the 
adipic dihydrazide to obviate the need for these stabilizers. It is indeed possible to carry out 
the crosslinking reaction with high yields at a pH ranging from 5 to 6 without the need for 
either NHS or HOBT. In this case, sufficient buffering capacity must however be provided by 
the addition of a suitable buffer such as a morpholino-ethane-sulfonate (MES). 
Likewise, for the fluorescent labeling, we use aminofluorescein. Indeed, aminofluorescein has 
an aromatic amino group that will react like the acid hydrazine groups at pH 5-6, without the 
need for NHS or HOBT. It can therefore be included in the reaction mixture without further 
precaution and will get bound to the carboxyl-groups with very high yield, making the 
fluorescent labeling very practical. As a drawback, it should be noted that fluorescein 
derivatives photobleach quite quickly, at least when compared to more advanced dyes such as 
the Alexa or Atto series. 
Due to its sensitivity to hydrolysis, we need to add the carbodiimide last. We use N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC) by dissolving it in an 
equal amount of water (e.g., 10μL of deionized water to dissolve 10mg EDC), and then 
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transferring the resulting solution to the reaction mixture. This initiates gel formation, such 
that mixing needs to be carried out quickly, with immediate transfer to a mold at -20°C if 
cryogel formation is desired. 
The following tables give the detailed recipes and procedures used throughout this study. DI 
is deionized water; AAD is adipic acid dihydrazide; CMC is carboxymethyl-cellulose; EDC is 
water-soluble carbodiimide; MES is morpholino-ethane-sulfonic acid; PBS is phosphate 
buffered saline; EDTA is ethylene-diamine-tetraacetic acid (adjusted to pH 8 with NaOH, 
e.g., approximately Na3H-EDTA). 
MES buffer pH 5.5 0.5M 
MES-hydrate (solid) NaOH (solid) Adjust to final volume with DI
97.6g 3.66g 1L
Table S1: Preparation of MES buffer. 
Alternatively, the NaOH can be provided as a liquid solution, for instance as 91.5mL of 
NaOH 1M. 
Alginate cryogels  
Nominal
percentage
Sodium 
alginate, 
30mg/mL in 
DI
DI MES 
buffer, pH 
5.5, 0.5M
AAD
50mg/mL
EDC
3% 1mL - 0.1mL 26 ?L 12mg 
dissolved in 
12 ?L DI
2.5% 1mL 0.2mL 0.1mL 26 ?L 12mg 
dissolved in 
12 ?L DI
2% 1mL 0.5mL 0.1mL 26 ?L 12mg 
dissolved in 
12 ?L DI
1.5% 0.5mL 0.5mL 50?L 13?L 6mg 
dissolved in 
6?L DI
1% 0.5mL 1mL 50?L 13?L 6mg 
dissolved in 
6?L DI
Table S2: Recipe for the alginate cryogels. 
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Carboxymethyl-Cellulose cryogels  
Nominal
percentage
CMC 
15mg/mL 
in DI
CMC 
10mg/mL 
in DI
DI MES 
buffer, 
pH 5.5, 
0.5M
AAD
50mg/mL
EDC
1.5% 1mL - - 0.1mL 10.5 ?L 8mg 
dissolved 
in 8 ?L DI
1.25% 0.5mL 0.5mL - 0.1mL 9 ?L 6mg 
dissolved 
in 6 ?L DI
1% - 1mL - 0.1mL 7 ?L 4mg 
dissolved 
in 4 ?L DI
0.75% - 1mL 0.333mL 0.1mL 7 ?L 4mg 
dissolved 
in 4?L DI
0.5% - 1mL 1mL 0.1mL 7?L 4mg 
dissolved 
in 4?L DI
0.25% - 1mL 3mL 0.1mL 7?L 4mg 
dissolved 
in 4?L DI
Table S3: Recipes for the CMC cryogels 
Detailed protocol  
The detailed protocol for production of sterile cryogels is outlined in Table S4: 
Illustration Description
1. Polymer premix 
Alginate or CMC + AAD + MES buffer; 
amounts see table above
2. Pre-cool to 4°C
This step is required for the CMC 
cryogels only
3. Add activator
The EDC is dissolved in an equal amount 
of water (e.g. 10?L for 10mg); it is 
typically possible to make a stock 
solution for several gels, provided the 
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stock is used within an hour
4. Transfer to mold
Mix rapidly, transfer to mold. A 
convenient way to make a mold is to use 
plastic spacers (on the order of 1mm 
height) and two coverslides
5. Transfer to -20°C
For large molds, the molds need to be 
precooled; for the coverslide molds 
described above, it is enough to place the 
assembled mold on a precooled metal 
block in the freezer
6. Incubate at -20°C
Freezing causes structuration
Polymerization time at least 24h
7. Thaw, unmold
Remove from mold; from this step on, 
the gels should never be allowed to dry 
completely.
8. Stamp
If desired, punch out disks of the desired 
size (typically, 4mm diameter disks)
9. Wash out unreacted products
We use the following washing steps: 1) 
DI, 2) 100mM NaOH, 3) 10mM EDTA 
pH 8, 4) DI, 5) PBS, 6) PBS. The 
washing steps can be done in Falcon 
tubes, with 5 min incubation for each 
step.
10. Autoclave
To minimize hydrolysis, the gels are 
autoclaved in PBS.
Table S4: Cryogel synthesis protocol 
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Fluorescently labeled gels  
In order to be able to use the fluorescent gels along with traditional cell labeling techniques 
such as visualization of actin filaments by rhodamine-phalloidin, the gels need to have a 
suitable brightness. If they are too bright, the spectral spillover makes observation of the 
neighboring channels (e.g., rhodamine) impossible; if they are too dim, too high laser 
intensities lead to exaggerated photobleaching. Empirically, we find the following cryogel 
compositions appropriate for confocal microscopy along with rhodamine-phalloidin labeling 
of the actin cytoskeleton: 
CMC 1%: Addition of 12 microliters of aminofluorescein 1mM to the reaction mixture 
outlined in Table S3, prior to the addition of EDC 
Alginate 3%: Addition of 24 microliters of aminofluorescein 1mM to the reaction mixture 
outlined in Table S2 , prior to the addition of EDC 
We prepare an aminofluorescein stock solution as follows: First, we prepare a 100mM stock 
solution by mixing 35mg aminofluorescein + 300 microliters NaOH 1M + 700 microliters DI; 
we then dilute this solution 1:100 with DI to obtain the 1mM solution used for the labeling. 
The washing steps outlined in Table S4, including the autoclave step, suffice to remove 
unreacted aminofluorescein. 
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Supporting Information 2: Bulk Young Modulus Estimation  
Mechanical testing of cryogels  
Bulk testing of cryogels can be performed in a setup for linear compression of a sample of 
known disk geometry (we use a TextureAnalyzer Plus apparatus from Stable Microsystems). 
In this setting, the deformation is imposed, and the resulting stress is recorded as the reaction 
force acting on the chuck. The deformation strain is given by:  
? = ?L/L0 (S5)
where L0 is the undeformed disk height, and ?L the distance of compression. The stress is 
given by: 
? = F/A (S6)
where F is the force exerted by the chuck and A=?r2 is the disk diameter. The Young modulus 
relates the strain to the stress: 
? = E*?? (S7)
Given an experimental stress-strain relation, the Young modulus can be determined by the 
slope of a regression line fitted to a linear portion of the stress-strain relation. For the 
cryogels, we use the portion from 0 to 0.5 strain (e.g., 50% compression) for the fitting of the 
Young modulus. 
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Sample Stress-Strain curve and extraction oft he Young modulus  
Figure S8: Raw force-distance curve for a 1% CMC cryogel (A) along with the stress-strain 
relation (B) extracted by low-pass filtering and application of equation S5 and S6. The linear 
fits in Figure S8-B are obtained by means of equation S7. 
Figure S8 shows the force distance curve as raw data obtained from the TextureAnalyzer Plus 
(Stable Microsystems) used for the mechanical testing (A) along with the stress-strain relation 
extracted and used for the determination of the Young modulus (B). The strain is extracted 
from the compression-distance curve by means of equation S5 and the known initial gel 
thickness whereas the stress is obtained by relating the force to the cross-section area by 
means of equation S6. Since the cryogels show some hysteresis, two separate Young modulus 
values are obtained by fitting straight lines according to S7, one in the compression phase, one 
in the release phase. The hysteresis is due to viscous, rather than plastic effects, since repeated 
measurements yield essentially identical stress-strain relations. Since one expects viscous 
effects to increase the stress in the compression phase, and to decrease it in the release phase 
of the mechanical test, we take the average of the two moduli to be representative of the true 
bulk elastic modulus. In the example shown, the mean Young modulus would have a value of 
709Pa. 
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Supporting Information 3: Imaging and local Young modulus 
quantification of cryogels by Atomic Force Microscopy AFM  
Sample preparation  
It is difficult to obtain local Young moduli of the cryogel wall material on intact macroscopic 
cryogels because of the presence of comparatively very large pores between the cryogel 
material to be analyzed. One way to address this problem consists in the selective probing of 
cryogel fibers localized by means of microscopic imaging simultaneously performed with the 
atomic force microscopy AFM measurements[1]. Even so, obtaining contiguous images 
remains a challenge. 
Hence, in order to obtain samples amenable to contiguous imaging, and to avoid the need for 
simultaneous optical microscopy and AFM instrumentation, we immobilize shallow pieces of 
cryogel walls on a solid, flat substrate. To do so, we carry out the cryogelation process on 
specially prepared slides, which provide for covalent attachment sides during the gel 
formation process, and then manually brush off most of the cryogel by using a water jet. In 
this way, it is possible to obtain cryogel material to be imaged with a topographical height 
between 100nm and 1?m, suitable for AFM. 
The detailed process of sample preparation is outlined in Figure S9. We start out with 
Novellas “Assistant” round coverslips made from borosilicate glass, onto which we deposit a 
drop of alginate solution (3%) or CMC solution (1%) depending on whether we ultimately 
need to image alginate or CMC cryogels.  
For the CMC slides, we dry the coverslips at 80°C in a well-ventilated oven for 30 minutes. 
We then wash of the bulk dry material, leaving behind an invisible, but strongly hydrophilic 
layer. We then hardbake this layer in dry heat at 190°C for another 30 minutes. 
160
For the alginate slides, we directly expose the slides to dry heat at 170°C for 30 minutes, and 
then wash off the dried, and slightly caramelized bulk material, and again obtain a strongly 
attached, highly hydrophilic, but invisible layer of attached polysaccharide. 
For both of types, we then proceed with the cryogel synthesis as outlined in the main text and 
Supporting Information 1. Once the cryopolymerization is complete, we find the cryogel to 
adhere firmly to the substrate; we remove most of the bulk cryogel by manually directing a 
weak water jet at the bulk material, leading to the formation of a cleavage plane some 100nm 
to 1?m above the glass surface. The adhesion of cryogel fragments to the glass slide can be 
confirmed by checking the slides under an optical microscope by the appearance of a network 
of fine lines corresponding to the cryogel wall fragments.  
As a side note, we sometimes find similar traces after removal of cryogels from untreated 
glass slides as well, but the process is made reproducible by the pre-treatment protocol 
outlined here. Likewise, it is fully possible to simply use tweezers to remove the bulk cryogel 
after the synthesis, but the water jet method is more reproducible in our hands. For reasons 
unclear to us, we need to perform a two-step procedure (80°C, wash, 190°C) for the CMC, 
whereas a one step heat procedure (170°C) is sufficient for the alginate attachment. 
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Figure S9. Sample preparation method for cryogel imaging. 
AFM measurement method  
The AFM measurements themselves are carried out in an aqueous environment, using 
Bruker’s peak force mode for Quantitative Nanomechanical Mapping (QNM) imaging. We 
use the TAP150A tip (Bruker, designated as MPP-12120-10) for the alginate samples, and the 
ScanAsyst-Fluid tip (Bruker) for the carboxymethyl-cellulose samples. We use the absolute 
calibration method for the following elements: 
- Calibration of the “deflection error” on a sapphire sample
- Calibration of the spring constant via the “thermal tune” method
- Checking of the tip integrity on a Tipcheck sample. 
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As outlined below (section “tip geometry”), constraints arising from lateral resolution and 
Young modulus quantification on very thin samples require us to work with an indentation 
too large for the DMT model[2], but too small for the Sneddon model[3], such that we use 
reference samples of known elastic modulus to calibrate the Young modulus measurement; 
the necessary correction factor is then applied to the Young modulus measurements for the 
unknown samples measured during the same AFM session. For our experimental settings, we 
find the correction factor to vary somewhat within the range of 0.5 to 2.0.  
Further, for an alginate and a CMC sample, we also have performed a direct comparison 
between a Force-Volume measurement and the QNM image. Indeed, historically, the Force-
Volume technique is older and therefore more generally accepted in the AFM field than the 
peak-force controlled QNM mode. It is also much slower, and suffers from a series of 
additional drawbacks and problems as compared to the more recent peak-force controlled 
QNM imaging mode, so once the equivalence of the two methods for our types of samples 
established, we consistently used the QNM imaging.  
Comparison with force-volume  
We performed a comparison between the Force-Volume (FV) mode and the peak-force 
controlled QNM imaging on a randomly chosen region on a 3% alginate sample, which we 
imaged with both techniques, and similarly, a randomly chosen region on a 1.25% CMC 
sample. 
The Figures S10 and S11 below show the comparison between the measurements: 
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Figure S10: Force-Volume vs. PeakForce for Alginate. Comparison of QNM Peak Force (A) 
to Force-Volume imaging (B) for a 3% alginate cryogel sample. For D) gel points are defined 
as points with a height of more than 120nm on the topographical image (C), all others are 
considered as “other points”.
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Figure S11: Force-Volume vs. PeakForce for CMC. Comparison of QNM PeakForce (A) and 
force-volume imaging (B) for a 1.25% CMC cryogel sample. For D) gel points are defined as 
points with a height of more than 120nm on the topographical image (C), all others are 
considered as “other points”.
The moduli determined with the two techniques are on the same order of magnitude 
(Alginate sample: PeakForce QNM 82 +/- 12 MPa vs. Force volume 68 +/- 28 MPa;  CMC: 
PeakForce QNM 3.2MPa +/- 0.7 MPa vs. 3.2MPa +/- 1.3MPa for the force-volume modulus; 
comparison on the gel points defined by having more than 120nm height on the height map), 
confirming that PeakForce QNM effectively gives quantitative results that are comparable to 
Force-Volume imaging.  
Given that the PeakForce imaging mode is much faster than the force-volume mode, we did 
not perform any supplementary experiments in force-volume mode. 
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In terms of the gel physics involved, the absence of an important difference between 
PeakForce and Force-Volume imaging also suggests that there is no important stress 
relaxation phenomenon taking place on the time scale between 1s (pixel acquisition time in 
FV) and 1ms (pixel acquisition time in PeakForce QNM) on the size scale of the tip radius 
(10-20nm).  
Discussion of systematic errors  
A series of potential systematic errors may affect the estimation of the local Young modulus 
via AFM imaging, the most important being limited sample thickness and a mismatch 
between the mathematical models used to extract the Young modulus and the actual tip 
geometry due to indentation beyond the spherical region of the tip. A minor source of 
systematic error is the unknown Poisson coefficient of the samples. 
Sample thickness  
Figure S12: Young moduli estimations as a function of sample thickness. The upper dots (red) 
are for the alginate samples, the lower dots (black) for the CMC samples. We have visually 
chosen 120nm as the minimal height required for the Young modulus estimation (left dashed 
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line); in order to avoid damage to the tip, we have also limited the measurements to regions 
with topographical features 400nm or less (right dashed line). Error bars indicate standard 
deviations of the mean. 
It is well-known that determination of the hardness of a material by indentation is in part 
influenced by the underlying material[4]. The practical question is how thick the soft cryogel 
fragments need to be such that the influence of the underlying hard glass substrate can be 
neglected. To answer this question, we have combined the data from all the samples 
underpinning Figure 4 in the main text, and plotted the estimated Young modulus as a 
function of the local topographical height. The result is shown in Figure S12. Based on this 
view of the data, we have chosen to consider only points with a minimal topographical height 
of 120nm to limit the influence of the underlying glass substrate, since beyond the Young 
modulus estimation for points with a gel thickness of more than 120nm remains essentially 
constant. 
Tip geometry  
Young moduli are defined for homogeneous deformation, and a model is needed to extract the 
Young modulus from the force distance curves obtained in AFM imaging. For shallow 
indentations, the tip can be considered spherical, and the appropriate model is the DMT 
model[2]. For deep indentations, the tip can be considered conical, and the appropriate model 
is known as the Sneddon model[3]. 
Ideally, the tips are chosen such that either the DMT model or the Sneddon model can be 
applied fully; with the specific sample at hand, we however face a series of limitations 
making this impossible in practice: 
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1. The signal to noise ratio is generally improved by large forces, and therefore large 
indentations. 
2. We are however limited by the low sample thickness, and too high indentation forces 
would lead to an exaggerated influence of the underlying glass substrate. 
3. In theory, large forces with shallow indentations can also be achieved with tips with 
large radii, by scarifying resolution; given the submicrometric feature size in our 
samples, this is not a feasible option.  
Overall, the need for sufficiently high resolution forces us to use tips with small radii 
(typically, 10-20nm); the need for a sufficient signal to noise ratio requires us to apply forces 
that produce indentations which are too large for the DMT model; and the shallow thickness 
precludes the use of forces sufficiently large to entirely warrant application of the Sneddon 
model. The scope of the present hydrogel study does not warrant the development and 
implementation of our own, intermediate model, and we systematically use the DMT model, 
but apply a correction by means of a reference sample. Indeed, Figure S13 shows that 
depending on the exact gel geometry, the blind use of a given model may lead to a systematic 
error of 50% in the force estimation for forces on the order of 20nN, employed in practice; 
this would typically result in a similar systematic error on the order of a factor of 2 or 3 for 
the Young modulus estimation. Assuming that the indentation process is similar for materials 
of similar Young modulus, this can be corrected for by the application of a correction factor 
obtained on a known reference sample (reference sample for the alginate cryogels: the 
100MPa regions on the PS-LDPE-12M reference sample from Bruker; reference sample for 
the CMC cryogels: PDMS-SOFT-2-12M from Bruker, 3.5MPa).  
168
Figure S13: Simulation of the indentation force, and comparison to the DMT and Sneddon 
model.
Poisson ratio  
The estimation of the Young modulus requires knowledge of the Poisson ratio. For hydrogels, 
many researchers assume a Poisson ratio of 0.5 on the basis the high water content makes the 
gel essentially incompressible[5]. In any case, the relative influence of the Poisson ratio on the 
determination of the Young modulus is limited to 25% in the DMT model in the range of a 
Poisson ratio of 0-0.5, making the potential error associated with this assumption small in 
comparison with the other systematic errors. 
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Supporting Information 4: Relation between local and apparent bulk 
mechanical properties  
Local and bulk Young modulus  
The hydrogel sponges used in this study consist of generally less than 10% wall material and 
more than 90% pore space (Figure 4E in the main text). Thus, they behave as mechanical 
meta-material with bulk (apparent) properties that can be very different from the local 
properties. A large body of theory is available for the mechanical description of such porous, 
regular mechanical materials, traditionally referred to as cellular solids[6], or more precisely, 
foams[6], for the 3D structures considered here. The “cells”, in this context, refer to the 
physical unit structure of the foam, which consists of a pore space and its associated walls. 
Foams in general are classified into open and closed structures. In fully closed foams, the pore 
spaces are separated by sheet-like polymer walls termed “faces”, whereas in fully open foams, 
the wall-material is wire-like, and the pore cells all communicate directly with their 
immediate neighbors[6]. The cryogels presented here are intermediate: although much of the 
pore space is interconnected, a continuous sheet of wall material often separates two 
neighboring pores, with fluidic connections through additional pore cells. Since the closed 
faces can bear mechanical loads, we deem it more appropriate to use the formalism of closed 
foams, despite the fluidic interconnectivity. 
For closed foams, the apparent bulk modulus of the structure Ebulk is known to be related to 
the third power of the volume fraction ? occupied by the solid phase (i.e. the cryogel walls), 
and the local Young modulus of the wall material Ewall[7]: 
Ebulk = C * ?3 * Ewall (S14)
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Where C is a proportionality constant, which depends on the exact geometry of the structures, 
but most importantly not on the absolute pore size[6, 7]. 
To further evaluate C, we shall consider a simple beam mechanical model of the cryogels. 
Given the overall irregularity of the cryogels, we replace the different elements by a single 
representative cantilever, of dimensions: 
h=?*D/2 (S15)
l=D/2 (S16)
w=D/2 (S17)
where h,l and represent respectively the height, length and width of the cantilever, while D is 
the mean pore diameter. Assuming a homogeneous rectangular cross section, the spring 
constant of such a cantilever is given by[8]: 
k=Ewall/4 * w * (h/l)3 = Ewall * D * ?3 (S18)
where Ewall is the intrinsic Young modulus of the wall material. 
In a hypothetical homogeneous bulk material of Young modulus Ebulk, the force necessary to 
uniaxially compress an element of D/2 x D/2 x D/2 would be given by: 
F = Ebulk * A * ?L/L = k*?L => k = Ebulk*A/L = Ebulk * D/2 (S19)
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By requiring the spring constant to be identical for the hypothetical bulk and the cryogel 
sample, we obtain: 
Ebulk * D/2 = Ewall * D * ?3 =>
Ebulk = 2* Ewall * ?3 (S20)
By comparing equation S20 and equation S14, we therefore obtain C=2. 
We do however not expect equation S20 to hold exactly for cryogels, since there are very 
strong underlying structural assumptions, which are probably not met strictly by the variety of 
structures produced from different polymers and varying conditions during cryosynthesis. To 
account for the potentially variable mechanical stability of different cryogel structures, we 
generalize equation S20 as follows: 
Ebulk = 2 * Ewall * ?3 * Fstruct (S21)
where Fstruct is a structural factor equal to 1 for an exact match with the simple beam 
mechanical model. Equation S21 implies that cryogels with low wall volume fraction (i.e., on 
the order of 1%) can exhibit a bulk elastic modulus 6 orders of magnitude weaker than the 
local Young modulus, underscoring the importance of the concept of a mechanical 
metamaterial. 
In the main text, we confirm equation S21 by comparison of AFM and bulk Young moduli. It 
is however noteworthy that we find equation S21 also to be quantitatively applicable to 
experimental data presented by others[1]. Indeed, in reference[1], local and bulk moduli are 
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given for starPEG:heparin cryogels, along with the corresponding porosity data for two 
different precursor concentrations (reported in Table S22). By comparing the reported wall 
fractions for the two precursor concentrations, we find that ? differs by a factor of 3.76, 
whereas the bulk Young modulus differs by a factor of 75, which is consistent with a power 
law near ?3, as predicted by equation S21.  
Precursor concentration Local Young 
modulus
Bulk Young modulus Wall fraction (1-
Porosity)
4.3% 1500kPa 4kPa 0.025
11.8% 1500kPa 300kPa 0.094
Table S22: Literature data for starPEG:heparin cryogels[1]. 
Local and bulk strain 
An order-of-magnitude estimate of the maximum strain encountered by the cryogel wall 
material can also be obtained from the beam model presented above. At a given macroscopic 
strain ?macroscopic the tip deflection of the equivalent cantilever is given by: 
?(x=L) = D/2/sqrt(2)*?macroscopic (S23)
where ?(x) is the deflection from the neutral position along the beam axis x, and L=D/2 the 
length of the beam as defined above. In beam mechanics, the local deformation of a singly 
supported beam is given by: 
?(x) = ?*L3/(6*Ewall*I)*(3*(x/L)^2-(x/L)^3) (S24)
where ? is the load applied to the cantilever tip, and I its cross-sectional moment of inertia. 
Applying equation S23 and S24, we obtain: 
D/2/sqrt(2)*?macroscopic = ?*L3/(3*Ewall*I) (S25)
The local deflection can also be used to get the local radius of curvature: 
R=1/??’’(x) = 1/(?*L/(Ewall*I)*(1-x/L)) (S26)
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The radius of curvature is minimal for x=0, such that with equation S25, we obtain: 
Rmin=2*sqrt(2)/3*L^2/D/?macroscopic ≈ L^2/D/?macroscopic (S27)
The maximum strain occurs at the beam surface, at z=h/2 from the equilibrium line, and has 
the magnitude: 
?max = h/2/Rmin = D*h/2/L^2*?macroscopic (S28)
By using the definitions given by equation S15 and S16, this evaluates to: 
?max = ???macroscopic (S29)
During the compression for injection, ?macroscopic≈1, since nearly all the pore space is lost. This 
indicates that during injection, the maximum strain encountered by the scaffold is simply 
given by the wall volume fraction: 
?max, injection = ?  (S30)
Homogeneous hydrogels typically break at a uniaxial compressive strain of about 20%.[9] The 
critical component is likely the lateral extension due to the isovolumetric nature of rapid 
hydrogel compression, which is half the compressive strain at a Poisson ratio of 0.5, such that 
we expect an upper bound for the volume fraction: 
??????? (S31)
Hence, for wall volume fractions less than 10%, we expect the cryogels to be compressible up 
to the obliteration of the pore space without loss of mechanical integrity, whereas we expect 
mechanical failure before pore obliteration otherwise. Equation S31 therefore places an upper 
bound on the wall volume fraction for injectable macroporous scaffolds.  
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Supporting Information 5: Design rules for injectable macroporous 
scaffolds  
Based on the comparison of the mechanical, geometrical and injectability properties of the 
cryogel scaffolds presented here, it is possible to extract elementary design rules for providing 
injectability for macroporous scaffolds. Firstly, at least for manual syringe loading, the 
scaffolds need to have a minimal stiffness. We find the lower threshold for successful manual 
handling to be roughly given by the 0.5% CMC and 1% alginate scaffolds, both of which 
have a bulk Young modulus of about 0.12kPa, such that we can consider a bulk Young 
modulus of 0.1kPa to be the lower threshold for successful manual handling, namely for 
manual compression prior to syringe loading.  
A second criterion arises through the requirement for reversible compression up to near 
complete obliteration of the pores without mechanical failure of the wall material. We show in 
Supporting Information 4 that a low wall volume fraction allows for lower local strains at a 
given bulk deformation (Equation S29), and that for typical hydrogel materials, the volume 
fraction of the wall material should be less than 10% to avoid wall material failure upon 
essentially complete compression (Equation S30, S31). In addition, the pore volume should 
obviously be interconnected to allow rapid evacuation of the pore fluid during the 
compression. Finally, equation 1 in the main text implies that a minimal bulk stiffness of 
0.1kPa at a volume fraction of 10% requires a wall material with a Young modulus at least 3 
orders of magnitudes higher, that is on the order of 100kPa or higher. 
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Chapter IV 
General discussion and perspectives 
177
 
 
IV.1) Discussion 
The A? peptides, believed to be the causative agents of AD, are generated by the subsequent 
cleavage of APP by ?- and ?-secretases. Alternative processing of APP by ?-, followed by ?-
secretase, generates the shorter p3 peptides, and precludes the generation of A? (see Fig. 4, Chapter 
I). Thus, ?- and ?-secretases directly regulate A? production111. Although modulating the activity of 
?-secretase emerged as a promising therapeutic targets to cure AD, clinical research was hampered 
by the lack of specificity and poor bioavailability of chemical compounds144,148,149. The next target 
on the list became ?-secretase whose inhibition abolishes the generation of A?. Unfortunately, ?-
secretase processes a growing list of substrates including the Notch receptor125. Thus, its in vivo 
inhibition altered numerous physiological processes and revealed strong adverse effects including 
the worsening of cognitive functions130–133. Importantly, the cleavage of sAPP? by the ?-secretase 
complex generates A? of various length: the forty amino-acid long A?40 is the main and non-
pathogenic peptide whereas the long A?42 and A?43 are the most aggregating and toxic species68–
70. Indeed, the A?42/A?40 ratio is a marker for AD: it remains low in healthy brains (0.1-0.2) and 
may increase up to two in the brain of AD patients42,71. 
The idea emerged that safe AD treatments should specifically block the processing of APP to 
reduce the production of A? as well as the A?42/A?40 ratio, without affecting the cleavage of other 
substrates. This goal can be achieved by the delivery of chemical compounds (?-secretase 
modulators222 and ?-secretase inhibitors223) or by the identification of endogenous modulators of ?-
secretase and APP processing.  
 
?-Secretase endogenous modulators 
A growing list of proteins modulating A? production were identified. They control various 
molecular mechanisms such as the regulation of APP maturation (Fe65183), processing by secretases 
(TMP21178, X11182, Reticulon family proteins224) or interfering with APP trafficking and/or 
lysosomal degradation (AP2186, APMAP72, Tspan672, Nogo72, Sorla181, Beclin1185, PICALM186,225). 
In accordance with our study in which we show that PS phosphorylation does not affect ?-secretase 
activity (see manuscript page 60), no kinase or phosphatase has yet been shown to regulate ?-
secretase activity. Most proteins interacting physically with the secretases or APP are well studied 
for their implication in protein trafficking or protein autophagic/lysosomal degradation. However 
these proteins may fulfill yet unknown physiological functions. This is particularly true for 
APMAP, whose only known function is related to in vitro adipogenesis226,227, it physiological 
function is currently under investigation in our lab. In our study page 31, we shed the light on the 
role of APMAP in AD brain as a suppressor of A? production. Yet, APMAP depletion increased 
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A? levels whereas its overexpression didn’t affect A? production in vitro. Thus, APMAP does not 
appear to have a therapeutic potential, but in vivo experiments have to be performed to clearly 
address this question. 
 
Biological functions of APMAP 
APMAP expression is necessary for in vitro adipogenesis and is stimulated by the peroxisome 
proliferator-activated receptor ? (PPAR?)226,227. Adipocyte play an active role in the regulation of 
two well-known modulators of A? production: cholesterol which stimulates the processing of APP 
by secretases123,170,228,229, and Leptin, which decreases the levels of A? peptides230,231. Indeed, 
PPAR? activation promote adipogenesis, and has been shown to inhibit the production of A? and 
increase its clearance232–237. The A?-lowering effects of PPAR? may be mediated by Leptin, 
cholesterol, APMAP (see manuscript page 31), or by other unknown molecular pathways. Yet, 
inhibition of the cleavage of Notch by ?-secretase induced PPAR? expression238,239, and points out a 
potential regulatory feedback loop. Interestingly, PPAR? is expressed in the human/mouse 
brain240,241 and displays neuroprotective effects (reviewed in 242,243). Indeed, its activation led to a 
decrease in A? burden together with decreased microglial activation in AD mouse models244–246. 
Additionally, it should be noticed that adipose tissues are subdivided into two classes: the white 
adipose tissue which is highly present in obese individuals and stores excess energy as triglycerides, 
and the brown adipose tissue which metabolizes fat to produce heat247. In addition to its A?-
lowering effect, PPAR? expression favors the generation of brown adipose tissue, thus increasing 
energy expend and decreasing body weight238,248. In agreement with these molecular mechanisms, 
obesity and metabolic syndromes are risk factors for sporadic AD249–251. Thus, we expect 
constitutive APMAP knock-out mice to display decreased brown adipose tissue, associated to 
increased body weight and A? levels. 
 
APMAP, APP processing and CTF production 
Due to its importance in AD pathogenesis and A? generation, APP has been widely studied. No 
clear physiological function has been assessed so far, but the APP gene family (including APP, 
APLP1 and APLP2) has been shown to be implicated in early stages development84,85 and lipid 
metabolism90,116. Furthermore, its processing appears to mediate an equilibrium between 
neurotrophic and neurotoxic effects mediated by ?- and ?-secretase cleavages, respectively99–106. 
Yet, the highly regulated processing of APP involves a high number of enzymes, including the well-
studied ?-, ?-, and ?-secretases as well as several caspases, but also ?- and ?-secretases (Fig. 9). 
Surprisingly and in agreement with the modified profile of APP-CTFs following APMAP depletion 
in HeLa cells (See Fig. 3 page 35), we observed in untreated HeLa cells high amounts of the 80 
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amino-acid long APP-CTF resulting from ? cleavage, in comparison to C83 and C9972. This either 
suggest a processing of C83 or C99 at by ? secretase252, or efficient APP processing by this enzyme. 
Furthermore, we observed N-terminal degradation of APP-CTF and identified 6 new cleavage sites 
located between the ? site and APP transmembrane domain72 (see Fig. 9, red arrows). The 
mechanism responsible for the generation of these shorter APP-CTFs may involve yet unknown 
secretases, or may be linked to APP degradation, possibly by cathepsins253. Further studies are 
required to draw a complete list of the enzymes implicated in the processing/degradation of APP, 
and investigate the physiological relevance of the generated APP fragments. 
 
 
 
Figure 9: APP cleavage sites. Human APP is cleaved at numerous sites by specific enzymes: ? 
(MT5-MMP62), ? (BACE1142), ? (ADAM10147 and TACE254), ? (Bace2255,256), ? (? secretase222), ? (? 
secretase222), Casp (Caspases 6, 8 and 9119–121). The 6 new APP cleavage sites reported in the 
manuscript page 31 are indicated by red arrowheads. The transmembrane domain (TMD) is 
highlighted in yellow. The sequences of sAPP?, A? and AICD are indicated above. 
 
 
Surprisingly, pharmacological inhibition of the ?-secretase complex increased the levels of the 
longest C80, in comparison to shorter APP-CTFs (Fig. S11 page 54). Because ?-secretase is an 
intramembrane cleaving protease, we exclude that short APP-CTFs (from C79 to C71) are 
generated by the proteolytic activity of this enzyme. Yet, we do not know if all APP-CTFs share the 
same affinity for being processed by ?-secretase. If not, we think that C80 may display the highest 
affinity. Also, one may hypothesize that shorter APP-CTFs are generated in the lysosome; the 
blockage of ?-secretase would leads to non-physiological accumulation of C80 which might impair 
C80 trafficking/degradation into the lysosome, thus altering the generation of short APP-CTFs. 
Moreover, PS is known to regulate endosomal and lysosomal function by acting on calcium 
homeostasis138. One cannot exclude that ?-secretase inhibitors may affect PS function, alter 
lysosomal trafficking/function and block the degradation of C80 into shorter APP-CTFs. 
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Phosphorylation and ?-secretase activity 
?-Secretase subunits carry various PTMs including glycosylation, palmitoylation and 
phosphorylation which appear to modulate the intracellular trafficking of the ?-secretase complex 
(see section II.1.b). We showed in the manuscript page 60 that PS1 phosphorylation does not affect 
the enzymatic activity of ?-secretase in our cell-free assays. In sharp contrast, previous studies 
showed that PS phosphorylation at residues S319-T320 and T354 increased A? production196,257, 
whereas addition of a phosphate at residues S353 and S357 decreased substrate processing and 
alters insulin signaling195,258. All previous studies are in vivo or cell-based experiments, thus we 
think that PS phosphorylation may influence stability/degradation or subcellular trafficking of the ?-
secretase complex rather than its enzymatic activity. Indeed, phosphorylation at S346 has been 
shown to decrease PS processing by caspases and inhibit apoptosis197. As ?-secretase trafficking 
may be influenced by PS phosphorylation, it would be of great interest to perform subcellular 
fractionation and phosphorylation analyses to identify subcellular compartment-specific 
phosphorylation patterns. 
 
?-Secretase and cytoskeleton dynamics 
In the last two decades, ?-secretase has fostered attention due to its role in A? production43. 
Nevertheless the physiological importance of ?-secretase also requires a special attention, as the 
lack of cleavage of its numerous substrates is embryonically lethal125,141. Cell differentiation126, 
synaptic plasticity127,128, cytoskeleton dynamics129,259, APP transcription regulation are some of the 
functions regulated by the proteolytic activity of ?-secretase. We recently showed that ?-secretase 
activity affects the phosphorylation state of the actin binding protein Cofilin, and regulates 
cytoskeleton dynamics259. In contrast, no developmental defects have been observed on individuals 
carrying PS-FAD mutation, all inducing a loss of enzymatic activity260,261. Therefore, other 
mechanisms may affect the phosphorylation state of Cofilin, and compensate the loss of ?-secretase 
activity in PS-FAD patients. We found that the phosphorylation/activation of Cofilin is mediated by 
the processing of APP by ?-secretase. Although fibrillary A? have been shown to modulate Cofilin 
phosphorylation262, the effect of FAD remains unclear: it could solely promote the aggregation of 
A? peptides or act via the activation of alternative signaling pathways. 
Also, several studies highlighted the implication of Cofilin in the aggressiveness and metastasis of 
various cancer types204,263–265, and suggest a critical role for ?-secretase via the Cofilin and the well-
studied Notch pathways in cancer pathologies (reviewed in 266,267). 
 
 
181
 
 
Electrical impedance and brain structures 
In addition to the investigation of the molecular mechanisms leading to neurodegeneration and 
brain shrinkage, we considered new and low-cost methods for monitoring brain structural changes. 
We optimized the detection of brain structures by electrical impedance measurements, which makes 
possible the discriminate between cortical layers, white matter and subcortical nuclei268. This 
method could for example assist the implantation of deep brain stimulation electrodes in the 
substantia nigra of Parkinson’s disease patients269, or allow monitoring of brain structural changes 
in AD or any neurodegenerative disorder. We indeed observed ex-vivo electrical impedance 
variations in AD mice hippocampus, induced by structural alterations caused by A? plaques270. 
Therefore in vivo experiments in living mice shall be performed to provide a proof of concept for 
our method, while accuracy in the measurements still remains to be improved for the detection of 
small nuclei such as the substantia nigra. 
 
Neuronal scaffold and brain repair 
In the context of stem cell therapies, electric impedance measurements may also be interesting for 
the accurate cell injection in damaged brain areas. To this extent, we developed a new injectable 
extracellular matrix-like scaffold to improve neuronal cell engraftment and integration in damaged 
tissues271. We optimized the in vitro neuronal culture on our cryogel with mouse primary cortical 
neurons. In the future, our cryogel could be injected alone in the brain of patients suffering from 
severe brain damages and serve as a bandage promoting brain tissue repair. Alternatively, neuronal 
stem cells may first be cultured in vitro in our cryogel and then be injected into the brain of patients, 
and potentiate the replacement of dead cells. For this last approach, it should be noticed that the 
origins of cells and their differentiation is critical for safe and potent stem cell therapies214,215. In 
parallel, previous studies reported the utilization of chemical-free stem cell differentiation 
procedures, based on the shape of cell culture substrates272–276. Further in vivo investigations are 
required to determine the cell-differentiation potential of our cryogel, improve this characteristic, 
and prove the efficiency of our cryogel scaffold in promoting the regeneration of brain tissues. 
 
 
IV.2) Perspectives 
Generation and characterization of an APMAP-KO mice 
We identified APMAP as an endogenous activator of A? production in AD. While APMAP is 
known to be necessary for in vitro adipogenesis, no in vivo experiments have been performed so far. 
We showed that depletion of APMAP yields strong A? phenotype, thus we want to investigate the 
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physiological functions of APMAP by generating a mouse lacking this gene (APMAP-KO). Mice 
stem cells heterozygous for the APMAP-KO allele are available at the KOMP repository277, thus 
accelerating the generation of homozygous APMAP-KO mice. We will first observe if such mice 
are viable, fertile or display any major phenotype. Secondly and in accordance with the 
adipogenesis-related function of APMAP, we will initiate metabolic characterization to assess fat 
storage, glucose/general metabolism and energy expenditure. Then and linked to the effect of 
APMAP on A? production, we will perform behavioral tests to determine learning capacity, 
memory and anxiety, as well as biochemical analyses to monitor the processing of APP in our mice. 
APMAP-KO mice can later be bred with the AD mouse model APPPS1208 to study the effect of 
APMAP suppression on A? plaques dynamics. 
The fact that in vitro APMAP depletion increases toxic A? while its overexpression shows no 
effects suggest that APMAP may not be used as a therapeutic target to decrease the production of 
A?. To further confirm these in vitro observations, a mouse overexpressing APMAP should be 
generated and characterized in order not to miss a potent therapeutic function for our protein. 
  
Biochemical analyses to decipher APMAP functions 
In parallel to the in vivo studies, we may take advantage of our highly purified APMAP to perform 
crystallization studies and X-ray diffraction and decipher APMAP three dimensional structure. 
Then, structure-function homology would allow the discovery of protein domains or enzymatic 
functions. Indeed, APMAP shares thirty percent homology with paraoxonases, both proteins display 
arylesterase enzymatic activity, which participate in the detoxification of organic compounds278–280. 
We aim at confirming the arylesterase activity of purified APMAP in cell-free activity assays. Also, 
the APMAP/paraoxonases sequence homology suggest similar biological roles such as anti-
inflammatory and anti-oxidant functions. This purified APMAP could also be used to identify 
binding partners and highlight APMAP-related signaling pathway. This approach, together with 
protein expression (Stable Isotope Labeling with Amino acids in Cell culture, SILAC) and gene 
expression (Illumina sequencing®) analysis of APMAP-KO mice would reveal signaling pathway 
affected by APMAP and suggest physiological function and biological mechanisms for our 
candidate. 
 
Investigate the degradation of APP-CTFs 
APP-CTF analysis (see Fig. S11 page 54) revealed 1) that C80 is the major APP-CTF fragment in 
these cells, 2) the existence of N-terminal processing of APP-CTFs and 3) the influence of APMAP 
and ?-secretase activity on APP-CTFs cleavage sites. We ignore if short APP-CTFs are generated by 
a regulated proteolytic cleavage or by a degradation by the autophagic/lysosomal pathway. We plan 
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to perform in vitro experiments to find in which cellular compartment these cleavages occur, and 
identify the enzymes/molecular mechanisms implicated. We also plan to conduct researches on the 
N-terminal cleavage of APP-CTFs in other cell types including primary cortical neurons, as well as 
in the mouse and human brain. Finally, we aim at observing the effect of PS-FAD and APP-FAD 
mutations on the generation of shorter APP-CTFs. 
Because APMAP modulates the production of short APP-CTFs, we will study the trafficking of 
recombinant APP fused with GFP inside primary cortical neurons from either WT mice or APMAP-
KO mice. Protein extract of both mice brains will also be performed to monitor the effect of 
APMAP on APP-CTFs processing in vivo. 
 
 
In conclusion, our data show that the adipocyte differentiation protein APMAP is an endogenous 
suppressor of A? production in the brain, by interfering with the degradation of APP-CTF by the 
lysosomal/autophagic pathway. Further work is ongoing to understand the biological functions and 
mechanisms of APMAP, and possibly identify new therapeutic targets to safely cure AD. 
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